

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 711 830 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
11.06.1997 Bulletin 1997/24

(51) Int. Cl.⁶: **C12N 15/12, C07K 14/72,
C12N 5/10, G01N 33/68,
C07K 14/575**

(43) Date of publication A2:
15.05.1996 Bulletin 1996/20

(21) Application number: **95115996.1**

(22) Date of filing: **11.10.1995**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **13.10.1994 JP 247599/94
28.12.1994 JP 326610/94
31.05.1995 JP 134412/95**

(71) Applicant: **Takeda Chemical Industries, Ltd.
Osaka-shi, Osaka 541 (JP)**

(72) Inventors:
• **Hinuma, Shuji
Tsukuba, Ibaraki 305 (JP)**
• **Fujii, Ryo
Tsukuba, Ibaraki 305 (JP)**

• **Fukusumi, Shoji
Tsukuba, Ibaraki 305 (JP)**
• **Ohtaki, Tetsuya
Tsukuba, Ibaraki 305 (JP)**
• **Hosoya, Masaki
Tsuchiura, Ibaraki 300 (JP)**
• **Ohgi, Kazuhiro
Tsukuba, Ibaraki 305 (JP)**
• **Onda, Haruo
Tsuchiura, Ibaraki 300 (JP)**

(74) Representative: **von Kreisler, Alek, Dipl.-Chem. et
al
Patentanwälte
von Kreisler-Selting-Werner
Postfach 10 22 41
50462 Köln (DE)**

(54) Human and murine galanin receptor

(57) Galanin receptor proteins, production and use thereof including screening of galanin receptor agonists and antagonists are provided. Galanin receptor proteins, etc. or salts thereof, partial peptides thereof, DNAs coding for the above galanin receptor protein, processes for producing the above receptor protein, methods of screening for a galanin receptor agonist and/or antagonist or screening kits therefor, agonist and/or antagonist compounds or salts thereof obtained by the above screening method or the screening kit, pharmaceutical compositions containing the above compound or its salt, and antibodies against the above receptor protein are provided. It is allowable to efficiently screen a galanin receptor agonist or antagonist by using the galanin receptor protein, the partial peptide thereof, the galanin receptor protein-encoding DNA, the receptor protein-containing cell or its membrane fraction. The pharmaceuticals thus screened or characterized permits various applications including prophylactic and/or therapeutic treatments against a variety of diseases, e.g., stomach ulcer, diabetes, Alzheimer's disease, dementia, etc. and a sedative.

EP 0 711 830 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 11 5996

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,X	PROC NATL ACAD SCI U S A, OCT 11 1994, 91 (21) P9780-3, UNITED STATES, XP002029082 HABERT-ORTOLI E ET AL: "Molecular cloning of a functional human galanin receptor." * the whole document *	1-10	C12N15/12 C07K14/72 C12N5/10 G01N33/68 C07K14/575
P,X	WO 95 22608 A (RHONE POULENC RORER SA ;AMIRANOFF BRIGITTE (FR); HABERT ORTOLI EST) 24 August 1995 * claims 1-20 *	1-10	
E	WO 96 05302 A (TAKEDA CHEMICAL INDUSTRIES LTD ;HINUMA SHUJI (JP); HOSOYA MASAKI ()) 22 February 1996 * claims 1-18; examples 8-10 *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 14 April 1997	Examiner Nauche, S
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (01.92) (P04C01)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 711 830 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
15.05.1996 Bulletin 1996/20

(51) Int. Cl.⁶: **C12N 15/12, C07K 14/72,
C12N 5/10, G01N 33/68,
C07K 14/575**

(21) Application number: **95115996.1**

(22) Date of filing: **11.10.1995**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **13.10.1994 JP 247599/94
28.12.1994 JP 326610/94
31.05.1995 JP 134412/95**

(71) Applicant: **Takeda Chemical Industries, Ltd.
Osaka-shi, Osaka 541 (JP)**

(72) Inventors:
• **Hinuma, Shuji
Tsukuba, Ibaraki 305 (JP)**
• **Fujii, Ryo
Tsukuba, Ibaraki 305 (JP)**

• **Fukusumi, Shoji
Tsukuba, Ibaraki 305 (JP)**
• **Ohtaki, Tetsuya
Tsukuba, Ibaraki 305 (JP)**
• **Hosoya, Masaki
Tsuchiura, Ibaraki 300 (JP)**
• **Ohgi, Kazuhiro
Tsukuba, Ibaraki 305 (JP)**
• **Onda, Haruo
Tsuchiura, Ibaraki 300 (JP)**

(74) Representative: **von Kreisler, Alek, Dipl.-Chem. et
al
Patentanwälte
von Kreisler-Selting-Werner
Postfach 10 22 41
50462 Köln (DE)**

(54) **Human and murine galanin receptor**

(57) Galanin receptor proteins, production and use thereof including screening of galanin receptor agonists and antagonists are provided. Galanin receptor proteins, etc. or salts thereof, partial peptides thereof, DNAs coding for the above galanin receptor protein, processes for producing the above receptor protein, methods of screening for a galanin receptor agonist and/or antagonist or screening kits therefor, agonist and/or antagonist compounds or salts thereof obtained by the above screening method or the screening kit, pharmaceutical compositions containing the above compound or its salt, and antibodies against the above receptor protein are provided. It is allowable to efficiently screen a galanin receptor agonist or antagonist by using the galanin receptor protein, the partial peptide thereof, the galanin receptor protein-encoding DNA, the receptor protein-containing cell or its membrane fraction. The pharmaceuticals thus screened or characterized permits various applications including prophylactic and/or therapeutic treatments against a variety of diseases, e.g., stomach ulcer, diabetes, Alzheimer's disease, dementia, etc. and a sedative.

EP 0 711 830 A2

Description

FIELD OF THE INVENTION

5 The present invention relates to novel galanin receptor proteins and partial peptides thereof; novel DNAs containing a galanin receptor protein or partial peptide-encoding DNA; processes for producing said galanin receptor protein (or partial peptide); use of said receptor protein (or partial peptide) and said protein (or partial peptide)-encoding DNA; a method of measuring the physiological actions of galanin using a galanin receptor protein-expressing cell or the galanin receptor protein; a method of screening galanin receptor agonists/antagonists using the galanin receptor protein-expressing cell or galanin receptor protein; a kit for said screening; an agonist or antagonist obtained by said screening method; and a pharmaceutical composition containing said agonist or antagonist.

10 The present invention also relates to a novel mouse pancreatic β cell line MIN6-derived galanin receptor protein and a partial peptide thereof; a novel DNA coding for said mouse galanin receptor protein or its partial peptide; processes for producing said mouse galanin receptor protein or its partial peptide; use of said mouse galanin receptor protein and said protein or peptide-encoding DNA; a method of measuring the physiological actions of galanin using a mouse-derived cell line MIN6 or the mouse galanin receptor protein; and a method of screening a galanin receptor agonist/antagonist using said mouse-derived cell line MIN6 or the receptor protein.

15 The present invention also relates to a novel human galanin receptor protein; a partial peptide of the human galanin receptor protein; a novel DNA which codes for the galanin receptor protein or partial peptide; a vector carrying said DNA; a transformant harboring said vector; a process for producing the human galanin receptor protein (or its partial peptide); a method of screening a galanin receptor agonist/antagonist using the human galanin receptor protein or a human galanin receptor protein-expressing cell (including the transformant); a kit for said screening; an agonist or an antagonist, obtained by said screening method; and a pharmaceutical composition containing said agonist or antagonist.

25 BACKGROUND OF THE INVENTION

A variety of hormones, neurotransmitters and the like control, regulate or adjust the functions of living bodies via specific receptors located in cell membranes. Many of these receptors mediate the transmission of intracellular signals via activation of a guanine nucleotide-binding protein (hereinafter, sometimes referred to as "G protein") with which the receptor is coupled and possess the common (homologous) structure, i.e. seven transmembranes (membrane-spanning regions (domains)). Therefore, such a receptor is generically referred to as "G protein coupled receptor" or "seven transmembrane (membrane-spanning) receptor".

30 G protein coupled receptor proteins which are widely distributed in the functional cellular surface of cells and organs in the living bodies have a very important role as targets for molecules such as hormones, neurotransmitters and physiologically active substances, which molecules control, regulate or adjust the functions of living bodies.

35 The pancreas plays an important role of carrying out the carbohydrate metabolism by secreting not only a digestive fluid but also glucagon and insulin. Insulin is secreted from the β cells and its secretion is promoted chiefly by glucose. It has been known that a variety of receptors exist in the β cells, and the secretion of insulin is controlled by various factors such as peptide hormones (galanin, somatostatin, gastric inhibitory polypeptide, glucagon, amylin, etc.), sugars (mannose, etc.), amino acids, and neurotransmitters in addition to glucose. As for the galanin and amylin, however, there has not yet been reported any discovery concerning the structure of their receptor protein cDNA. It is not known whether there exist any unknown receptor proteins or receptor protein subtypes.

40 It is a very important means in investigating development of new pharmaceuticals to clarify the relation between substances controlling the complicated functions of pancreas and specific receptors thereto. In order to develop new pharmaceuticals by conducting an effective screening of agonists and antagonists to the receptor proteins for controlling the functions of pancreas, it was necessary to investigate the function of receptor protein genes and also to express them in a suitable expression system.

45 By utilizing the fact that a G protein coupled receptor protein exhibits homology in part of the structure thereof at the amino acid sequence level, an experiment of looking at DNAs coding for novel receptor proteins relying upon a polymerase chain reaction (hereinafter simply referred to as "PCR") has recently been made.

50 Galanin is a peptide existing in central and peripheral areas and, in central area, it shows an action of inhibition of liberation of neurotransmitter (acetylcholine) (European Journal of Pharmacology, vol.164, 355-360, 1989) and an action of antagonizing foreign acetylcholine (Proceedings of National Academy of Sciences, U.S.A., vol.85, 9841-9845, 1988) while, in pancreas, it shows a pharmacological action such as inhibition of insulin secretion (Diabetes, vol. 34, 192-196, 1985). It has been also confirmed that galanin has an effect of inhibiting the behavior of learning (Neuroscience Letters, vol.88, 331-335, 1988) and of inhibiting the feeling of fullness after a meal. Such findings suggest a possibility that, if pharmaceuticals which inhibit the action of galanin are developed, they may be used as intelligence tropic agents and as remedies for obesity and for diabetes.

All of the pharmacological actions of galanin take place via a specific galanin receptor existing in target tissues. Accordingly, the simplest means for inhibiting the action of galanin is to develop pharmaceuticals which specifically inhibit the reaction of galanin with the receptor, i.e. galanin receptor antagonists. In the development of galanin receptor antagonists, it is usually necessary to conduct a receptor binding experiment. In the case of galanin, experiments on galanin receptor binding using membrane fractions of brain hippocampal formation (European Journal of Biochemistry, vol. 181, 269-276, 1989) and of stomach and duodenum (Peptides, vol. 11, 333-338, 1990) have been reported already.

It has been also reported that there is a specific galanin receptor in Rin-m-5F cells obtained from rat pancreas (Endocrinology, vol. 124, 2635-2641, 1989). According to the above-mentioned reports, it is already possible to conduct a galanin receptor binding experiment. However, the amount of the galanin receptor in those membrane fractions is as

low as around 50 fmol/mg and, therefore, it was necessary to use a large amount of cell fractions for one measurement. Galanin exhibits the above-mentioned pharmacological actions in living body and, if the actions can be easily measured *in vitro*, that will be meaningful for the process of developing the receptor antagonists. It has been reported already that the action of inhibiting the insulin secretion by galanin can be substituted with an *in vitro* measurement using Langerhans islet isolated from pancreas (European Journal of Pharmacology, Vol. 203, 111-114, 1991). However, Langerhans island is required to be isolated upon each experiment and, therefore, this method is not easily accomplished.

As easier means, several methods using pancreatic β -cell strains (Rin-m-5F cells) have reported. They are, for example, a method in which an effect of galanin receptor to a second messenger system (i.e. an activity of inhibiting the adenylate cyclase) is measured (European Journal of Biochemistry, Vol. 177, 147-152, 1988) and a method in which an activity of opening the potassium channel is measured (Proceedings of National Academy of Sciences, U.S.A., Vol. 85, 1312-1316, 1988). A method in which the activity of inhibiting the insulin secretion of galanin using said cell strain has been reported too. However, those methods are applicable only for insulin secretion which is dependent upon forskolin (an adenylate cyclase activator) and the measurement for secretion of glucose-dependent insulin is not possible. Further, the secretion amount of insulin is small and the sensitivity is low.

After those, a method of preparing the β -cell strains using pancreas of transgenic mice (Proceedings of National Academy of Sciences, U.S.A., Vol. 85, 9037-9041, 1988) has been developed and establishments of cell strains such as β TC-1 cells (Proceedings of National Academy of Sciences, U.S.A., Vol. 85, 9037-9041, 1988), IgSV 195 cells (Diabetes, Vol. 38, 1056-1062, 1989) and MIN6 cells (Endocrinology, Vol. 127, 126-132, 1990) have been reported. Among those, MIN6 cells hold the ability of insulin secretion depending upon the glucose concentration (which is a differentiating function inherent to β -cells) in the best manner and, in addition, they secrete insulin in a high amount. However, it has not been known yet that galanin receptor protein is expressed in said MIN6 cells. In addition, there has been no proposal yet for an evaluating system for the biological activity of galanin and also for an effective method for screening the galanin receptor agonist or antagonist using the MIN6 cells.

Recently, cDNA which codes for human galanin receptor protein was cloned and its nucleotide sequence and also its amino acid sequence encoded by said cDNA have been disclosed (Proceedings of National Academy of Sciences, U.S.A., Vol. 91, 9780-9783, October 11, 1994). However, there is no disclosure at all for a specific means for screening the galanin receptor agonist/antagonist using said receptor. Under such circumstances, a method for screening and assessing galanin receptor agonist/antagonist in an efficient manner is still desired.

Galanin is a polypeptide comprising 29 amino acid residues separated from porcine small intestine [Tatemoto, K. et al., FEBS Letter, 164, 124-128(1983)] and its primary structure is hardly similar to those of other brain and intestinal hormones. Galanin immunoactivity is widely distributed in central nervous system and peripheral nervous system together with its receptor [Schoffitsch, G. and Jacobowitz, D. M., Peptides, 6, 509-546(1985); Melander, T. et al., Journal of Comparative Neurology, 248, 475-517(1986); Rokaeus, A., Trends in Neuroscience, 10, 158-164(1987)] and, since its distribution pattern is identical with the region containing the traditional neurotransmitters such as 5-HT, noradrenaline and acetylcholine, it is likely that galanin is present together with such neurotransmitters and controls the preneurotransmission and postneurotransmission actions by those neurotransmitters.

Galanin has many physiological actions and, in central nervous system, it strongly inhibits the single synaptic reflection in spinal nerve [Yanagisawa, M. et al., Neuroscience Letter, 70, 278-282(1986)] and its action is known to be far stronger than somatostatin. In addition, the physiological importance of galanin in nerve center has been greatly suggested because of stimulation of action for taking food [Kyrokoili, S. E. et al., European Journal of Pharmacology, 122, 159-160(1986)], participation in formation of memory [Crawley, J. N. and Wenk, G. L., Trends in Neuroscience, 12, 278-282(1989)], inhibition of dopamine in median elevation [Nordstrom, O. et al., Neuroscience Letter, 73, 21-26(1987)], inhibition of release of acetylcholine in hippocampal double sides [Fisone, G. et al., Proceedings of the National Academy of Sciences of U. S. A., 84, 7339-7343(1987)], a decrease in metabolic circulation of 5-HT [Fuxe K., et al., Acta. Physiol. Scand., 133, 579-581(1988)] and a decrease in a glutamic acid release by activation of ATP-sensitive K^+ channel [Ben-Ari, Y., European Journal of Neuroscience, 2, 62-68(1990)] as a result of administration of galanin to paraventricular nucleus of rats.

Especially, galanin is an only neuropeptide in which choline acetyltransferase is coexisting in the medial septal nucleus, nucleus of diagonal band and basal nucleus [Melander, T. et al., Brain Research, 360, 130-138(1985); Melander, T. et al., Neuroscience Letter, 19, 223-240(1986); Chen-Palay, V., Brain Research Bulletin, 21, 465-472(1988)] and is

known to act on cholinergic nerves in an inhibiting manner while, on the other hand, it is expected that, since denaturation in cholinergic nerves is noted in those sites in Alzheimer's disease, galanin antagonist may prevent the denaturation of the cholinergic nerves in Alzheimer's disease or the like [Whitehouse, P. J., et al., Science, 215, 1237-1239(1982); Chen-Palay, V., Journal of Comparative Neurology, 273-543-557 (1988)]. In hypophysis, action of stimulating the secretion of growth hormones and prolactin has been noted [Tanoh, T., et al., Neuroendocrinology, 54, 83-88(1991); Koshiyama, H., et al., Neuroscience Letter, 75, 49-54(1987)]. Particularly in the secretion of growth hormones, participation of cholinergic neuron via adjustment of secretion of hypothalamic somatostatin is noted.

On the other hand, in peripheral systems, galanin inhibits the basal secretion of insulin both *in vivo* and *in vitro* [McDonald, T. J. et al., Diabetes, 34, 192-196(1985); Takeda, Y. et al., Biomedical Research, 8 (Suppl.), 117-125 (1987); Lindskog, S. et al., Acta. Physiol. Scand., 129, 305-309(1987)] and, in addition, it inhibits the release of insulin by stimulation of glucose [Dunning, B. E. and Taborsky, G. J., Jr., Diabetes, 37, 1157-1162(1988)]. When further immunohistological observation that nerve fiber net containing a dense galanin immunoactivity is noted around Langerhans islet of β cells is taken into consideration, it has been strongly suggested that galanin is one of the nerve controlling factors for secretion of pancreatic hormones, especially insulin. It is also noted that, in stomach, galanin inhibits the basal secretion of somatostatin on a dose-depending manner or it inhibits the secretion of somatostatin or gastrin by stimulation of GRP and that nerve fiber net containing galanin immunoactivity is observed in stomach and, accordingly, it is suggested that, even in stomach, galanin acts as one of the important nerve controlling factors for adjusting the secretion in stomach [Yanaihara, N. et al., in "Galanin" (ed. by Høkfelt, T. et al.), Macmillan Press, 185-196(1991)].

From the above descriptions, it is understood that galanin agonist is useful as a pharmaceutical agent such as a stimulant for secretion of growth hormones and an inhibitor for secretion of insulin and that galanin antagonist is useful as another pharmaceutical agent such as an inhibitor for secretion of growth hormones and a stimulant for secretion of insulin.

Usually, in developing agonists and antagonists for physiologically-active substances, investigations are made on the compounds which have high affinity with the receptors to which said substance is specifically bonded. At present, bovine hippocampal membrane fraction is used as a galanin receptor but, because of the difference in the animal species used, there is no guarantee that the compound exhibiting a high affinity to said membrane fraction has a high affinity to human galanin receptor as well. Human galanin receptor cDNA has been cloned and reported to exhibit an expression in COS cells [Habert-Ortoll, E. et al., Proceedings of the National Academy of Sciences, U. S. A., 91, 9780-9783(1994)] but, since the expressed amount is small and the expression is mere transient, it is thought to be unsuitable for screening.

SUMMARY OF THE INVENTION

One object of the present invention is to provide novel galanin receptor proteins and partial peptides thereof or salts thereof; DNAs comprising a DNA coding for said galanin receptor protein or its partial peptide; vectors carrying said DNA; transformants harboring said vector; cell membrane fractions obtained from said transformant; processes for producing said receptor protein or its partial peptide, or a salt thereof; methods for measuring the physiological actions of galanin using the galanin receptor protein (including a cell membrane fraction containing the receptor protein) or a galanin receptor protein-expressing cell (including the transformant); screening methods for a galanin receptor agonist/antagonist using the galanin receptor protein or a galanin receptor protein-expressing cell (including the transformant); kits for said screening; agonists or antagonists, obtained by said screening method; pharmaceutical compositions containing said agonist or antagonist; antibodies against said receptor protein; immunoassays using said receptor protein or said antibody; and use of said receptor protein and encoding DNA.

Another object of the present invention is to provide novel mouse pancreatic β cell line MIN6-derived galanin receptor proteins or partial peptides thereof; DNAs comprising a DNA coding for said galanin receptor protein or partial peptide; processes for producing said receptor protein or its partial peptide; methods of measuring the physiological actions of galanin using a mouse-derived cell line MIN6 or the galanin receptor protein; screening methods for a galanin receptor agonist/antagonist using said mouse-derived cell line MIN6 or the receptor protein; antibodies against said receptor protein; immunoassays using said receptor protein or said antibody; and use of said galanin receptor protein or said receptor protein peptide-encoding DNA.

Human galanin receptor proteins manufactured by the conventional method and the COS cells which express said human galanin receptor protein are insufficient as receptor samples for conducting a screening for galanin receptor agonist/antagonist. Consequently, there has been a demand for developing a more practical method for manufacturing human galanin receptor proteins.

If it is possible to screen the agonist/antagonist of galanin receptor using human galanin receptor protein, it is now possible to overcome the disadvantage by the use of experimental animals (for example, the possibility that, due to a difference in species, compounds which do not achieve an effect to human being may be obtained) whereby it is expected to conduct a development of pharmaceutical agents effective to human being in an efficient manner.

Yet another object of the present invention is to provide novel human galanin receptor proteins; partial peptides of the human galanin receptor protein; novel DNAs which code for the galanin receptor protein or partial peptide; vectors

carrying said DNA; transformants harboring said vector; cell membrane fractions obtained from said transformant; processes for producing the human galanin receptor protein (or its partial peptide); methods for measuring the physiological actions of galanin using a human galanin receptor protein-expressing cell, said human galanin receptor protein; screening methods for a galanin receptor agonist/antagonist using a human galanin receptor protein-expressing cell (including the transformant); kits for said screening; agonists or antagonists, obtained by said screening method; pharmaceutical compositions containing said agonist or antagonist; antibodies against said human galanin receptor protein; immunoassays using said receptor protein or said antibody; and use of said human galanin receptor protein and encoding DNA.

In order to achieve the above-mentioned aims, the present inventors have made extensive investigations. As a result, the present inventors have succeeded in synthesizing DNA primers effective in efficiently isolating DNAs (DNA fragments) coding for G protein coupled receptor proteins by PCR techniques. The present inventors have succeeded in amplifying cDNA derived from various cells with said synthetic DNA primer, and have forwarded the analysis. Thus, the present inventors have succeeded in isolating novel G protein coupled receptor protein-encoding cDNAs, in determining the partial structure thereof, and have considered that the isolated cDNAs are homologous to known G protein coupled receptors at the nucleotide sequence level and at the amino acid sequence level and are each coding for a novel galanin receptor protein. Based upon the above knowledge, the present inventors have discovered that these DNAs make it possible to obtain a cDNA having a full length open reading frame (ORF) of the receptor protein, hence, to produce the receptor protein. The inventors have further succeeded in sequencing an entire amino acid sequence and entire nucleotide sequence of said galanin receptor protein.

The present inventors have found that, when said receptor protein expressed by a suitable means is used, an agonist or an antagonist to said receptor protein can be screened *in vivo* or from natural or nonnatural compounds by a receptor protein binding experiment or by a measurement of intracellular second messenger as an index. The present inventors have further found that said agonist and antagonist can be developed as preventive and therapeutic agents for the diseases or symptoms related to or caused by galanin.

The present inventors have furthermore found that the glucose or forskolin-dependent insulin secretion in cells expressing said galanin receptor protein is inhibited by galanin. That has been a finding for the first time. Depending upon said finding, the present inventors have found an easy and simple method for measuring the activity of galanin and galanin antagonist. At the same time, the present inventors have also found that the cell membrane fractions of cells expressing said galanin receptor protein contain large amount of galanin receptors and succeeded in establishing a screening for galanin receptor agonist/antagonist using the cell membrane fractions thereof.

For example, the present inventors have amplified G protein coupled receptor protein-encoding cDNA derived from mouse pancreatic β -cell strain MIN6 using a synthetic DNA primer for more effective isolation thereof, whereby its analysis has been carried out.

As a result thereof, the present inventors have succeeded in isolating the mouse-derived cDNA fragment which codes for a novel G protein coupled receptor protein and in elucidating its partial structure. In said mouse-derived G protein coupled receptor protein, there are similarities (homologies) at DNA and amino acid levels to the known G protein coupled receptor and, therefore, it is believed that it codes for a novel receptor protein exhibiting an expressing function in mouse pancreas.

The present inventors further continued their studies and have succeeded in cloning cDNA having a full-length translation unit and in analyzing an entire amino acid sequence and an entire nucleotide sequence of said receptor protein. Since said mouse-derived G protein coupled receptor protein has a high homology at DNA and amino acid levels to the human-derived galanin receptor protein (Proceedings of National Academy of Sciences, U.S.A., 91, 9780-9783, 1994), it has been found that said mouse-derived G protein coupled receptor protein is identical with a mouse-derived galanin receptor protein.

Furthermore, the present inventors have newly found that the glucose or forskolin-dependent insulin secretion of MIN6 cells is inhibited by galanin. Based upon said finding, the present inventors have found an easy and simple method for measuring the activity of galanin and galanin antagonist. At the same time, the present inventors have also found that the cell membrane fractions of MIN6 cells contain large amount (0.5-1.0 pmol/mg) of galanin receptor and succeeded in establishing a method of screening galanin receptor agonist/antagonist using the cell membrane fractions of MIN6 cells.

To be more specific, the present inventors have amplified and cloned novel cDNA fragments derived from mouse pancreatic β -cell strain MIN6 as shown in FIG. 1 by PCR and, from the result of analysis of their sequence, have clarified that they code for a novel receptor protein. When said sequence was translated into amino acid sequences, third, fourth, fifth and sixth transmembrane domains were confirmed on hydrophobic plots (FIG. 2). The size of the amplified DNA was about 400 bp which was almost same as that of the known G protein coupled receptor protein.

The inventors have retrieved the data base based on, as a template, the nucleotide sequence of the isolated DNA and observed 36% homology to human-derived somatostatin receptor subtype 4 (JN0605), 30% homology to human-derived somatostatin receptor subtype 2 (B41795), and 30% homology to rat-derived ligand unknown receptor (A39297), respectively (FIG. 3), which are known G protein coupled receptor proteins. The aforementioned abbreviations in paren-

theses are reference numbers that are assigned when they are registered as data to NBRF-PIR/Swiss-PROT and are, usually, each called "Accession Number" or "Entry Name".

Moreover, the present inventors have prepared cDNA from the poly(A)⁺RNA fractions extracted from MIN6 cells and have inserted said cDNA into lambda gt22 phage to prepare a cDNA library. Further, the present inventors have screened the cDNA library using, as a probe, the G protein coupled receptor protein cDNA fragment p3H2-34 obtained by PCR and succeeded in cloning cDNA which completely codes for the G protein coupled receptor protein of the present invention. A nucleotide sequence of said cDNA and an amino acid sequence encoded thereby are given in FIG. 4. A hydrophobic plotting was conducted based upon said amino acid sequence and the first, second, third, fourth, fifth, sixth and seventh transmembrane domains were confirmed (FIG. 5). The G protein coupled receptor protein of the present invention has 92% homology at the amino acid level to the known human galanin receptor protein.

In another aspect, the present inventors have succeeded, for example, in cloning a DNA which codes for novel human galanin receptor protein having an amino acid sequence which differs from that of known human galanin receptor protein. In the known human galanin receptor protein, the fifteenth amino acid in its amino acid sequence is Cys while, in the human galanin receptor protein of the present invention, the fifteenth amino acid in its amino acid sequence (SEQ ID NO: 5 and FIGs. 12 & 13) is Trp. In addition, in the nucleotide sequence of DNA which codes for the known human galanin receptor protein, the base sequence which codes for the fifteenth amino acid of said human galanin receptor protein is ¹⁵Cys (TGT) while, in the base sequence of DNA which codes for the human galanin receptor protein of the present invention, the base sequence which codes for the fifteenth amino acid in said human galanin receptor protein is ¹⁵Trp (TGG).

The present inventors have further succeeded in manufacturing a CHO cell strain which expresses far more amount of the human galanin receptor protein of the present invention than the COS cells which express the known human galanin receptor protein [Habert-Ortoll, E. et al., Proceedings of the National Academy of Sciences of the U. S. A., 91, 9780-9783 (1994)]. It has been furthermore found that, when said CHO cell strain of the human galanin receptor protein of the present invention or partial peptide thereof is used, it is now possible to screen the human galanin receptor agonist/antagonist in an effective and reliable manner. Based upon those findings, the present inventors have continued various investigations and, as a result, they have achieved the present invention.

Accordingly, one aspect of the present invention is

- (1) a galanin receptor protein comprising an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 5 and substantial equivalents thereto, or a salt thereof;
- (2) the receptor protein according to the above (1), which is produced by a transformant CHO cell;
- (3) a DNA which comprises a nucleotide sequence coding for a galanin receptor protein of the above (1);
- (4) a vector comprising the DNA according to the above (3);
- (5) a transformant carrying the vector according to the above (4);
- (6) the transformant according to the above (5), wherein the host cell is a CHO cell;
- (7) a process for producing a galanin receptor protein according to the above (1), which comprises culturing a transformant of the above (5) under conditions suitable to express said galanin receptor protein;
- (8) a screening method for an agonist or antagonist of a galanin receptor protein according to the above (1), which comprises carrying out a comparison between:

- (i) at least one case where galanin is contacted with at least one component selected from the group consisting of a galanin receptor protein according to the above (1), a partial peptide thereof and a mixture thereof,

and

- (ii) at least one case where galanin together with a compound to be tested is contacted with at least one component selected from the group consisting of a galanin receptor protein according to the above (1), a partial peptide thereof and a mixture thereof;

- (9) a kit for the screening of one or more agonists or antagonists to a galanin receptor protein according to the above (1), which comprises at least one component selected from the group consisting of a galanin receptor protein according to the above (1), a partial peptide thereof and a mixture thereof; and
- (10) an agonist or antagonist of a galanin receptor, which is obtained by the screening method according to the above (8) or by the kit according to the above (9).

Another aspect of the present invention is

- (11) a mouse-derived galanin receptor protein comprising an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1 and substantial equivalents thereto; or a salt thereof;
- (12) a mouse-derived galanin receptor protein according to the above (11), which comprises an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 2 and substantial equivalents thereto; or a salt thereof;
- (13) a human galanin receptor protein comprising an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 5 and substantial equivalents thereto; or a salt thereof;
- (14) a partial peptide of a galanin receptor protein according to the above (1), or a salt thereof;
- (15) a partial peptide of a mouse-derived galanin receptor protein according to the above (11) or (12), or a salt thereof;
- (16) a partial peptide of a human galanin receptor protein according to the above (13), or a salt thereof;
- (17) a DNA which comprises a nucleotide sequence coding for a mouse-derived galanin receptor protein of the above (11) or (12);
- (18) a DNA which comprises a nucleotide sequence coding for a human galanin receptor protein of the above (13);
- (19) a DNA of the above (17) comprising a nucleotide sequence represented by SEQ ID NO: 3;
- (20) a DNA of the above (17) comprising a nucleotide sequence represented by SEQ ID NO: 4;
- (21) a DNA of the above (18) comprising a nucleotide sequence represented by SEQ ID NO: 6;
- (22) a vector comprising a DNA according to the above (17);
- (23) a vector comprising a DNA according to the above (18);
- (24) a transformant (including a transfectant) carrying a vector of the above (22);
- (25) a transformant (including a transfectant) carrying a vector of the above (23);
- (26) a process for producing a mouse-derived galanin receptor protein or a salt thereof according to the above (11), which comprises culturing a transformant of the above (24) to produce said galanin receptor on the membrane of the transformant;
- (27) a process for producing a human galanin receptor protein or a salt thereof according to the above (13), which comprises culturing a transformant of the above (25) under conditions to express said galanin receptor;
- (28) a cell or membrane fraction containing a galanin receptor protein according to the above (1);
- (29) a cell or membrane fraction containing a mouse-derived galanin receptor protein according to the above (11) or (12);
- (30) a cell or membrane fraction containing a human galanin receptor protein according to the above (13);
- (31) a screening method for a galanin receptor agonist and/or antagonist, which comprises using a galanin receptor protein according to the above (1), a partial peptide according to the above (14) or a cell or membrane fraction according to the above (28);
- (32) a screening method for a mouse-derived galanin receptor agonist and/or antagonist, which comprises using a mouse-derived galanin receptor protein according to the above (11) or (12), a partial peptide according to the above (15) or a cell or membrane fraction according to the above (29);
- (33) a screening method for a human galanin receptor agonist and/or antagonist, which comprises using a human galanin receptor protein according to the above (13), a partial peptide according to the above (16) or a cell or membrane fraction according to the above (30);
- (34) a screening method for a galanin receptor agonist and/or antagonist, which comprises carrying out a comparison between:

(i) at least one case where galanin is contacted with at least one component selected from the group consisting of a galanin receptor protein or a salt thereof according to the above (1), a partial peptide or a salt thereof according to the above (14), a cell or membrane fraction according to the above (28), and a mixture thereof,

and

(ii) at least one case where galanin together with a sample (including a compound) to be tested is contacted with at least one component selected from the group consisting of a galanin receptor protein or a salt thereof according to the above (1), a partial peptide or a salt thereof according to the above (14), a cell or membrane fraction according to the above (28), and a mixture thereof;

(35) a screening method for a mouse-derived galanin receptor agonist and/or antagonist, which comprises carrying out a comparison between:

(i) at least one case where galanin is contacted with at least one component selected from the group consisting of a mouse-derived galanin receptor protein or a salt thereof according to the above (11), a partial peptide or a salt thereof according to the above (15), and a mixture thereof,

and

(ii) at least one case where galanin together with a sample (including a compound) to be tested is contacted with at least one component selected from the group consisting of a mouse-derived galanin receptor protein or a salt thereof according to the above (11), a partial peptide or a salt thereof according to the above (15), and a mixture thereof;

(36) a screening method for a human galanin receptor agonist and/or antagonist, which comprises carrying out a comparison between:

(i) at least one case where galanin is contacted with at least one component selected from the group consisting of a human galanin receptor protein or a salt thereof according to the above (13), a partial peptide or a salt thereof according to the above (16), a cell or membrane fraction according to the above (30), and a mixture thereof,

and

(ii) at least one case where galanin together with a sample (including a compound) to be tested is contacted with at least one component selected from the group consisting of a human galanin receptor protein or a salt thereof according to the above (13), a partial peptide or a salt thereof according to the above (16), a cell or membrane fraction according to the above (30), and a mixture thereof;

(37) a kit for the screening of a galanin receptor agonist and/or antagonist, which comprises at least one component selected from the group consisting of a galanin receptor protein or a salt thereof according to the above (1), a partial peptide or a salt thereof according to the above (14), a cell or membrane fraction according to the above (28), and a mixture thereof;

(38) a kit for the screening of a mouse-derived galanin receptor agonist and/or antagonist, which comprises at least one component selected from the group consisting of a mouse-derived galanin receptor protein or a salt thereof according to the above (11) or (12), a partial peptide or a salt thereof according to the above (15), a cell or membrane fraction according to the above (29), and a mixture thereof;

(39) a kit for the screening of a human galanin receptor agonist and/or antagonist, which comprises at least one component selected from the group consisting of a galanin receptor protein or a salt thereof according to the above (13), a partial peptide or a salt thereof according to the above (16), a cell or membrane fraction according to the above (30), and a mixture thereof;

(40) a galanin receptor agonist and/or antagonist, obtained by a method according to any of the above (31) to (36) or a kit according to any of the above (37) to (39);

(41) a galanin receptor agonist and/or antagonist, obtained by a method according to the above (32) or (35) or a kit according to the above (38);

(42) a galanin receptor agonist and/or antagonist, obtained by a method according to the above (33) or (36) or a kit according to the above (39);

(43) a pharmaceutical composition comprising an effective amount of the galanin receptor agonist according to (40);

(44) a pharmaceutical composition comprising an effective amount of the galanin receptor agonist according to (41);

(45) a pharmaceutical composition comprising an effective amount of the galanin receptor agonist according to (42);

(46) a pharmaceutical composition comprising an effective amount of the galanin receptor antagonist according to (40);

(47) a pharmaceutical composition comprising an effective amount of the galanin receptor antagonist according to (41);

(48) a pharmaceutical composition comprising an effective amount of the galanin receptor antagonist according to (42);

(49) a pharmaceutical composition according to (43) which is an inhibitor for acetylcholine liberation, an inhibitor for insulin secretion, a stimulant for growth hormone secretion, an inhibitor for learning behavior or satiety;

(50) a pharmaceutical composition according to (46) which is an agent for promoting the acetylcholine liberation, an agent for inhibiting the growth hormone secretion, an agent for promoting the insulin secretion, an agent for promoting the learning behavior or an agent for promoting satiety;

(51) an antibody against at least one component selected from the group consisting of a galanin receptor protein or a salt thereof according to the above (1) and a partial peptide or a salt thereof according to the above (14);

(52) an antibody against at least one component selected from the group consisting of a mouse-derived galanin receptor protein or a salt thereof according to the above (11) or (12) and a partial peptide or a salt thereof according to the above (15); and

(53) an antibody against at least one component selected from the group consisting of a human galanin receptor protein or a salt thereof according to the above (13) and a partial peptide or a salt thereof according to the above (16).

To be more specific, the present invention relates to the following:

(54) a method of screening a galanin receptor agonist or antagonist, characterized in that, the binding amount of the labeled galanin with the galanin receptor protein or its salt according to (1) (e.g., the mouse-derived galanin receptor protein or its salt according to (11), etc.) or with the partial peptide or its salt according to (14) (e.g., the partial peptide of the mouse-derived galanin receptor protein or its salt according to (15), etc.) is measured in the case where the labeled galanin is contacted with the galanin receptor protein or its salt according to (1) (e.g., the mouse-derived galanin receptor protein or its salt according to (11), etc.) or with the partial peptide or its salt according to (14) (e.g., the partial peptide of the mouse-derived galanin receptor protein or its salt according to (15), etc.) and also in the case where the labeled galanin and the test compound are contacted with the galanin receptor protein or its salt according to (1) (e.g., the mouse-derived galanin receptor protein or its salt according to (11), etc.) or with the partial peptide or its salt according to (14) (e.g., the partial peptide of the mouse-derived galanin receptor protein or its salt according to (15), etc.) and the comparison is made between them;

(55) a method of screening a galanin receptor agonist or antagonist, characterized in that, the labeled galanin is contacted with the cells (except mouse-derived MIN6 cells [FERM BP-4954]) containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) and the labeled galanin and the test compound are contacted with the cells (except mouse-derived MIN6 cells [FERM BP-4954]) containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) and the binding amounts of the labeled galanin with said cells in both cases are measured and compared;

(56) a method of screening a galanin receptor agonist or antagonist, characterized in that, the labeled galanin is contacted with the cell membrane fractions of cells (except mouse-derived MIN6 cells [FERM BP-4954]) containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) and the labeled galanin and the test compound are contacted with the cell membrane fraction of cells (except mouse-derived MIN6 cells [FERM BP-4954]) containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) and the binding amounts of the labeled galanin with the membrane fractions of said cells in both cases are measured and compared;

(57) a method of screening a galanin receptor agonist or antagonist, characterized in that, the labeled galanin is contacted with the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) expressed in cell membranes of the transformant according to (5) (e.g., the mouse-derived galanin receptor protein-expressible transformant according to (24), etc.) by culturing said transformant and the labeled galanin and the test compound are contacted with the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) expressed in cell membranes of the transformant according to (5) (e.g., the mouse-derived galanin receptor protein-expressible transformant according to (24), etc.) by culturing said transformant and the binding amounts of the labeled galanin with said galanin receptor in both cases are measured and compared;

(58) a method of screening a galanin receptor agonist or antagonist, characterized in that, galanin is contacted with the cells (except the mouse-derived MIN6 cells [FERM BP-4954]) containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) and galanin and the test compound are contacted with the cells (except the mouse-derived MIN6 cells [FERM BP-4954]) containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) and the resulting cell-stimulating activities via the galanin receptor protein in both cases are measured and compared;

(59) a method of screening a galanin receptor agonist or antagonist, characterized in that, galanin is contacted with the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) expressed in cell membranes of the transformant according to (5) (e.g., the mouse-derived galanin receptor protein-expressible transformant according to (24), etc.) by culturing said transformant and galanin and the test compound are contacted with the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.) expressed in cell membranes of the transformant according to (5) (e.g., the mouse-derived galanin receptor protein-expressible transformant according to (24), etc.) by culturing said transformant and the resulting cell stimulating activities via the galanin receptor protein are measured and compared;

(60) a method of screening according to (58) or (59) in which the cell-stimulating activity is an activity which accelerates or inhibits arachidonic acid liberation, acetylcholine liberation, intracellular Ca^{2+} liberation, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos, a decrease in pH, insulin secretion, etc. (especially the activity which accelerates or inhibits the intracellular cAMP production or insulin secretion);

(61) a galanin receptor agonist or antagonist obtained by a screening methods according to any of (31), (34) (e.g., (32), (35), etc.) and (54) to (60);

(62) an agent for inhibiting acetylcholine liberation, insulin secretion, learning behavior or feeling of satiety after a meal characterized in containing the galanin receptor agonist according to (61);

(63) an agent for accelerating acetylcholine liberation, insulin secretion, behavior of learning or feeling of fulfillment after a meal characterized in containing the galanin receptor antagonist according to (61);

(64) an intelligence tropic agent or a remedy for obesity or for diabetes characterized in containing the galanin receptor antagonist according to (40) (e.g., (41), etc.) or (61);

(65) a kit for screening according to (37) (e.g., (38), etc.), characterized in comprising a cell containing the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.);

(66) a kit for screening according to (37) (e.g., (38), etc.), characterized in containing the membrane fractions of the cells which contain the galanin receptor protein according to (1) (e.g., the mouse-derived galanin receptor protein according to (11), etc.);

(67) a galanin receptor agonist or antagonist obtained by the use of the kit for screening according to (37) (e.g., (38), etc.), (65) or (66);

(68) an agent for inhibiting acetylcholine liberation, insulin secretion, learning behavior or feeling of fulfillment after a meal characterized in containing the galanin receptor agonist according to (67);

(69) an agent for accelerating acetylcholine liberation, insulin secretion, behavior of learning or feeling of fulfillment after a meal characterized in containing the galanin receptor antagonist according to (67);

(70) an intelligence tropic agent or a remedy for obesity or for diabetes characterized in containing the galanin receptor antagonist according to (40) (e.g., (41), etc.) or (69); and

(71) a method of quantitative determination of the galanin receptor protein or its salt according to (1) (e.g., the mouse-derived galanin receptor protein or its salt according to (11), etc.) or the partial peptide or its salt according to (14) (e.g., the partial peptide of the mouse-derived galanin receptor protein or its salt according to (15), etc.), characterized in that, the antibody according to (51) (e.g., the antibody according to (52), etc.) is contacted with the galanin receptor protein or its salt according to (1) (e.g., the mouse-derived galanin receptor protein or its salt according to (11), etc.) or the partial peptide or its salt according to (14) (e.g., the partial peptide of the mouse-derived galanin receptor protein or its salt according to (15), etc.).

The present invention furthermore provides the following:

(72) a method of measuring the physiological activity of galanin, characterized in that, the biological activity of the mouse-derived MIN6 cells when the mouse-derived MIN cells (FERM BP-4954) or the cell membrane fractions thereof are contacted with galanin;

(73) a method of screening a galanin receptor agonist or antagonist, characterized in that, a comparison is made between the cases where (i) galanin is contacted with the mouse-derived MIN6 cells (FERM BP-4954) or cell membrane fractions thereof and (ii) galanin and the test compound are contacted with the mouse-derived MIN6 cells (FERM BP-4954) or cell membrane fractions thereof;

(74) a kit for screening for a galanin receptor agonist or antagonist characterized in containing the mouse-derived MIN6 cells (FERM BP-4954) or cell membrane fractions thereof;

(75) a galanin receptor agonist or antagonist obtained by the method for screening according to (73) or by the kit for screening according to (74);

(76) an inhibitor for liberation of acetylcholine, an inhibitor for secretion of insulin, an inhibitor for the behavior of learning or an inhibitor for feeling satiety after a meal characterized in containing the galanin receptor agonist according to (75);

(77) an accelerator for liberation of acetylcholine, an accelerator for secretion of insulin, an accelerator for the behavior of learning or an accelerator for feeling satiety after a meal characterized in containing the galanin receptor antagonist according to (75);

(78) a method for screening a galanin receptor agonist or antagonist, characterized in that, the labeled galanin is contacted with the mouse-derived MIN6 cells (FERM BP-4954) and the labeled galanin and the test compound are contacted with the mouse-derived MIN6 cells (FERM BP-4954) and the binding amounts of the labeled galanin with said mouse-derived galanin MIN6 cells in both cases are measured and compared;

(79) a method of screening a galanin receptor agonist or antagonist, characterized in that, the labeled galanin is contacted with the cell membrane fractions of the mouse-derived MIN6 cells (FERM BP-4954) and the labeled galanin and the test compound are contacted with the cell membrane fractions of the mouse-derived MIN6 cells (FERM BP-4954) and the binding amounts of the labeled galanin with said membrane fractions of the mouse-derived MIN6 cells in both cases are measured and compared;

(80) a method of screening a galanin receptor agonist or antagonist, characterized in that, galanin is contacted with the mouse-derived MIN6 cells (FERM BP-4954) and galanin and the test compound are contacted with the mouse-derived MIN6 cells (FERM BP-4954) and the resulting cell-stimulating activities via the mouse-derived galanin recep-

tor (especially the activity of secretion of insulin from MIN6 cells or the activity of inhibiting or accelerating the cAMP production in the MIN6 cells) in both cases are measured and compared;

(81) a method of screening according to the above (80) in which the cell-stimulating activity is an activity for accelerating or inhibiting the arachidonic acid liberation, acetylcholine liberation, intracellular Ca^{2+} liberation, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos, a decrease in pH, secretion of insulin, etc. (especially the activity which accelerates or inhibits the intracellular cAMP production or the insulin secretion);

(82) a galanin receptor agonist or antagonist obtained by a method of screening according to any of (73) and (78) to (81);

(83) an inhibitor for liberation of acetylcholine, an inhibitor for secretion of insulin, an inhibitor for the behavior of learning and an inhibitor for feeling fulfillment after a meal characterized in containing the galanin receptor agonist according to (75) or (82);

(84) an accelerator for liberation of acetylcholine, an accelerator for secretion of insulin, an accelerator for the behavior of learning and an accelerator for feeling satiety after a meal characterized in containing the galanin receptor antagonist according to (75) or (82); and

(85) an intelligence tropic agent or a remedy for obesity or for diabetes characterized in containing the galanin receptor antagonist according to (75) or (82).

Yet another aspect of the present invention is:

(86) a partial peptide according to (16) in which the partial peptide is a region exposed outside the cell membrane of the human galanin receptor protein molecule according to (13);

(87) a vector according to (23) in which the vector is an expression vector for the human galanin receptor protein as indicated by pTS863;

(88) a transformant according to (25) in which the host cell is a CHO cell;

(89) a CHO cell according to (88) in which the CHO cell is CHO/pTS863-5 or CHO/pTS863-7;

(90) a cell or cell membrane fraction thereof according to (30) in which the cell is CHO/pTS863-5 or CHO/pTS863-7;

(91) a method of screening the galanin receptor agonist or antagonist according to (33), which comprises carrying out a comparison between the cases where (i) galanin is contacted with the human galanin receptor protein or salt thereof according to (13) or with the partial peptide or salt thereof according to (16) and (ii) galanin and the test compound are contacted with the human galanin receptor protein or salt thereof according to (13) or with the partial peptide or salt thereof according to (16);

(92) a method of screening the galanin receptor agonist or antagonist according to (33), which comprises measuring and comparing the binding amounts of the labeled galanin to said human galanin receptor protein, partial peptide thereof or salt thereof in the cases where (i) the labeled galanin is contacted with the human receptor protein or salt thereof according to (13) or with the partial peptide or salt thereof according to (16) and (ii) the labeled galanin and the test compound are contacted with the human galanin receptor protein or salt thereof according to (13) or with the partial peptide or salt thereof according to (16);

(93) a method of screening the galanin receptor agonist or antagonist according to (33), which comprises carrying out a comparison between the cases where (i) the labeled galanin is contacted with the cell or cell membrane fraction thereof according to (30) and (ii) the labeled galanin and the test compound are contacted with the cell or the cell membrane fraction thereof according to (30);

(94) a method of screening the galanin receptor agonist or antagonist according to (33), which comprises measuring and comparing the binding amounts of the labeled galanin with said cell or cell membrane fraction thereof in the cases where (i) the labeled galanin is contacted with the cell or the cell membrane fraction thereof according to (30) and (ii) the labeled galanin and the test compound are contact with the cell or the cell membrane fraction thereof according to (30);

(95) a method of screening the galanin receptor agonist or antagonist according to (33), which comprises measuring and comparing cell stimulating activities via the recombinant human galanin receptor (for example, activities which promote or inhibit the opening of K^+ channel, closing of N type Ca^{2+} channel, liberation of arachidonic acid, liberation of acetylcholine, variations in intracellular Ca^{2+} concentration, inhibition of intracellular cAMP production, production of inositol phosphate, cell membrane potential changes, phosphorylation of intracellular protein, activation of c-fos, decrease in pH, cell migration activity, secretion of hormones, activation of G protein and cell promulgation, etc.) in the cases where (i) galanin is contacted with the cell or the cell membrane fraction thereof according to (30) and (ii) galanin and the test compound are contacted with the cell or the cell membrane fraction thereof according to (30);

(96) a pharmaceutical composition according to (45) for inhibiting liberation of acetylcholine, inhibiting secretion of insulin, stimulating secretion of growth hormones, inhibiting learning behavior or inhibiting satiety;

(97) a pharmaceutical composition according to (45) which is a prophylactic or therapeutic agent for schizophrenic illness or stomach ulcer or is a sedative;

(98) a pharmaceutical composition according to (48) for promoting the acetylcholine liberation, inhibiting the growth hormone secretion, promoting the insulin secretion, promoting the learning behavior or promoting satiety;

(99) a pharmaceutical composition according to (48) which is a prophylactic and therapeutic agent for diabetes, Alzheimer's disease or dementia;

(100) a preventive and therapeutic agent containing the DNA according to (18) for a galanin receptor protein-deficient disease; and

(101) a preventive and therapeutic agent according to (100) in which the galanin receptor protein-deficient disease is diabetes, Alzheimer's disease or dementia.

Yet another aspect of the present invention is:

(102) a galanin receptor protein according to the above (1) which comprises

an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1, amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are deleted from the amino acid sequence of SEQ ID NO: 1, amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are added to the amino acid sequence of SEQ ID NO: 1, and amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) in the amino acid sequence of SEQ ID NO: 1 are substituted with one or more other amino acid residues, or a salt thereof;

(103) a galanin receptor protein according to the above (1) which comprises

an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 2, amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are deleted from the amino acid sequence of SEQ ID NO: 2, amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are added to the amino acid sequence of SEQ ID NO: 2, and amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) in the amino acid sequence of SEQ ID NO: 2 are substituted with one or more other amino acid residues, or a salt thereof; and

(104) a galanin receptor protein according to the above (1) which comprises

an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 5, amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are deleted from the amino acid sequence of SEQ ID NO: 5, amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are added to the amino acid sequence of SEQ ID NO: 5, and amino acid sequences wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) in the amino acid sequence of SEQ ID NO: 5 are substituted with one or more other amino acid residues, or a salt thereof.

Yet another aspect of the present invention is:

(105) a process according to the above (27), wherein said transformant is produced by transforming a host cell, CHO cell, with a vector comprising a nucleotide sequence coding for a human-derived galanin receptor protein;

(106) a pharmaceutical composition comprising an effective amount of an agonist according to the above (40) or a salt thereof in admixture with a pharmaceutically acceptable diluent, carrier or excipient;

(107) a pharmaceutical composition according to the above (106), which inhibits liberation of acetylcholine, secretion insulin, learning action, or satiety;

(108) a pharmaceutical composition comprising an effective amount of an antagonist according to the above (40) or a salt thereof in admixture with a pharmaceutically acceptable diluent, carrier or excipient;

(109) a pharmaceutical composition according to the above (108), which promotes liberation of acetylcholine, secretion insulin, learning action, or satiety; and

(110) a transformant CHO cell capable of expressing human-derived galanin receptor proteins.

As used herein the term "substantial equivalent(s)" means that the activity of the protein, e.g., nature of the ligand binding activity, and physical characteristics are substantially the same. Substitutions, deletions or insertions of amino acids often do not produce radical changes in the physical and chemical characteristics of a polypeptide, in which case

polypeptides containing the substitution, deletion, or insertion would be considered to be substantially equivalent to polypeptides lacking the substitution, deletion, or insertion. Substantially equivalent substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. The non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the partial nucleotide sequence of the novel receptor protein cDNA clone, p3H2-34, obtained from mouse pancreatic β -cell line, MIN6, by PCR amplification and the amino acid sequence encoded thereby, wherein the underlined parts correspond to the synthetic primers used for the PCR amplification.

FIG. 2 is the hydrophobicity plotting profile, prepared based upon the amino acid sequence shown in FIG. 1, wherein the axis of ordinate represents an index of hydrophobicity, the axis of abscissa represents the number of amino acids and numerals 3 to 6 represent the presence of hydrophobic domains.

FIG. 3 is the partial amino acid sequence encoded by the novel receptor protein cDNA included in p3H2-34, relative to the partial amino acid sequence each of human somatostatin receptor subtype 4 protein (JN0605), human somatostatin receptor subtype 2 protein (B41795) and rat-derived ligand unknown receptor protein (A39297), wherein reverse amino acid residues are in agreement.

FIG. 4 shows the nucleotide sequence of the mouse-derived galanin receptor protein cDNA clone, pMGR20, which has been cloned with, as a probe, the cDNA insert in p3H2-34 and the amino acid sequence encoded thereby.

FIG. 5 is the hydrophobicity plotting profile, prepared based upon the amino acid sequence shown in FIG. 4, wherein the axis of ordinate represents an index of hydrophobic property, the axis of abscissa represents the number of amino acids, and numerals 1 to 7 represent the presence of hydrophobic domains.

FIG. 6 is the amino acid sequence (MOUSEGALRECE) of the mouse-derived galanin receptor protein encoded by pMGR20, relative to the amino acid sequence (HUMAGALAMI) of the human-derived galanin receptor protein, wherein reverse amino acid residues are in agreement.

FIG. 7 is the plotting profile of the binding amounts (PMB) of labeled galanin to MIN 6 cells against the concentrations of standard porcine galanin, rat galanin, galanin (1-16) partial peptide or galanin antagonist (galantide).

FIG. 8 is the plotting profile of the amount of insulin secretion from MIN 6 cells against the amount of galanin.

FIG. 9 is the plotting profile of the amount of insulin secretion from MIN 6 cells against the amount of galanin.

FIG. 10 is the plotting profile of the amount of intracellular cAMP in MIN 6 cells against the amount of galanin.

FIG. 11 is the nucleotide sequence and deduced amino acid sequence (1st to 135th) of the human galanin receptor protein obtained in Example 11.

FIG. 12 is the nucleotide sequence and deduced amino acid sequence (136th to 349th) of the human galanin receptor protein obtained in Example 11.

FIG. 13 is the construction of expression plasmid, pTS863, containing the human galanin receptor protein cDNA obtained in Example 12. The striped region of expression plasmid, pTS863, indicates the human galanin receptor protein cDNA. DHFR; dhfr gene and Amp^r; ampicillin resistant gene.

FIG. 14 depicts a profile of northern blot analysis of poly(A)⁺RNA from mouse tissues, Neuro-2a, and MIN6 cells with p3H2-34. Poly(A)⁺RNA (5 μ g/lane) was denatured by treatment with glyoxal and then electrophoresed on a 1.2% agarose gel. The RNAs were transferred onto a nitrocellulose filter and hybridized with a ³²P-labeled cDNA insert of p3H2-34 as a probe.

Lanes: 1, Neuro-2a; 2, MIN6; 3, intestinal smooth muscle; 4, testis; 5, pancreas; 6, kidney; 7, liver; 8, heart; 9, lung; 10, spleen; 11, thymus; 12, brain.

Arrowheads indicate the sizes of the molecular weight markers.

FIG. 15 illustrates a comparison of porcine [¹²⁵I]galanin binding to CHO cells transformed with or without a mouse galanin receptor cDNA. CHO-MGR20 cells transformed with a full-length translation unit or mock transformed CHO cells were incubated with [¹²⁵I]galanin (100 pM at final concentration) at 37 °C for 1 hr in the absence (open column) or presence (closed column) of unlabeled porcine galanin (1 μ M at final concentration). The amounts of [¹²⁵I]galanin bound are represented as a percentages of the radioactivity remaining on the cells after washing. Values indicated are mean \pm S.E.M. in triplicate.

FIG. 16 is a primary structure comparison of mouse and human galanin receptors. Identical residues are indicated by the vertical line. Putative membrane spanning domains I-VII are boxed.

FIG. 17 depicts a profile of Scatchard analysis of [¹²⁵I]galanin binding to the membranes from CHO cells transformed with the mouse galanin receptor cDNA. Membrane fractions (1 μ g of protein) were incubated with increasing concentrations of porcine [¹²⁵I]galanin for 75 min at 25 °C. The results shown are from one representative experiment performed

in triplicate assays. Each symbol represents the mean value \pm S.E.M. The values for K_d and B_{MAX} were 45 pM and 5 pmol/mg protein, respectively. B, [125 I] galanin bound (pmol/mg protein), B/F, bound to free ratio (pmol/mg protein \cdot nM).

FIG. 18 illustrates a result of competitive experiments on the binding of porcine [125 I] galanin to mouse galanin receptor. Competitions to the porcine [125 I] galanin (100 pM at final concentrations) bindings were examined with unlabeled porcine (Δ), rat (\bullet), human (\blacksquare) galanins, galanin (1-16) (\circ), and M15 (\blacktriangle). Membrane fractions (1 μ g of protein) were incubated with the ligands for 75 min at 25 $^{\circ}$ C. The amounts of [125 I] galanin bound were expressed as percentages against the control. Each symbol represents the mean value \pm S.E.M. of the triplicate assays. IC_{50} values were 0.25 ± 0.03 nM (porcine galanin), 0.25 ± 0.01 nM (rat galanin), 0.43 ± 0.03 nM (human galanin), 0.83 ± 0.01 nM (M15), and 3.6 ± 0.04 nM [galanin-(1-16)], respectively.

FIG. 19 shows a galanin receptor-mediated inhibition of forskolin-stimulated cAMP production. CHO-MGR20 or mock transformed CHO cells were incubated with forskolin (10 μ M) and porcine galanin (0.1 μ M) at 37 $^{\circ}$ C for 30 min. The reaction was terminated by extracting the cells with ice-cold ethanol. The amounts of intracellular cAMP were quantitated by EIA. Values indicated are mean \pm S.E.M. in triplicate assays.

15 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

According to the present invention, galanin receptor proteins and partial peptides thereof or salts thereof; DNAs comprising a DNA coding for said galanin receptor protein or its partial peptide; vectors carrying said DNA; transformants harboring said vector; cell membrane fractions obtained from said transformant; processes for producing said receptor protein or its partial peptide, or a salt thereof; methods for measuring the physiological actions of galanin using the galanin receptor protein (including a cell membrane fraction containing the receptor protein) or a galanin receptor protein-expressing cell (including the transformant); screening methods for a galanin receptor agonist/antagonist using the galanin receptor protein or a galanin receptor protein-expressing cell (including the transformant); kits for said screening; agonists or antagonists, obtained by said screening method; pharmaceutical compositions containing said agonist or antagonist; antibodies against said receptor protein; immunoassays using said receptor protein or said antibody; use of said receptor protein and encoding DNA; etc. may be successfully provided. For example, template DNAs coding for part or all of the polypeptide sequence of galanin receptor protein, can be successfully obtained and various DNA sequences encoding part or all of the polypeptide sequence of galanin receptor protein can be isolated and characterized. Further, galanin receptor proteins, partial peptides derived from the galanin receptor protein, modified derivatives or analogues thereof, and salts thereof are recognized, predicted, deduced, produced, expressed, isolated and characterized. More specifically, DNA sequences comprising each a nucleotide sequence indicated by a SEQ ID NO selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 6 have been isolated and characterized. Galanin receptor proteins comprising each part or all of an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 5 and its substantial equivalents thereto, or a salt thereof.

These galanin receptor proteins are those derived from all cells and tissues (e.g. amygdaloid nucleus, pituitary gland, pancreas, brain (including whole brain, midbrain nigra and other regions), kidney, liver, gonad, thyroid gland, cholecyst, bone marrow, adrenal, skin, muscle, lung, digestive duct, stomach, blood vessel, heart, thymus, spleen, leukocyte, etc.) of warm-blooded animals (e.g. guinea pig, rat, mouse, swine, sheep, cattle, horse, monkey, human being, rabbit, cat, dog, etc.), and any of galanin receptor proteins as long as they comprise an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1, an amino acid sequence represented by SEQ ID NO: 2, an amino acid sequence represented by SEQ ID NO: 5, and substantial equivalents to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 5. These galanin receptor proteins may include proteins having an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1, an amino acid sequence represented by SEQ ID NO: 2, and an amino acid sequence represented by SEQ ID NO: 5, proteins wherein the amino acid sequence thereof is about 90% to 99.9% homologous to an amino acid sequence represented by SEQ ID NO: 1, an amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence represented by SEQ ID NO: 5 and the activity thereof is substantially equivalent to the protein having an amino acid sequence represented by SEQ ID NO: 1, an amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence represented by SEQ ID NO: 5 and the like. The substantially equivalent activity may include ligand binding activity, signal information transmitting, etc. The term "substantially equivalent" or "substantial equivalent" means that the nature of the ligand binding activity and the like is equivalent. Therefore, it is allowable that even differences among grades such as ligand binding affinity grades and ligand binding activity grades and quantitative factors such as molecular weights of receptor proteins are present.

In one embodiment of the present invention, mouse-derived galanin receptor proteins are those derived from all mouse-derived cells and tissues (e.g. amygdaloid nucleus, pituitary gland, pancreas, brain, kidney, liver, gonad, thyroid gland, cholecyst, bone marrow, lung, digestive duct, blood vessel, heart, thymus, spleen, leukocyte, etc.), and any of proteins as long as they comprise an amino acid sequence represented by SEQ ID NO: 1, and substantial equivalents thereto. The mouse-derived galanin receptor proteins may include proteins having an amino acid sequence represented

by SEQ ID NO: 1, proteins wherein the amino acid sequence thereof is about 90% to 99.9% homologous to an amino acid sequence represented by SEQ ID NO: 1 and the activity thereof is substantially equivalent to the protein having an amino acid sequence represented by SEQ ID NO: 1 and the like. The substantially equivalent activity may include ligand binding activity, signal information transmitting, etc. The term "substantially equivalent" or "substantial equivalent" means that the nature of the ligand binding activity and the like is equivalent. Therefore, it is allowable that even differences among grades such as ligand binding affinity grades and ligand binding activity grades and quantitative factors such as molecular weights of receptor proteins are present.

In another embodiment of the present invention, mouse-derived galanin receptor proteins include mouse pancreatic β -cell line, MIN6 (FERM BP-4954)-derived galanin receptor proteins comprising an amino acid sequence represented by SEQ ID NO: 1, etc. Examples of the mouse-derived galanin receptor protein are mouse-derived galanin receptor proteins having an amino acid sequence represented by SEQ ID NO: 1, proteins wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are deleted from the amino acid sequence of SEQ ID NO: 1, proteins wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are added to the amino acid sequence of SEQ ID NO: 1, proteins wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) in the amino acid sequence of SEQ ID NO: 1, are substituted with one or more amino acid residues, etc.

More specific examples of the mouse-derived galanin receptor protein are mouse pancreatic β -cell line, MIN6-derived galanin receptor proteins having an amino acid sequence represented by SEQ ID NO: 2, proteins having a substantial amino acid sequence thereto (for example, the amino acid sequence thereof is about 90% to 99.9% homologous to an amino acid sequence represented by SEQ ID NO: 2), proteins wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are deleted from the amino acid sequence of SEQ ID NO: 2, proteins wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) are added to the amino acid sequence of SEQ ID NO: 2, proteins wherein one or more amino acid residues (preferably from 1 to 30 amino acid residues, more preferably from 1 to 10 amino acid residues) in the amino acid sequence of SEQ ID NO: 2, are substituted with one or more amino acid residues, etc.

In yet another embodiment of the present invention, human galanin receptor proteins are those derived from all human-derived cells and tissues (e.g. stomach, pituitary gland, pancreas, brain (including whole brain, midbrain nigra and other regions), kidney, liver, gonad, thyroid gland, cholecyst, bone marrow, adrenal, skin, muscle, lung, digestive duct, blood vessel, heart, etc.), and any of proteins as long as they comprise an amino acid sequence represented by SEQ ID NO: 5, and substantial equivalents thereto. The human galanin receptor proteins may include proteins having an amino acid sequence represented by SEQ ID NO: 5, proteins wherein the amino acid sequence thereof is about 90% to 99.9% homologous to an amino acid sequence represented by SEQ ID NO: 5 and the activity thereof is substantially equivalent to the protein having an amino acid sequence represented by SEQ ID NO: 5 and the like. The substantially equivalent activity may include ligand binding activity, signal information transmitting, etc. The term "substantially equivalent" or "substantial equivalent" means that the nature of the ligand binding activity and the like is equivalent. Therefore, it is allowable that even differences among grades such as ligand binding affinity grades and ligand binding activity grades and quantitative factors such as molecular weights of receptor proteins are present.

In another embodiment of the present invention, human galanin receptor proteins include human-derived galanin receptor proteins comprising an amino acid sequence represented by SEQ ID NO: 5, etc. Examples of the human galanin receptor protein are human-derived galanin receptor proteins having an amino acid sequence represented by SEQ ID NO: 5, proteins wherein one or more amino acid residues (preferably from 1 to 20 amino acid residues, more preferably from 1 to 10 amino acid residues) are deleted from the amino acid sequence of SEQ ID NO: 5, proteins wherein one or more amino acid residues (preferably from 1 to 20 amino acid residues, more preferably from 1 to 10 amino acid residues) are added to the amino acid sequence of SEQ ID NO: 5, proteins wherein one or more amino acid residues (preferably from 1 to 20 amino acid residues, more preferably from 1 to 10 amino acid residues) in the amino acid sequence of SEQ ID NO: 5, are substituted with one or more amino acid residues, etc.

A portion of the amino acid sequence may be modified (e.g. addition, deletion, substitution with other amino acids, etc.) in the galanin receptor proteins of the present invention.

Furthermore, the galanin receptor proteins of the present invention includes those wherein N-terminal Met is protected with a protecting group (e.g., C₁₋₆ acyl group such as formyl, acetyl, etc.), those wherein the N-terminal side of Glu is cleaved *in vivo* to make said Glu pyroglutaminated, those wherein the intramolecular side chain of amino acids is protected with a suitable protecting group (e.g., C₁₋₆ acyl group such as formyl, acetyl, etc.), conjugated proteins such as so-called "glycoproteins" wherein saccharide chains are bonded, etc.

However, the known human galanin receptor protein having an amino acid sequence in which the fifteenth Trp in the amino acid sequence represented by SEQ ID NO: 5 is substituted with Cys is excluded from the coverage of the human galanin receptor protein of the present invention.

The salt of said galanin receptor protein of the present invention includes preferably physiologically acceptable acid addition salts. Examples of such salts are salts thereof with inorganic acids (e.g. hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts thereof with organic acids (e.g. acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.), etc.

The galanin receptor protein or its salt of the present invention may be manufactured from the tissues or cells of warm-blooded animals by purifying methods which are known *per se* by those skilled in the art or methods similar thereto or may be manufactured by culturing the transformant (or transfectant) (as described herein below) containing galanin receptor protein encoding DNA. The protein or its salt of the present invention may be manufactured by the peptide synthesis as described herein below.

The galanin receptor protein fragment (the partial peptide of said galanin receptor protein) may include, for example, the site which is exposed outside cell membranes, among the galanin receptor protein molecule. Examples of the partial peptide are peptides containing a region which is analyzed as an extracellular area (hydrophilic region or site) in a hydrophobic plotting analysis on the galanin receptor protein. A peptide which partly contains a hydrophobic region or site may be used as well. Further, a peptide which separately contains each domain may be used too although the partial peptide (or peptide fragment) which contains plural domains at the same time will be used as well.

In an embodiment of the present invention, the partial peptide of said mouse-derived galanin receptor protein may include, for example, the site which is exposed outside cell membranes, among the galanin receptor protein molecule. Examples of the mouse-derived galanin receptor partial peptide are peptides containing a region which is analyzed as an extracellular area (hydrophilic region or site) in a hydrophobic plotting analysis on the galanin receptor protein, represented by FIG. 2.

The salt of said galanin receptor partial peptide includes preferably physiologically acceptable acid addition salts. Examples of such salts are salts thereof with inorganic acids (e.g. hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), salts thereof with organic acids (e.g. acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.), etc.

The partial peptide of the galanin receptor protein may be manufactured by synthesizing methods for peptides which are known *per se* by those skilled in the art or methods similar thereto or by cleaving (digesting) galanin receptor proteins by a suitable peptidase. Methods of synthesizing peptide may be any of a solid phase synthesis and a liquid phase synthesis. Thus, a partial peptide (peptide fragment) or amino acids which can construct the protein of the present invention is condensed with the residual part thereof and, when the product has a protective group, said protective group is detached whereupon a desired peptide can be manufactured. Examples of the known methods for condensation and for detachment of protective groups include the following ① to ⑤ :

- ① M. Bodanszky and M. A. Ondetti: Peptide Synthesis, Interscience Publishers, New York (1966).
- ② Schroeder and Luecke: The Peptide, Academic Press, New York, (1965).
- ③ Nobuo Izumiya et al.: Fundamentals and Experiments of the Peptide Synthesis, Maruzen KK, Japan (1975).
- ④ Haruaki Yajima and Shumpei Sakakibara: "Seikagaku Jikken Koza 1" (Experiments of Biochemistry, Part 1), "Tanpakusitu No Kagaku IV" (Chemistry of Protein, IV), p.205 (1977), Japan.
- ⑤ Haruaki Yajima (ed): Development of Pharmaceuticals (Second Series), Vol. 14, Peptide Synthesis, Hirokawa Shoten, Japan.

After the reaction, conventional purifying techniques such as salting-out, extraction with solvents, distillation, column chromatography, liquid chromatography, electrophoresis, recrystallization, etc. are optionally combined so that the protein of the present invention can be purified and isolated. When the protein obtained as such is a free compound, it may be converted to a suitable salt by known methods while, when it is obtained as a salt, the salt may be converted to a free compound or other salt compounds by known methods.

Furthermore, the product may be manufactured by culturing the transformant (transfectant) containing the DNA coding for said partial peptide.

The galanin receptor protein-encoding DNA of the present invention may be any coding DNA as long as it contains a nucleotide sequence coding for a galanin receptor protein which contains an amino acid sequence substantially equivalent to the amino acid sequence having SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 5 and/or which has an activity substantially equivalent to the amino acid sequence having SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 5, provided that the known galanin receptor protein wherein 15th Trp in the amino acid sequence of SEQ ID NO: 5 is replaced with Cys is excluded.

The DNA of the present invention may be any one of a genome DNA, a genome DNA library, a tissue and cell-derived cDNA, a tissue and cell-derived cDNA library and a synthetic DNA. The vector used for the library may include bacteriophage, plasmid, cosmid, phagemid, etc. The DNA can be further amplified directly by the reverse transcriptase

polymerase chain reaction (hereinafter briefly referred to as "RT-PCR") using mRNA fractions prepared from tissues and cells.

In an embodiment, the DNA coding for the mouse-derived galanin receptor protein may be any coding DNA as long as it contains a nucleotide sequence coding for a mouse-derived galanin receptor protein which contains an amino acid sequence substantially equivalent to the amino acid sequence having SEQ ID NO: 1 and/or which has an activity substantially equivalent to the amino acid sequence having SEQ ID NO: 1. Examples of the DNA coding for the mouse-derived galanin receptor protein comprising the amino acid sequence of SEQ ID NO: 1 includes DNA having a nucleotide sequence represented by SEQ ID NO: 3, etc. The DNA coding for the mouse-derived galanin receptor protein comprising the amino acid sequence of SEQ ID NO: 2 includes DNA having a nucleotide sequence represented by SEQ ID NO: 4, etc.

In another embodiment, the DNA coding for the human galanin receptor protein may be any coding DNA as long as it contains a nucleotide sequence coding for a human-derived galanin receptor protein which contains an amino acid sequence substantially equivalent to the amino acid sequence having SEQ ID NO: 5 and/or which has an activity substantially equivalent to the amino acid sequence having SEQ ID NO: 5, provided that the known human galanin receptor protein wherein 15th Trp in the amino acid sequence of SEQ ID NO: 5 is replaced with Cys is excluded. Examples of the DNA coding for the human galanin receptor protein comprising the amino acid sequence of SEQ ID NO: 5 includes DNA having a nucleotide sequence represented by SEQ ID NO: 6, etc.

The DNA completely coding for the galanin receptor protein of the present invention can be cloned by

(1) carrying out the PCR amplification using a synthetic DNA primer having a partial nucleotide sequence (nucleotide fragment) of the galanin receptor protein; or

(2) effecting the selection of a DNA constructed in a suitable vector, based on the hybridization with a labeled DNA fragment having part or all of the region encoding a galanin receptor protein (e.g., human galanin receptor protein, etc.) or a labeled synthetic DNA having part or all of the coding region thereof. The hybridization is carried out according to methods as disclosed in, for example, Molecular Cloning, 2nd Ed., J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989. When a DNA library commercially available in the market is used, the hybridization is carried out according to protocols or manuals attached thereto.

For example, the DNA completely coding for the mouse-derived galanin receptor protein of the present invention is cloned by (1) carrying out the PCR amplification using a synthetic DNA primer having a partial nucleotide sequence (nucleotide fragment) of the mouse-derived galanin receptor protein; or (2) effecting the selection of a DNA constructed in a suitable vector, based on the hybridization with a labeled DNA fragment having part or all of the region encoding a human or mouse-derived galanin receptor protein or a labeled synthetic DNA having part or all of the coding region thereof.

The cloned galanin receptor protein-encoding DNA of the present invention can be used as it is, or can be used, as desired, after modifications including digestion with a restriction enzyme or addition of a linker or adapter, etc. depending upon objects. The DNA may have an initiation codon, ATG, on the 5' terminal side and a termination codon, TAA, TGA or TAG, on the 3' terminal side. These initiation and termination codons can be ligated by using a suitable synthetic DNA adapter.

A vector containing the galanin receptor protein-encoding DNA (for example, an expression vector for the galanin receptor protein; specifically, an expression plasmid comprising the human galanin receptor protein-encoding DNA, etc.) can be produced by, for example, (a) cutting out a target DNA fragment from the galanin receptor protein-encoding DNA of the present invention and (b) ligating the target DNA fragment with the downstream site of a promoter in a suitable expression vector (for example, an expression plasmid compatible with the human galanin receptor protein-encoding DNA, etc.).

The vector may include plasmids derived from *Escherichia coli* (e.g., pBR322, pBR325, pUC12, pUC13, etc.), plasmids derived from *Bacillus subtilis* (e.g., PUB110, pTP5, pC194, etc.), plasmids derived from yeasts (e.g., pSH19, pSH15, etc.), bacteriophages such as λ -phage, and animal virus such as retrovirus, vaccinia virus and baculovirus.

According to the present invention, any promoter can be used as long as it is compatible with a host which is used for expressing a gene. When the host for the transformation is *E. coli*, the promoters are preferably trp promoters, lac promoters, recA promoters, λ_{P_L} promoters, lpp promoters, etc. When the host for the transformation is the *Bacillus*, the promoters are preferably SPO1 promoters, SPO2 promoters, penP promoters, etc. When the host is a yeast, the promoters are preferably PHO5 promoters, PGK promoters, GAP promoters, ADH promoters, etc. When the host is an animal cell, the promoters include SV40-derived promoters, retrovirus promoters, metallothionein promoters, heat shock promoters, cytomegalovirus (CMV) promoters, SR α promoters, etc. An enhancer can be effectively utilized for the expression.

As required, furthermore, a host-compatible signal sequence is added to the N-terminal side of the galanin receptor protein. When the host is *E. coli*, the utilizable signal sequences may include alkaline phosphatase signal sequences, OmpA signal sequences, etc. When the host is the *Bacillus*, they may include α -amylase signal sequences, subtilisin signal sequences, etc. When the host is a yeast, they may include mating factor α signal sequences, invertase signal

sequences, etc. When the host is an animal cell, they may include insulin signal sequences, α -interferon signal sequences, antibody molecule signal sequences, etc.

Further, a preferred method of constructing an expression plasmid among the vectors containing the human galanin receptor protein DNA of the present invention will be concretely given as hereunder.

Examples of the plasmid used are pAKKO-111 (sometimes referred to as pA1-11), pRc/CMV, pRc/RSV, etc. and, among them, the use of pAKKO-111 (pA1-11) is preferred. With respect to a promoter, anything may be used so far as it functions in an effective manner in host cells and its examples are SV40 early gene promoter, CMV promoter, HSV-TK promoter, SR α promoter, RSV promoter, etc. Among them, CMV promoter and SR α promoter are preferred and the use of SR α promoter is particularly preferred.

With respect to an expression plasmid, the use of the agent containing an enhancer, a splicing signal, a poly A adding signal, a selective marker, etc. besides the above-mentioned ones is preferred. Examples of the selective marker are dihydrofolate reductase (hereinafter, sometimes referred to as "dhfr") gene and neomycin phosphate transferase (hereinafter, sometimes referred to as "neo" gene). The dhfr gene gives a resistance to methotrexate (MTX) while the neo gene gives a resistance to G-418. Especially when a dhfr gene-deficient CHO cell is used and a dhfr gene is utilized as a selective marker, it is possible to select even by a medium free from thymidine.

Specific and preferred examples of the expression plasmid carrying the human galanin receptor protein encoding DNA of the present invention are those in which the above-mentioned promoters (e.g., particularly, SR α -promoter, etc.) are inserted in the upstream of the human galanin receptor protein DNA and, preferably, an SV early gene poly A addition signal is inserted to the downstream of the human galanin receptor protein DNA followed by inserting dhfr gene, ampicillin-resisting gene, etc. into the downstream of the poly A addition signal.

More specific and preferred example is an expression plasmid designated pTS863 (FIG. 13) in which SR α promoter is inserted in an upstream of the human galanin receptor protein DNA, an SV early gene poly A addition signal is inserted in a downstream of the human galanin receptor protein DNA, a dhfr gene is inserted in a downstream thereof and then an ampicillin-resisting gene is inserted in the downstream thereof, etc.

When the expression plasmid containing the human galanin receptor protein DNA prepared as such is introduced into a host cell, it is possible to produce a cell which is able to highly express the DNA which codes for the human galanin receptor protein.

A transformant or transfectant is produced by using the vector thus constructed, which carries the galanin receptor protein-encoding DNA of the present invention. The host may be, for example, *Escherichia* microorganisms, *Bacillus* microorganisms, yeasts, insect cells, animal cells, etc. Examples of the *Escherichia* and *Bacillus* microorganisms include *Escherichia coli* K12-DH1 [Proc. Natl. Acad. Sci. USA, Vol. 60, 160 (1968)], JM103 [Nucleic Acids Research, Vol. 9, 309 (1981)], JA221 [Journal of Molecular Biology, Vol. 120, 517 (1978)], HB101 [Journal of Molecular Biology, Vol. 41, 459 (1969)], C600 [Genetics, Vol. 39, 440 (1954)], etc. Examples of the *Bacillus* microorganism are, for example, *Bacillus subtilis* MI114 [Gene, Vol. 24, 255 (1983)], 207-21 [Journal of Biochemistry, Vol. 95, 87 (1984)], etc. The yeast may be, for example, *Saccharomyces cerevisiae* AH22, AH22R⁻, NA87-11A, DKD-5D, 20B-12, etc. The insect may include a silkworm (*Bombyx mori* larva), [Maeda et al. Nature, Vol. 315, 592 (1985)] etc. The host animal cell may be, for example, monkey-derived cell line, COS-7, Vero, Chinese hamster ovary cell line (CHO cell), DHFR gene-deficient Chinese hamster cell line (dhfr⁻ CHO cell), CHO K-1, human FL cell, 293 cell, L cell, myeloma cell, C127 cell, Balb/c3T3 cell, Sp-2/O cell, etc.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. Transformation of *Escherichia* microorganisms can be carried out in accordance with methods as disclosed in, for example, Proc. Natl. Acad. Sci. USA, Vol. 69, 2110 (1972), Gene, Vol. 17, 107 (1982), etc. Transformation of *Bacillus* microorganisms can be carried out in accordance with methods as disclosed in, for example, Molecular & General Genetics, Vol. 168, 111 (1979), etc. Transformation of the yeast can be carried out in accordance with methods as disclosed in, for example, Proc. Natl. Acad. Sci. USA, Vol. 75, 1929 (1978), etc. The insect cells can be transformed in accordance with methods as disclosed in, for example, Bio/Technology, 6, 47-55, 1988. The animal cells can be transformed by methods as disclosed in, for example, Virology, Vol. 52, 456, 1973, etc. The transformants or transfectants harboring the expression vector carrying a galanin receptor protein-encoding DNA are produced according to the aforementioned techniques.

Among the above-mentioned host cells, animal cells are particularly preferred as the host cell for an expression plasmid containing the human galanin receptor protein DNA of the present invention. The examples thereof are 293 cell, CHO cell, Vero cell, L cell, myeloma cell, C127 cell, Balb/c3T3 cell and Sp-2/O cell, etc. Among them, CHO cell and 293 cell are preferred and particularly CHO cell [Journal of Experiment of Medicine, 108, 945(1958)] is more preferred. Among said CHO cell, the preferred ones are dhfr gene-deficient CHO cell (hereinafter, sometimes referred to as CHO (dhfr⁻) cell) [Proceedings of the National Academy of Sciences of the U. S. A., 77, 4216-4220(1980)], CHO K-1 cell [Proceedings of the National Academy of Sciences of the U. S. A., 60, 1275(1968)], etc. When dhfr gene is inserted in an expression plasmid as a selective marker, CHO(dhfr⁻) and the like are suitable.

With respect to the combination of the expression plasmid with the host cell, the preferred one can be suitably selected and, for example, CHO(dhfr⁻) cell and the like are suitable as the host cell of the expression plasmid (FIG. 13) indicated by pTS863. In introducing the expression plasmid into animal cells, known methods such as a calcium phos-

phate method [Graham, F. L. and van der Eb, A. J.: Virology, 52, 456-467(1973)], an electroporation [Neumann, E. et al., EMBO Journal, 1,841-845(1982)], etc. may be used.

As such, a transformant in which a transformation is carried out using a vector containing a human galanin receptor protein DNA is produced. In addition, the transformant prepared by a transformation using an expression plasmid containing the human galanin receptor protein DNA may be used for the manufacture of human galanin receptor protein.

Cells which are able to highly express the human galanin receptor protein can be obtained by selecting the cells wherein the above-mentioned expression plasmid is incorporated in the chromosome by means of clone selection. Briefly, the transformant is first selected using the above-mentioned selective marker as an index for selection. Then the transformant produced as such using the selective marker is repeatedly subjected to a clone selection to give a cell strain which stably exhibits a high ability of expressing the human galanin receptor protein. When a dhfr gene is used as a selective marker, the resisting cells are selected by a culture with a sequential increase in the methotrexate (MTX) concentration to amplify the introduced gene in the cells whereby a cell strain exhibiting far higher expression can be obtained.

Even when CHO (dhfr⁻) cell is used as a host, the CHO containing an expression plasmid indicated by pTS863 also has a dhfr gene as a result because a dhfr gene is introduced, for example, into an expression plasmid indicated by pTS863 (FIG. 13). In this specification, the CHO cell obtained by giving an expression plasmid (e.g. pTS 863, etc.) containing dhfr gene may be sometimes referred to as "CHO(dhfr⁺) cell".

An example of the transformant which is able to highly express the human galanin receptor protein DNA in the present invention is a CHO (dhfr⁺) cell obtained by giving an expression plasmid indicated by pTS863 obtained in Example 11 (mentioned herein later) to a CHO (dhfr⁻) cell, etc. More specific examples are CHO (dhfr⁺) cell indicated by CHO/pTS863-5, CHO (dhfr⁺) cell indicated by CHO/pTS863-7, etc. As compared with the known human galanin receptor protein-expressing COS cells, the above-mentioned CHO (dhfr⁺) cells are able to express more amount of human galanin receptor protein and, further, there are some which exhibit a receptor activity (e.g., ligand binding activity, etc.) of about 10 to 100-fold (preferably about 100-fold) as compared with natural tissues containing human galanin receptor proteins (e.g. human melanoma Bowes cells, etc.). Accordingly, those CHO (dhfr⁺) cells are effective in conducting a method of screening for the human galanin receptor agonist/antagonist which will be mentioned herein later.

The cells which contain the human galanin receptor protein of the present invention can be also manufactured by culturing the transformant containing the vector (particularly, the expression plasmid) carrying the human galanin receptor protein DNA of the present invention under a condition where the human galanin receptor protein DNA can be expressed.

Cultivation of the transformant (transfectant) in which the host is Escherichia or Bacillus microorganism can be carried out suitably in a liquid culture medium. The culture medium may contains carbon sources, nitrogen sources, minerals, etc. necessary for growing the transformant. The carbon source may include glucose, dextrin, soluble starch, sucrose, etc. The nitrogen source may include organic or inorganic substances such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, bean-cakes, potato extracts, etc. Examples of the minerals may include calcium chloride, sodium dihydrogen phosphate, magnesium chloride, etc. It is further allowable to add yeasts, vitamins, growth-promoting factors, etc. It is desired that the culture medium is pH from about 5 to about 8.

The Escherichia microorganism culture medium is preferably an M9 medium containing, for example, glucose and casamino acid (Miller, Journal of Experiments in Molecular Genetics), 431-433, Cold Spring Harbor Laboratory, New York, 1972. Depending on necessity, the medium may be supplemented with drugs such as 3 β -indolyl acrylic acid in order to improve efficiency of the promoter. In the case of the Escherichia host, the cultivation is carried out usually at about 15 to 43 °C for about 3 to 24 hours. As required, aeration and stirring may be applied. In the case of the Bacillus host, the cultivation is carried out usually at about 30 to 40 °C for about 6 to 24 hours. As required, aeration and stirring may be also applied. In the case of the transformant in which the host is an yeast, the culture medium used may include, for example, a Burkholder minimum medium [Bostian, K.L. et al., Proc. Natl. Acad. Sci. USA, Vol. 77, 4505 (1980)], an SD medium containing 0.5% casamino acid [Bitter, G.A. et al., Proc. Natl. Acad. Sci. USA, Vol. 81, 5330 (1984)], etc. It is preferable that pH of the culture medium is adjusted to be from about 5 to about 8. The cultivation is carried out usually at about 20 to 35 °C for about 24 to 72 hours. As required, aeration and stirring may be applied. In the case of the transformant in which the host is an insect, the culture medium used may include those obtained by suitably adding additives such as passivated (or immobilized) 10% bovine serum and the like to the Grace's insect medium (Grace, T.C.C., Nature, 195, 788 (1962)). It is preferable that pH of the culture medium is adjusted to be about 6.2 to 6.4. The cultivation is usually carried out at about 27 °C for about 3 to 5 days. As desired, aeration and stirring may be applied. In the case of the transformant in which the host is an animal cell, the culture medium used may include MEM medium [Science, Vol. 122, 501 (1952)], DMEM medium [Virology, Vol. 8, 396 (1959)], RPMI 1640 medium [Journal of the American Medical Association, Vol. 199, 519 (1967)], 199 medium [Proceedings of the Society for the Biological Medicine, Vol. 73, 1 (1950)], α -MEM medium, etc. which are containing, for example, about 5 to 20% of fetal calf serum. Especially when CHO (dhfr⁻) cells and dhfr selective marker gene are used, it is preferred to use a DMEM medium containing a dialyzed fetal bovine serum which rarely contains thymidine. It is preferable that the pH is from about 6 to about 8. The

cultivation is usually carried out at about 30 to 40 °C for about 15 to 72 hours. As required, medium exchange, aeration and stirring may be applied.

As such, cells containing the human galanin receptor protein can be manufactured from the transformant retaining the vector (particularly, expression plasmid) containing the human galanin receptor protein-encoding DNA. Examples of the cell containing the human galanin receptor protein are CHO cells containing the human galanin receptor protein and the like. The cells containing the human galanin receptor protein can be obtained by culturing CHO (dhfr^r) cell indicated by CHO/pTS863-5, CHO (dhfr^r) cell indicated by CHO/pTS863-7, etc.

Separation and purification of the galanin receptor protein (for example, human galanin receptor protein, etc.) from the above-mentioned cultures can be carried out according to methods described herein below.

To extract galanin receptor proteins from the cultured microorganisms or cells, the microorganisms or cells are collected by known methods after the cultivation, suspended in a suitable buffer solution, disrupted by ultrasonic waves, lysozyme and/or freezing and thawing, etc. and, then, a crude extract of the galanin receptor protein is obtained by centrifugation or filtration. Other conventional extracting or isolating methods can be applied. The buffer solution may contain a protein-denaturing agent such as urea or guanidine hydrochloride or a surfactant such as Triton X-100 (registered trademark, hereinafter often referred to as "TM").

In the case where galanin receptor proteins are secreted into culture media, supernatant liquids are separated from the microorganisms or cells after the cultivation is finished and the resulting supernatant liquid is collected by widely known methods. The culture supernatant liquid and extract containing galanin receptor proteins can be purified by suitable combinations of widely known methods for separation, isolation and purification. The widely known methods of separation, isolation and purification may include methods which utilizes solubility, such as salting out or sedimentation with solvents methods which utilizes chiefly a difference in the molecular size or weight, such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide gel electrophoresis, methods utilizing a difference in the electric charge, such as ion-exchange chromatography, methods utilizing specific affinity such as affinity chromatography, methods utilizing a difference in the hydrophobic property, such as inverse-phase high-performance liquid chromatography, and methods utilizing a difference in the isoelectric point such as isoelectric electrophoresis, etc.

In case where the galanin receptor protein thus obtained is in a free form, the free protein can be converted into a salt thereof by known methods or method analogous thereto. In case where the galanin receptor protein thus obtained is in a salt form vice versa, the protein salt can be converted into a free form or into any other salt thereof by known methods or method analogous thereto.

The galanin receptor protein produced by the transformant can be arbitrarily modified or a polypeptide can be partly removed therefrom, by the action of a suitable protein-modifying enzyme before or after the purification. The protein-modifying enzyme may include trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase, etc. The activity of the galanin receptor protein thus formed can be measured by experimenting the coupling (or binding) with a ligand including galanin or by enzyme immunoassays (enzyme linked immunoassays) using specific antibodies.

When the DNA which codes for the known human galanin receptor protein is used in the above-mentioned means instead of that which codes for the human galanin receptor protein of the present invention, it is also possible to isolate the cells which highly express recombinant human galanin receptor protein or to isolate recombinant human galanin receptor protein.

Although the known human galanin receptor protein is expressed by COS cells, the expressed amount in the case of the COS cells are usually small. However, in accordance with a method of constructing the expression plasmid of the present invention, it is possible to manufacture not only the cells (particularly CHO cells) which highly express the human galanin receptor protein of the present invention but also the cells (particularly CHO cells) which highly express the known human galanin receptor protein.

The cell membrane fraction of a cell containing said galanin receptor protein (for example, cell membrane fraction of a cell containing human galanin receptor protein, cell membrane fraction of a cell containing mouse-derived galanin receptor protein, etc.) is a cell membrane-rich fraction which is prepared by methods per se known to those of skill in the art or methods similar thereto after disruption of cells containing the galanin receptor protein (for example, the human galanin receptor protein, the mouse-derived galanin receptor protein, etc.). Examples of cell disruption may include a method for squeezing cells using a Potter-Elvehjem homogenizer, a disruption by a Waring blender or a Polytron (manufactured by Kinematica), a disruption by ultrasonic waves, a disruption via blowing out cells from small nozzles together with applying a pressure using a French press or the like, etc. In the fractionation of the cell membrane, a fractionation method by means of centrifugal force such as a fractional centrifugal separation and a density gradient centrifugal separation is mainly used. For example, disrupted cellular liquid is centrifuged at a low speed (500 rpm to 3,000 rpm) for a short period (usually, from about one to ten minutes), the supernatant liquid is further centrifuged at a high speed (15,000 rpm to 30,000 rpm) usually for 30 minutes to two hours and the resulting precipitate is used as a membrane fraction. Said membrane fraction contains a lot of the expressed galanin receptor protein (for example, the human galanin receptor protein, the mouse-derived galanin receptor protein, etc.) and a lot of membrane components such as phospholipids and membrane proteins derived from the cells.

The amount of the galanin receptor protein in the membrane fraction cell containing said galanin receptor protein is preferably 10^3 to 10^8 molecules per cell or, suitably, 10^5 to 10^7 molecules per cell. Incidentally, the more the expressed amount, the higher the ligand binding activity (specific activity) per membrane fraction whereby the construction of a highly sensitive screening system becomes possible and, moreover, it may enable us to measure a large amount of samples within the same lot.

The galanin receptor protein, the partial peptide thereof and the galanin receptor protein-encoding DNA of the present invention can be used for:

- ① obtaining an antibody and an antiserum,
- ② constructing a system for expressing a recombinant receptor protein,
- ③ developing a receptor-binding assay system using the above developing system and screening pharmaceutical candidate compounds,
- ④ designing drugs based upon the comparison with ligands and receptors which have a similar or analogous structure,
- ⑤ preparing a probe in the analysis of genes and preparing a PCR primer,
- ⑥ gene manipulating therapy,
- ⑦ producing a transgenic animal (for example, transgenic mouse, etc.),
- ⑧ producing a model animal suffering from diseases caused by gene deficiency, etc.

In particular, it is allowable to screen a galanin receptor agonist or antagonist specific to a warm-blooded animal such as human being by a receptor-binding assay system which uses a system for expressing a recombinant galanin receptor protein of the present invention. The agonist or antagonist thus screened or characterized permits various applications including prevention and/or therapy of a variety of diseases.

For example, the mouse-derived galanin receptor protein, the partial peptide of the mouse-derived galanin receptor protein and the DNA which codes for the mouse-derived galanin receptor protein can be used for ① obtaining antibody and antiserum; ② construction of an expression system of the recombinant receptor protein; ③ development of the receptor-binding assay system using said expression system and screening of the candidate compounds as pharmaceuticals; ④ conducting a drug design based upon a comparison with ligands and receptors which have a similar or analogous structure; ⑤ preparing probes and designing PCR primers in gene diagnosis; ⑥ gene therapy, etc.

The human galanin receptor protein, the partial peptide of the human galanin receptor protein and the DNA which codes for the human galanin receptor protein can be used for ① obtaining antibody and antiserum; ② construction of an expression system of the recombinant receptor protein; ③ development of the receptor-binding assay system using said expression system and screening of the candidate compounds as pharmaceuticals; ④ conducting a drug design based upon a comparison with ligands and receptors which have a similar or analogous structure; ⑤ preparing probes and designing PCR primers in gene diagnosis; ⑥ gene therapy, etc. Especially when the receptor binding assay system utilizing the expression system for the human galanin receptor protein of the present invention is used, it is possible to screen the galanin receptor agonist or antagonist which is specific to warm-blooded animals (especially, human being) whereupon said agonist or antagonist can be used as a preventive and therapeutic agent for various diseases.

Concretely described below are uses of galanin receptor proteins, partial peptides thereof (peptide fragments thereof), galanin receptor protein-encoding DNAs and antibodies against the galanin receptor protein according to the present invention.

(1) Quantitative Measurement of Galanin

The galanin receptor protein, a partial peptide thereof or a salt thereof has a binding property to galanin and, therefore, it is capable of determining quantitatively an amount of galanin *in vivo* with good sensitivity.

This quantitative measurement may be carried out by, for example, combining with a competitive method. Thus, samples to be measured is contacted with galanin receptor proteins or partial peptide thereof so that the galanin concentration in said sample can be measured. In one embodiment of the quantitative measurement, the protocols described in the following ① and ② or the methods similar thereto may be used:

- ① Hiroshi Irie (ed): "Radioimmunoassay" (Kodansha, Japan, 1974); and
- ② Hiroshi Irie (ed): "Radioimmunoassay, Second Series" (Kodansha, Japan, 1979).

Further, the quantitative determination method of galanin according to the present invention can be used as a diagnostic method for the diseases caused by increase/decrease in galanin concentrations such as stomach ulcer, diabetes and Alzheimer's disease.

(2) Screening of Galanin Receptor Agonist and/or Antagonist

Galanin receptor proteins or partial peptides thereof are used. Alternatively, expression systems for recombinant type galanin receptor proteins or partial peptides thereof are constructed and receptor binding assay systems using said expression system are used. In these assay systems, it is possible to screen compounds (e.g. peptides, proteins, non-peptidic compounds, synthetic compounds, fermented products, cell extracts, plant extracts, animal tissue extracts, etc.) or salts thereof which inhibits the binding of galanin with the galanin receptor protein. Such a compound includes a compound exhibiting a galanin receptor-mediated cell stimulating activity (e.g. activity of promoting or activity of inhibiting physiological reactions including liberation of arachidonic acid, liberation of acetylcholine, endocellular Ca^{2+} liberation, endocellular cAMP production, endocellular cGMP production, production of inositol phosphate, changes in cell membrane potential, phosphorylation of endocellular proteins, activation of c-fos, lowering of pH, secretion of insulin, etc.; in particular, activity of promoting or activity of inhibiting endocellular cAMP production and secretion of insulin) (so-called "galanin receptor agonist"), a compound free of such a cell stimulating activity (so-called "galanin receptor antagonist"), etc.

Thus, the present invention provides a method of screening a galanin receptor agonist and/or galanin receptor antagonist with a galanin receptor protein or a salt thereof, characterized in comparing the following cases:

- (i) the case wherein galanin is contacted with the galanin receptor protein or salt thereof, or a partial peptide thereof or a salt thereof; and
- (ii) the case wherein galanin is contacted with a mixture of the galanin receptor protein or salt thereof or the partial peptide or salt thereof and said test sample (including a test compound).

In said screening method, one characteristic feature of the present invention resides in that the amount of galanin bonded with said galanin receptor protein (for example, human or mouse-derived galanin receptor protein) or partial peptide thereof, the cell stimulating activity of galanin, etc. are measured in the case where (i) galanin is contacted with said galanin receptor protein (for example, human or mouse-derived galanin receptor protein) or its partial peptide and in the case where (ii) galanin and a test sample (including a test compound) are contacted with the galanin receptor protein or its partial peptide, respectively and then compared therebetween.

In the screening of the galanin receptor agonist or antagonist, it may be considered to use human hippocampus as a human galanin receptor protein source. However, tissues derived from human being are hardly available and, therefore, they are not suitable for use in screening whereupon recombinant human galanin receptor proteins which are abundantly expressed in cells (particularly, animal cells such as CHO cells) are suitable in practice. More preferably, the cell strain in which human galanin receptor proteins are continuously and stably expressed is advantageously used.

Accordingly, the human galanin receptor protein of the present invention or the salt thereof, the human galanin receptor protein-partial peptide of the present invention or the salt thereof and the cell or cell fraction thereof containing the human galanin receptor protein of the present invention are remarkably useful as a reagent for screening the galanin receptor agonist or antagonist.

Briefly, the present invention offers a method of screening galanin receptor agonist or antagonist, characterized in that, the human galanin receptor protein of the present invention or the salt thereof, the partial peptide of the human galanin receptor protein of the present invention or the salt thereof or the cells or cell fraction thereof containing the human galanin receptor protein of the present invention is used.

More specifically, the present invention offers:

- (I) a method of screening the human galanin receptor agonist or antagonist, characterized in that, a comparison is conducted between the cases where (i) the human galanin receptor protein of the present invention or the partial peptide or the salt thereof is contacted with galanin and where (ii) the human galanin receptor protein of the present invention or the partial peptide or the salt thereof is contacted with galanin and a test compound; and
- (II) a method of screening the galanin receptor agonist or antagonist, characterized in that, a comparison is conducted between the cases where (i) cells containing the human galanin receptor protein of the present invention or cell membrane fraction thereof are contacted with galanin and where (ii) cells containing the human galanin receptor protein of the present invention or cell membrane fraction thereof are contacted with galanin and a test compound.

To be more specific, in the screening methods (I) and (II) of the present invention, the cell-stimulating activity and/or binding amount of galanin to said human galanin receptor protein or partial peptide or salt thereof or cells containing the human galanin receptor protein or cell membrane fraction thereof in (i) and (ii) are measured and compared.

In one more specific embodiment of the present invention,

- ① a method of screening a galanin receptor agonist and/or galanin receptor antagonist or a salt thereof, characterized in that, when a labeled galanin is contacted with a galanin receptor protein (e.g., human-derived galanin

receptor protein, etc.) or a partial peptide thereof and when a labeled galanin and a test compound are contacted with a galanin receptor protein (e.g., human-derived galanin receptor protein, etc.) or a partial peptide thereof, the amounts of the labeled galanin bonded with said protein or partial peptide thereof or salt thereof are measured and compared;

② (a) (i) a method of screening a galanin receptor agonist and/or galanin receptor antagonist or a salt thereof, characterized in that, when a labeled galanin is contacted with galanin receptor protein (e.g., human or mouse galanin receptor protein, etc.)-containing cells (e.g., mouse MIN 6 cell (FERM BP-4954), etc.) or a membrane fraction of said cells and when a labeled galanin and a test compound are contacted with galanin receptor protein (e.g., human or mouse galanin receptor protein, etc.)-containing cells (e.g., mouse MIN 6 cell (FERM BP-4954), etc.) or a membrane fraction of said cells, the amounts of the labeled galanin binding with said protein or partial peptide thereof or a salt thereof are measured and compared;

(b) (ii) a method of screening a galanin receptor agonist and/or galanin receptor antagonist or a salt thereof, characterized in that, when a galanin receptor protein-activating compound (e.g. galanin) is contacted with galanin receptor protein (e.g., human or mouse galanin receptor protein, etc.)-containing cells (e.g., mouse MIN 6 cell (FERM BP-4954), etc.) or a membrane fraction of said cells and when the galanin receptor protein-activating compound and a test compound are contacted with galanin receptor protein (e.g., human or mouse galanin receptor protein, etc.)-containing cells (e.g., mouse MIN 6 cell (FERM BP-4954), etc.) or a membrane fraction of said cells, the resulting galanin receptor protein-mediated cell stimulating activities (e.g. activities of promoting or activities of inhibiting physiological responses including the opening of K⁺ channel, closing of N type Ca²⁺ channel liberation of arachidonic acid, liberation of acetylcholine, endocellular Ca²⁺ changes, endocellular cAMP production (or its depression), endocellular cGMP production, insulin secretion, production of inositol phosphate, cell membrane potential changes, phosphorylation of endocellular proteins, activation of c-fos, decrease of pH, cell migration activity, secretion of hormones, activation of G protein, cell promulgation, etc.) are measured and compared; and

③ a method of screening a galanin receptor agonist and/or galanin receptor antagonist or a salt thereof, characterized in that, when a labeled galanin is contacted with galanin receptor proteins (e.g., human or mouse galanin receptor proteins, etc.) expressed on the cell membrane by culturing a transformant containing a galanin receptor protein encoding DNA and when a labeled galanin and a test compound are contacted with galanin receptor proteins (e.g., human or mouse galanin receptor proteins, etc.) expressed on the cell membrane by culturing a transformant containing a galanin receptor protein encoding DNA, the amounts of the labeled galanin binding with said galanin receptor protein are measured and compared;

④ a method of screening a galanin receptor agonist and/or galanin receptor antagonist or a salt thereof, characterized in that, when a galanin receptor protein-activating compound (e.g. galanin) is contacted with galanin receptor proteins (e.g., human or mouse galanin receptor proteins, etc.) expressed on cell membranes by culturing transformants containing galanin receptor protein-encoding DNA and when a galanin receptor protein-activating compound and a test compound are contacted with the galanin receptor protein expressed on the cell membrane by culturing the transformant containing the galanin receptor protein-encoding DNA, the resulting galanin receptor protein-mediated cell stimulating activities (activities of promoting or activities of inhibiting physiological responses such as liberation of arachidonic acid, liberation of acetylcholine, endocellular Ca²⁺ liberation, endocellular cAMP production, endocellular cGMP production, production of inositol phosphate, changes in cell membrane potential, phosphorylation of endocellular proteins, activation of c-fos, lowering of pH, insulin secretion, etc.) are measured and compared: are provided.

In the above-mentioned screening methods ① or ② (a), a compound which binds with a galanin receptor protein (e.g., human galanin receptor protein, etc.) and inhibits the binding of galanin with the galanin receptor protein can be selected as a galanin receptor agonist or antagonist.

Further, in the above-mentioned screening method ② (b), a compound which exhibits a cell-stimulating activity (for example, activities of promoting or inhibiting the opening of K⁺ channel, closing of N type Ca²⁺ channel, liberation of arachidonic acid, liberation of acetylcholine, variations in intracellular Ca²⁺ concentration, inhibition of intracellular cAMP production, production of inositol phosphate, variations in cell membrane potential, phosphorylation of intracellular protein, activation of c-fos, decrease in pH, cell migration activity, secretion of hormones, activation of G protein, cell promulgation, etc.) via the galanin receptor (e.g., human galanin receptor, etc.) upon said galanin receptor binding can be selected as a galanin receptor agonist.

On the other hand, in the above-mentioned screening methods ① and ② (a), a compound having no stimulating activity to said cells among the test compounds which exhibit an activity of inhibiting the binding of galanin with the galanin protein receptor (e.g., human galanin receptor protein, etc.) can be selected as a galanin receptor antagonist.

Before the cells containing the galanin receptor protein (e.g., human galanin receptor protein, etc.) of the present invention were developed, there was no cell which highly expressed the galanin receptor protein (e.g., human galanin receptor protein, etc.) and, therefore, it has not been possible to conduct an effective screening of galanin receptor agonists or antagonists.

Specific explanations of the screening method will be given as hereunder.

First, with respect to the galanin receptor protein such as the mouse-derived galanin receptor protein used for the screening method of the present invention, any product may be used so far as it contains galanin receptor proteins or partial peptide thereof such as mouse-derived galanin receptor proteins or partial peptide thereof although the use of a membrane fraction derived from mammalian organs, tissues, cells, including mouse, is suitable. Galanin receptor proteins which are expressed in a large amount using a recombinant are suitable for the screening.

In the manufacture of the galanin receptor protein (for example, mouse-derived galanin receptor protein, etc.), the above-mentioned method can be used and it may be carried out by expressing the DNA coding for said protein in mammalian cells or in insect cells. With respect to the DNA fragment coding for the target region, complementary DNA may be used although it is not limited thereto. Thus, for example, gene fragments or synthetic DNA may be used as well.

In order to introduce the galanin receptor protein-encoding DNA fragment (for example, mouse-derived galanin receptor protein-encoding DNA fragment, etc.) into host animal cells and to express it efficiently, it is preferred that said DNA fragment is incorporated into the downstream of polyhedron promoter of nuclear polyhedrosis virus belonging to baculovirus, promoter derived from SV40, promoter of retrovirus, metallothionein promoter, human heat shock promoter, cytomegalovirus promoter, SR α promoter, etc. Examinations of the quantity and the quality of expressed receptors can be carried out by known methods per se or modified methods substantially analogous thereto. For example, they may be conducted by the method described in publications such as Nambi, P. et al.: The Journal of Biochemical Society, vol.267, pages 19555-19559 (1992).

Accordingly, in the screening method, the substance containing a galanin receptor protein or a partial peptide thereof (for example, mouse-derived galanin receptor protein or its partial peptide, etc.) may be a galanin receptor protein or its partial peptide (for example, mouse-derived galanin receptor protein or its partial peptide, etc.) which is purified by known methods per se or a cell containing said protein or a cell membrane fraction of the cell containing said protein, etc.

When the galanin receptor protein-containing cells are used in the screening method, said cells may be immobilized with glutaraldehyde, formalin, etc. The immobilization may be carried out by known methods per se or modified methods substantially analogous thereto.

For example, the mouse-derived galanin receptor protein-containing cells are host cells expressing the mouse-derived galanin receptor, naturally occurring cells containing the mouse-derived galanin receptor protein, etc. Examples of said host cells may include *Escherichia coli*, *Bacillus subtilis*, yeasts, insect cells, animal cells such as CHO cell and COS cell, etc. The host cell expressing the mouse-derived galanin receptor can be produced by the method according to the above-mentioned transformant production.

In conducting the above-mentioned methods ①, ② (a) and ③ for screening the galanin receptor agonist and/or galanin receptor antagonist, a suitable galanin receptor fraction and a labeled galanin are necessary. With respect to the galanin receptor fraction, it is preferred to use naturally occurring galanin receptors (natural type galanin receptors), recombinant type galanin receptor fractions with the activity equivalent to that of the natural type galanin receptor, cells expressing the recombinant type mouse-derived galanin receptor, naturally occurring cells containing the mouse-derived galanin receptor, etc. Here the term "activity equivalent to" means the same galanin binding activity, or the substantially equivalent galanin binding activity.

With respect to the labeled galanin, it is possible to use labeled galanin, labeled galanin analogized compounds, etc. For example, galanin labeled with [^3H], [^{125}I], [^{14}C], [^{35}S], etc. and other labeled substances may be utilized. Known galanin agonists and antagonists labeled with [^3H], [^{125}I], [^{14}C], etc. may be utilized. Preferred examples of the labeled galanin are galanin labeled with [^{125}I] (Dupont/NEN), etc.

Specifically, galanin receptor protein-containing cells or cell membrane fractions (for example, human or mouse galanin receptor protein-containing cells or cell membrane fractions of the present invention) or the galanin receptor proteins or partial peptides thereof are first suspended in a buffer which is suitable for the measuring method to prepare the receptor sample in conducting the screening for a galanin receptor agonist and/or galanin receptor antagonist. With respect to the buffer, any buffer such as Tris-HCl buffer or phosphate buffer of pH 4-10 (preferably, pH 6-8) which does not inhibit the binding of galanin with the receptor may be used.

In addition, a surface-active agent such as CHAPS, Tween 80™ (Kao-Atlas, Japan), digitonin, deoxycholate, etc. and/or various proteins such as bovine serum albumin (BSA), gelatin, etc. may be added to the buffer with an object of decreasing the nonspecific binding. Further, a protease inhibitor such as PMSF, leupeptin, bacitracin, aprotinin, E-64 (manufactured by Peptide Laboratory, Japan), pepstatin, etc. may be added with an object of inhibiting the decomposition of the receptor and galanin by protease. A labeled galanin in a certain amount (for example, about 10,000 cpm to 1,000,000 cpm in case of 2000Ci/mmol; 5,000 cpm to 500,000 cpm in other cases) is added to 0.01 ml to 10 ml of said receptor solution and, at the same time, 10^{-4} M to 10^{-10} M of a test compound coexists. In order to determine the nonspecific binding amount (NSB), a reaction tube to which a great excessive amount of unlabeled test compounds is added is prepared as well.

The reaction is carried out at 0-50°C (preferably at 4-37°C) for 20 minutes to 24 hours (preferably 30 minutes to three hours). After the reaction, it is filtered through a glass fiber filter, a filter paper, or the like, washed with a suitable amount of the same buffer and the radioactivity (for example, the amount of [^{125}I], etc.) retained in the glass fiber filter,

etc. is measured by means of a liquid scintillation counter or a γ -counter. Although a manifold or a cell harvester may be used for the filtration, the use of cell harvester is recommended for improving the efficiency. Supposing that the count (B_0 - NSB) obtained by subtracting the nonspecific binding amount (NSB) from the total binding amount (B_0) wherein an antagonizing substance is not present is set at 100%, the test compound in which the specific binding amount (B - NSB) obtained by subtracting the nonspecific binding amount (NSB) from the total binding amount (B) is, for example,

less than 50% may be selected as an inhibitory candidate substance, i.e., agonist and/or antagonist candidate compound.

In an embodiment of the screening using human galanin receptor proteins, the operation is carried out in accordance with the following procedures:

- (i) A reaction buffer (pH: 7.4) comprising 20 mM of Tris-HCl, 1 mM of EDTA, 0.1% of BSA, 0.05% of CHAPS, 0.5mM of PMSF, 40 μ g/ml of leupeptin, 20 μ g/ml of E-64 and 10 μ g/ml of pepstatin is prepared.
- (ii) A test compound solution (2 μ l) in which the test compound is suspended in the reaction buffer is placed in a reaction tube on an ice bath. The final concentration of the test compound is adjusted to 100 μ M.
- (iii) The cell membrane fraction containing human galanin receptor protein freeze-dried at -80 °C is returned to a room temperature and then vortex is gently generated and diluted to a suitable concentration to prepare a cell membrane fraction solution (for example, 0.5 mg protein/ml (bovine hippocampal membrane fraction, CHO cell membrane fraction) etc.). This cell membrane fraction solution is passed through a cell strainer and each 200 μ l of it is placed in each reaction tube using a separator.
- (iv) Each 2 μ l of [125 I] galanin diluted in a reaction buffer is placed in a reaction tube on an ice bath.
- (v) The reaction is carried out at 25 °C for 60 or 75 minutes.
- (vi) A B/F separation is conducted using a manifold. The filter (GF/F, Whatman) which is used therefor is previously dipped in a PEI solution (20 mM Tris-HCl and 0.3% polyethyleneimine; pH: 7.4) for more than one hour.
- (vii) The filter is counted using a gamma-counter. The compound which inhibits the specific binding to an extent of 40-50% or more and of 50% or more is evaluated as \pm and +, respectively.

In conducting the above-mentioned methods ② (b) and ④ for screening the galanin receptor agonist and/or galanin receptor antagonist, the galanin receptor protein (e.g., mouse-derived galanin receptor protein)-mediated cell stimulating activity (e.g., activities of promoting or activities of inhibiting physiological responses such as liberation of arachidonic acid, liberation of acetylcholine, endocellular Ca^{2+} liberation, endocellular cAMP production, endocellular cGMP production, production of inositol phosphate, changes in the cell membrane potential, phosphorylation of endocellular proteins, activation of c-fos, lowering of pH, secretion of insulin, etc.) may be measured by known methods or by the use of commercially available measuring kits.

In conducting a screening method of the above-mentioned ② (b), it is possible to measure the cell stimulating activity via the galanin receptor protein (e.g., human galanin receptor protein, etc.) (for example, activities of promoting or inhibiting the opening of K^+ channel, closing of N type Ca^+ channel, liberation of arachidonic acid, liberation of acetylcholine, variations in intracellular Ca^{2+} concentration, inhibition of intracellular cAMP production, production of inositol phosphate, variations in cell membrane potential, phosphorylation of intracellular protein, activation of c-fos, decrease in pH, cell migration activity, secretion of hormones, activation of G protein, cell promulgation, etc.) by known method or by commercially-available measuring kits. To be more specific, galanin receptor protein (e.g., human or mouse-derived galanin receptor protein, etc.)-containing cells are at first cultured in a multiwell plate or the like.

In conducting the screening, it is substituted with a suitable buffer which does not show toxicity to fresh media or cells in advance, incubated for a certain period after adding a test compound, etc. thereto. The resultant cells are extracted or the supernatant liquid is recovered and the resulting product is determined, preferably quantitatively, by each of the methods. When it is difficult to identify the production of the index substance (e.g. arachidonic acid, etc.) which is to be an index for the cell stimulating activity due to the presence of decomposing enzymes contained in the cell, an assay may be carried out by adding an inhibitor against said decomposing enzyme. With respect to the activities such as an inhibitory action against cAMP production, it may be detected as an inhibitory action against the cAMP production in the cells whose fundamental production has been increased by forskolin or the like.

In conducting a screening by measuring the cell stimulating activity, cells in which a suitable galanin receptor protein (e.g., mouse-derived galanin receptor protein) is expressed are necessary. Preferred galanin receptor protein (e.g., mouse-derived galanin receptor protein)-expressing cells are naturally occurring mouse-derived galanin receptor protein (natural type mouse-derived galanin receptor protein)-containing cell lines or strains (e.g., mouse MIN6 (FERM BP-4954), etc.), the above-mentioned recombinant type mouse-derived galanin receptor protein-expressing cell lines or strains, etc. Among them, the natural type mouse-derived galanin receptor protein-containing cell line, mouse pancreas-derived MIN6 cell, is capable of secreting insulin from intracellular regions when galanin binds with galanin receptors on the cell membrane of said cell. In case where the insulin secretion is used as an index for the cell stimulating activity, mouse pancreas-derived MIN6 cell is particularly preferred.

Examples of the test compound includes peptides, proteins, non-peptidic compounds, synthesized compounds, fermented products, cell extracts, plant extracts, animal tissue extracts, serum, blood, body fluid, etc. Those compounds may be novel or known.

A kit for screening the galanin receptor agonist and/or galanin receptor antagonist comprises a galanin receptor protein or a salt thereof according to the present invention (e.g., human or mouse-derived galanin receptor protein or its salt) or a partial peptide thereof according to the present invention (e.g., human or mouse-derived galanin receptor partial peptide or its salt), a galanin receptor protein (e.g., human or mouse-derived galanin receptor protein)-containing cell or its cell membrane fraction according to the present invention, etc.

Examples of the screening kit include as follows:

1. Reagent for Determining Ligand.

① Buffer for Measurement and Buffer for Washing.

The product wherein 0.05% of bovine serum albumin (manufactured by Sigma) is added to Hanks' Balanced Salt Solution (manufactured by Gibco).

This may be sterilized by filtration through a membrane filter with a 0.45 μ m pore size, and stored at 4°C or may be prepared upon use.

② Sample of Mouse-Derived Galanin Receptor Protein.

CHO cells in which a mouse-derived galanin receptor protein is expressed are subcultured at the rate of 5×10^5 cells/well in a 12-well plate and cultured at 37°C with a 5% CO₂ and 95% air atmosphere for two days to prepare the sample.

③ Labeled Galanin.

The galanin which is labeled with commercially available [³H], [¹²⁵I], [¹⁴C], [³⁵S], etc.

The product in a state of an aqueous solution is stored at 4°C or at -20°C and, upon use, diluted to 5 μ M with a buffer for the measurement.

④ Standard Galanin Solution.

Galanin is dissolved in PBS containing 0.1% of bovine serum albumin (manufactured by Sigma) to make 100 μ M and stored at -20°C.

2. Method of the Measurement.

① CHO cells are cultured in a 12-well tissue culture plate to express mouse-derived galanin receptor proteins. The receptor protein-expressing CHO cells are washed with 1 ml of buffer for the measurement twice. Then 490 μ l of buffer for the measurement is added to each well.

② Five μ l of a test compound solution of 10^{-3} to 10^{-10} M is added, then 5 μ l of a labeled galanin is added and is made to react at room temperature for one hour. For knowing the non-specific binding amount, 5 μ l of the galanin of 10^{-4} M is added instead of the test compound.

③ The reaction solution is removed from the well, which is washed with 1 ml of buffer for the measurement three times. The labeled ligand binding with the cells is dissolved in 0.2N NaOH-1% SDS and mixed with 4 ml of a liquid scintillator A (manufactured by Wako Pure Chemical, Japan).

④ Radioactivity is measured using an automatic γ -counter or a liquid scintillation counter (manufactured by Beckmann) and PMB (percent of maximum binding) is calculated by the following expression (1):

$$\text{PMB} = [(B - \text{NSB}) / (B_0 - \text{NSB})] \times 100 \quad (1)$$

PMB: Percent of maximum binding

B: Value when a sample is added

NSB: Nonspecific binding

B_0 : Maximum binding

Another example of the screening kit is as follows:

5 [Reagents for the Screening]

① Buffer for measurement and for washing.

Hanks buffer to which 0.01% of bovine serum albumin and 0.05% of CHPS are added is used. This is filtered through
10 a filter with a pore size of 0.22 μ m, sterilized and stored at 4 °C or may be prepared upon use.

② Human galanin receptor protein sample.

Cells containing the human galanin receptor protein are subcultured in a 12-well plate at 5×10^5 /well and cultured
15 at 37 °C with 5% CO₂ and 95% air until cells become confluent.

③ Labeled galanin.

Commercially-available galanin which is labeled with [³H], [¹²⁵I], [¹⁴C], etc. is used. That which is in a state of solution
20 is stored at 4 °C or -20 °C and, upon use, it is diluted to 1 μ l with a buffer for the measurement.

④ Standard galanin solution.

Galanin is diluted with sterilized water to make 10^{-4} M and stored at -20 °C.
25

[Method of Measurement]

① Cells containing human galanin receptor protein cultured in a 12-well culturing plate are washed, about twice,
30 with 1 ml of a buffer for measurement.

② After the buffer for measurement is sucked out, 5 μ l of a test compound solution (10^{-3} to 10^{-10} M) cooled at 4
°C is added, then 0.5 ml of a buffer for measurement, containing 100 pM of a labeled galanin, is added and the
mixture is made to react at 37 °C for one hour with 5% CO₂ and 95% air. In order to know the nonspecific binding
amount, 1 μ M of galanin is added together with the test compound.

③ The reaction solution is removed and washed, three times, with 1 ml of buffer for washing which is kept at 37
35 °C. The labeled galanin bonded to the cells is removed with 0.5 ml of 0.2N NaOH and the radioactivity is measured
by a γ -counter to calculate the PMB (percent of maximum binding) from the above formula (1).

In the above-mentioned screening methods and screening kit, it is also possible to use recombinant human galanin
receptor protein manufactured from DNA such as known human galanin receptor protein DNA or the like or partial
40 peptide thereof or cells containing said recombinant human galanin receptor protein or a cell membrane fraction thereof
instead of the human galanin receptor protein of the present invention or the partial peptide thereof or cells containing
the human galanin receptor protein or a cell membrane fraction thereof.

The compound or its salt obtained by the screening method or screening kit of the present invention is a compound
which inhibits the binding of galanin with a galanin receptor protein and, more particularly, it is a compound having a
45 cell stimulating activity mediated via a galanin receptor or a salt thereof (so-called "galanin receptor agonist") or a com-
pound having no said stimulating activity (so-called "galanin receptor antagonist"). Examples of said compound are
peptides, proteins, non-peptidic compounds, synthesized compounds, fermented products, etc. and the compound may
be novel or known. The galanin receptor agonist or antagonist obtained by the screening method or the screening kit of
the present invention is a compound or salt thereof selected from the test sample including the compounds (for example,
50 peptides, proteins, nonpeptidic compounds, synthesized compounds, fermented products, cell extracts, plant extracts,
animal tissue extracts, cell or tissue cultures, biological fluids, etc.; said test compounds may be either novel or known)
using the screening method or the screening kit of the present invention and is a compound which inhibits the binding
of galanin with the recombinant human galanin receptor protein of the present invention. Among those compounds,
galanin receptor agonist is a compound which exhibits a cell-stimulating activity via a human galanin receptor while
55 galanin receptor antagonist is a compound which does not exhibit said cell-stimulating activity.

In addition, the compounds in which the structure of said galanin receptor agonist or antagonist obtained by the
screening method or the screening kit of the present invention is chemically modified or substituted or the compounds
in which a design is conducted based upon said structure are also included in the galanin receptor agonist or antagonist
obtained by the screening method or the screening kit of the present invention.

With respect to the salt of said galanin receptor agonist or antagonist, physiologically-acceptable acid addition salts thereof are particularly preferred. Examples of such salts are those with inorganic acids (for example, hydrochloric acid, phosphoric acid, hydrobromic acid and sulfuric acid) or with organic acids (for example, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid and benzenesulfonic acid).

The galanin receptor agonist exhibits all or part of the physiological activities of galanin or its equivalent and, therefore, it is useful as an active ingredient for a pharmaceutical composition with safety and low toxicity depending upon said physiological activities. On the other hand, the galanin receptor antagonist may inhibit all or part of the physiological activities of galanin or its equivalent and, therefore, it is useful as an active ingredient for a pharmaceutical composition with safety and low toxicity inhibiting said physiological activities.

More specifically, galanin receptor agonists are useful as an inhibitor for liberation of acetylcholine, an inhibitor for insulin secretion, a stimulant for growth hormone secretion, an inhibitor for learning behavior or an inhibitor for satiety, etc. and, moreover, it is useful as a preventive and therapeutic agent for schizophrenic disease, gastric ulcer, as a sedative, etc. On the other hand, galanin receptor antagonists are useful as an accelerator for liberation of acetylcholine, an accelerator for insulin secretion, an inhibitor for growth hormone secretion, an accelerator for learning behavior and an accelerator for satiety, etc. and, moreover, it is useful as a preventive and therapeutic agent for diabetes, Alzheimer's disease, dementia, etc.

When the galanin receptor agonist and/or galanin receptor antagonist or the salt thereof obtained by the screening method or by the screening kit is used as the above-mentioned pharmaceutical composition, a conventional means may be applied therefor. The compound or the salt thereof may be orally, parenterally, by inhalation spray, rectally, or topically administered as pharmaceutical compositions or formulations (e.g. powders, granules, tablets, pills, capsules, injections, syrups, emulsions, elixirs, suspensions, solutions, etc.). For example, it may be used by an oral route as tablets (sugar-coated if necessary), capsules, elixirs, microcapsules, etc. or by a parenteral route as injections such as an aseptic solution or a suspension in water or in other pharmaceutically acceptable liquid. The pharmaceutical compositions or formulations may comprise at least one such compound alone or in admixture with pharmaceutically acceptable carriers, adjuvants, vehicles, excipients and/or diluents. The pharmaceutical compositions can be formulated in accordance with conventional methods. For example, said compound or the salt thereof is mixed in a unit dose form which is required for preparing a generally approved pharmaceutical preparations together with a physiologically acceptable carriers, flavoring and/or perfuming agents (fragrances), fillers, vehicles, antiseptics, stabilizers, binders, etc. whereupon the preparation can be manufactured. An amount of the effective component in those preparations is to be in such an extent that the suitable dose within an indicated range is achieved.

Examples of the additives which can be admixed in the tablets, capsules, etc. are binders such as gelatin, corn starch, tragacanth and gum arabicum; fillers such as crystalline cellulose; swelling agents such as corn starch, gelatin and alginic acid; lubricants such as magnesium stearate; sweetening agents such as sucrose, lactose and saccharine; preservatives such as parabens and sorbic acid; antioxidants such as ascorbic acid, α -tocopherol and cysteine; fragrances such as peppermint, akamono oil and cherry; disintegrants; buffering agents; etc. Other additives may include mannitol, maltitol, dextran, agar, chitin, chitosan, pectin, collagen, casein, albumin, synthetic or semi-synthetic polymers, glyceride, lactide, etc. When the unit form of the preparation is a capsule, a liquid carrier such as fat/oil may be further added besides the above-mentioned types of materials. The aseptic composition for injection may be formulated by a conventional technique or practice for the preparations such as that the active substance in a vehicle such as water for injection is dissolved or suspended in a naturally occurring plant oil such as sesame oil and palm oil.

Examples of an aqueous liquid for the injection are a physiological saline solution and isotonic solutions containing glucose and other auxiliary agents (e.g. D-sorbitol, D-mannitol, sodium chloride, etc.) wherein a suitable auxiliary solubilizers such as alcohol (e.g. ethanol, etc.), polyalcohol (e.g. propylene glycol, polyethylene glycol, etc.), nonionic surface-active agent (e.g. Polysorbate 80™, HCO-50, etc.), etc. may be jointly used. In the case of the oily liquid, sesame oil, soybean oil, etc. may be exemplified wherein benzyl benzoate, benzyl alcohol, etc. may be jointly used as auxiliary solubilizers.

In addition, buffers (e.g. phosphate buffer, sodium acetate buffer, etc.), analgesic agents (e.g. benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g. human serum albumin, polyethylene glycol, etc.), stabilizers (e.g. benzyl alcohol, phenol, etc.), antioxidants, etc. may be compounded therewith too. The prepared injection solution is filled in suitable ampoules. The formulation prepared as such is safe and less toxic and, therefore, it can be administered to warm-blooded mammals such as rats, rabbits, sheep, swines, cattle, cats, dogs, monkeys, human being, etc.

Dose levels of said galanin receptor agonist and/or galanin receptor antagonist or the salt thereof may vary depending upon the symptom. Specific dose levels for any particular patient will be employed depending upon a variety of factors including the activity of specific compounds employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. In the case of oral administration, it is usually about 0.1-100 mg, preferably about 1.0-50 mg or, more preferably, about 1.0-20 mg per day for adults (as 60 kg). When it is administered parenterally, its dose at a time may vary depending upon the object to be administered, organs to be administered, symptoms, administering methods,

etc. The term "parenteral" as used herein includes subcutaneous injections, intravenous, intramuscular, intraperitoneal injections, or infusion techniques. In the case of injections, it is usually convenient to give by an intravenous route in an amount of about 0.01-30 mg, preferably about 0.1-20 mg or, more preferably, about 0.1-10 mg per day to adults (as 60 kg). In the case of other animals, the dose calculated for 60 kg may be administered as well.

(3) Preventive and Therapeutic Agent for of Galanin Receptor Protein Deficiency Diseases

The galanin receptor protein (e.g., human galanin receptor protein)-encoding DNA can be used a preventive and/or therapeutic agent for treating said galanin receptor protein deficiency diseases.

For example, when there is a patient for whom the physiological action of galanin cannot be expected because of a decrease in the galanin receptor protein (e.g., human galanin receptor protein) *in vivo*, the amount of the galanin receptor protein in the cells of said patient can be increased whereby the action of galanin can be fully achieved by:

(a) administering the galanin receptor protein (e.g., human galanin receptor protein)-encoding DNA to the patient to express it; or

(b) inserting the galanin receptor protein (e.g., human galanin receptor protein)-encoding DNA into cells or the like to express it, followed by transplanting said cells or the like to said patient. Accordingly, the galanin receptor protein (e.g., human galanin receptor protein)-encoding DNA can be used as a safe and less toxic preventive and therapeutic agent for the galanin receptor protein (e.g., human galanin receptor protein) deficiency diseases (e.g., diabetes, Alzheimer's disease, dementia, etc.). It may be used in treating or remedying defects by promoting the acetylcholine liberation, inhibiting the growth hormone secretion, promoting the insulin secretion, promoting the learning behavior, promoting satiety, etc.

When the DNA of the present invention is used as the above-mentioned agent, said DNA may be used alone or after inserting it into a suitable vector such as retrovirus vector, adenovirus vector, adenovirus-associated virus vector, etc. followed by subjecting the product vector to a conventional means. Thus, it may be administered orally parenterally, by inhalation spray, rectally, or topically as pharmaceutical compositions or formulations. Oral formulations include tablets (sugar-coated if necessary), capsules, elixirs, microcapsules, etc. Parenteral formulations include injections such as an aseptic solution or a suspension in water or in other pharmaceutically acceptable liquid. For example, the DNA of the present invention is admixed in a unit dose form which is required for preparing generally approved pharmaceutical preparations together with a physiologically acceptable carriers, flavoring agents, adjuvants, excipients, diluents, fillers, vehicles, antiseptics, stabilizers, binders, etc. whereupon the preparation can be manufactured. The amount of the effective component in those preparations is to be in such an extent that the suitable dose within an indicated range is achieved.

Examples of the additives which can be admixed in the tablets, capsules, etc. are binders such as gelatin, corn starch, tragacanth and gum arabicum; fillers such as crystalline cellulose; swelling agents such as corn starch, gelatin and alginic acid; lubricating agents such as magnesium stearate; sweetening agents such as sucrose, lactose and saccharine; and flavoring agents such as pepper mint, akamono oil and cherry. When the unit dose form of the preparation is a capsule, a liquid carrier such as fat/oil may be further added in addition of the above-mentioned types of materials. The aseptic composition for injection may be formulated by conventional practices for the preparations such as that the active substance in a vehicle such as water for injection is dissolved or suspended in naturally occurring plant oil such as sesame oil and palm oil.

Examples of an aqueous liquid for injection are a physiological saline solution and isotonic solutions containing glucose and other auxiliary agents (e.g. D-sorbitol, D-mannitol, sodium chloride, etc.) wherein a suitable auxiliary solubilizers such as alcohol (e.g. ethanol, etc.), polyalcohol (e.g. propylene glycol polyethylene glycol, etc.), nonionic surface-active agent (e.g. Polysorbate 80™, HCO-50, etc.), etc. may be jointly used. Examples of an oily liquid include sesame oil, soybean oil, etc. wherein benzyl benzoate, benzyl alcohol, etc. may be jointly used as auxiliary solubilizers. In addition, buffers (e.g. phosphate buffer, sodium acetate buffer, etc.), analgesic agents (e.g. benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g. human serum albumin, polyethylene glycol, etc.), stabilizers (e.g. benzyl alcohol phenol, etc.), antioxidants, etc. may be admixed therewith too. The prepared injection solution is filled in suitable ampoules. The preparation prepared as such is safe and less toxic and, therefore, it can be administered to warm-blooded animals (e.g., rat, rabbit, sheep, swine, cattle, cat, dog, monkey, human beings, etc.).

Specific dose levels of said DNA may vary depending upon a variety of factors including the activity of drugs employed, the age, body weight, general health, sex, diet, time of administration, route of administration, drug combination, and the severity of the symptom. In the case of oral administration, it is usually about 0.1-100 mg, preferably about 1.0-50 mg or, more preferably, about 1.0-20 mg per day for adults (as 60 kg). When it is administered parenterally, its dose at a time may vary depending upon the object (patient) to be administered, organs to be administered, symptoms, administering methods, etc. but, in the case of injections, it is usually convenient to give by an intravenous route in an amount of about 0.01-30 mg, preferably about 0.1-20 mg or, more preferably, about 0.1-10mg per day to adults (as 60 kg). For other animals, the dose calculated from the above based upon the body weight may be administered.

Furthermore, the method of inserting the DNA of the present invention into cells to express said galanin receptor protein (e.g., human galanin receptor protein, etc.) followed by transplanting said cells to the patient may be carried out by a method which is known per se or is similar thereto.

5 (4) Manufacture of Antibody or Antiserum against the Galanin Receptor Protein of the Present Invention, Its Partial Peptide or Its Salt.

Antibodies (e.g. polyclonal antibody and monoclonal antibody) and antisera against the galanin receptor protein or salt thereof of the present invention or against the peptide fragment of the galanin receptor protein or salt thereof of the present invention may be manufactured by antibody or antiserum-manufacturing methods per se known to those of skill in the art or methods similar thereto, using the galanin receptor protein or its salt of the present invention or the partial peptide (fragment) of the galanin receptor protein or its salt of the present invention. For example, monoclonal antibodies can be manufactured by the method as given herein below.

15 [Preparation of Monoclonal Antibody]

(a) Preparation of Monoclonal Antibody-Producing Cells.

The galanin receptor protein of the present invention or its salt or the partial peptide of the galanin receptor protein of the present invention or its salt is administered to warm-blooded animals either solely or together with carriers or diluents to the site where the production of antibody is possible by the administration. In order to potentiate the antibody productivity upon the administration, complete Freund's adjuvants or incomplete Freund's adjuvants may be administered. The administration is usually carried out once every two to six weeks and two to ten times in total. Examples of the applicable warm-blooded animals are monkeys, rabbits, dogs, guinea pigs, mice, rats, sheep, goats chickens and hamsters and the use of mice, rats and hamsters is preferred.

In the preparation of the cells which produce monoclonal antibodies, an animal wherein the antibody titer is noted is selected from warm-blooded animals (e.g. mice) immunized with antigens, then spleen or lymph node is collected after two to five days from the final immunization and antibody-producing cells contained therein are fused with myeloma cells to give monoclonal antibody-producing hybridomas. Measurement of the antibody titer in antisera may, for example, be carried out by reacting a labeled galanin receptor protein (which will be mentioned later) with the antiserum followed by measuring the binding activity of the labeling agent with the antibody. The operation for fusing may be carried out, for example, by a method of Koehler and Milstein (Nature, 256, 495, 1975). Examples of the fusion accelerator are polyethylene glycol (PEG), Sendai virus, etc. and the use of PEG is preferred.

Examples of the myeloma cells are NS-1, P3U1, SP2/0, AP-1, etc. and the use of P3U1 is preferred. The preferred fusion ratio of the numbers of antibody-producing cells used (spleen cells) to the numbers of myeloma cells is within a range of about 1:1 to 20:1. When PEG (preferably, PEG 1000 to PEG 6000) is added in a concentration of about 10-80% followed by incubating at 20-40°C (preferably, at 30-37°C) for one to ten minutes, an efficient cell fusion can be carried out.

Various methods may be applied for screening a hybridoma which produces anti-galanin receptor antibody. For example, a supernatant liquid of hybridoma culture is added to a solid phase (e.g. microplate) to which the galanin receptor protein antigen is adsorbed either directly or with a carrier, then anti-immunoglobulin antibody (anti-mouse immunoglobulin antibody is used when the cells used for the cell fusion are those of mouse) which is labeled with a radioactive substance, an enzyme or the like, or protein A is added thereto and then anti-galanin receptor monoclonal antibodies bound on the solid phase are detected; or a supernatant liquid of the hybridoma culture is added to the solid phase to which anti-immunoglobulin or protein A is adsorbed, then the galanin receptor labeled with a radioactive substance or an enzyme is added and anti-galanin receptor monoclonal antibodies bonded with the solid phase is detected.

Selection and cloning of the anti-galanin receptor monoclonal antibody-producing hybridoma may be carried out by methods per se known to those of skill in the art or methods similar thereto. Usually, it is carried out in a medium for animal cells, containing HAT (hypoxanthine, aminopterin and thymidine). With respect to a medium for the selection, for the cloning and for the growth, any medium may be used so far as hybridoma is able to grow therein. Examples of the medium are an RPMI 1640 medium (Dainippon Pharmaceutical Co., Ltd., Japan) containing 1-20% (preferably 10-20%) of fetal calf serum (FCS), a GIT medium (Wako Pure Chemical, Japan) containing 1-20% of fetal calf serum and a serum-free medium for hybridoma culturing (SFM-101; Nissui Seiyaku, Japan). The culturing temperature is usually 20-40°C and, preferably, about 37°C. The culturing time is usually from five days to three weeks and, preferably, one to two weeks. The culturing is usually carried out in 5% carbon dioxide gas. The antibody titer of the supernatant liquid of the hybridoma culture may be measured by the same manner as in the above-mentioned measurement of the antibody titer of the anti-galanin receptor in the antiserum.

The cloning can be usually carried out by methods known per se such as techniques in semi-solid agar and limiting dilution. The cloned hybridoma is preferably cultured in modern serum-free culture media to obtain optimal amounts of

antibody in supernatants. The target monoclonal antibody is also preferably obtained from ascitic fluid derived from a mouse, etc. injected intraperitoneally with live hybridoma cells.

(b) Purification of the Monoclonal Antibody.

Like in the separation/purification of conventional polyclonal antibodies, the separation/purification of the anti-galanin receptor monoclonal antibody may be carried out by methods for separating/purifying immunoglobulin (such as salting-out, precipitation with an alcohol, isoelectric precipitation, electrophoresis, adsorption/deadsorption using ion exchangers such as DEAE, ultracentrifugation, gel filtration, specific purifying methods in which only an antibody is collected by treatment with an active adsorbent (such as an antigen-binding solid phase, protein A or protein G) and the bond is dissociated whereupon the antibody is obtained.

The galanin receptor antibody of the present invention which is manufactured by the aforementioned method (a) or (b) is capable of specifically recognizing galanin receptors and, accordingly, it can be used for a quantitative determination of the galanin receptor in test liquid samples and particularly for a quantitative determination by sandwich immunoassays.

Thus, the present invention provides, for example, the following methods:

(i) a quantitative determination of a galanin receptor in a test liquid sample, which comprises

- (a) competitively reacting the test liquid sample and a labeled galanin receptor with an antibody which reacts with the galanin receptor of the present invention, and
- (b) measuring the ratio of the labeled galanin receptor binding with said antibody; and

(ii) a quantitative determination of a galanin receptor in a test liquid sample, which comprises

- (a) reacting the test liquid sample with an antibody immobilized on an insoluble carrier and a labeled antibody simultaneously or continuously, and
- (b) measuring the activity of the labeling agent on the insoluble carrier wherein one antibody is capable of recognizing the N-terminal region of the galanin receptor while another antibody is capable of recognizing the C-terminal region of the galanin receptor.

When the monoclonal antibody of the present invention recognizing a galanin receptor (hereinafter, may be referred to as "anti-galanin receptor antibody") is used, galanin receptors can be measured and, moreover, can be detected by means of a tissue staining, etc. as well. For such an object, antibody molecules per se may be used or $F(ab')_2$, Fab' or Fab fractions of the antibody molecule may be used too. There is no particular limitation for the measuring method using the antibody of the present invention and any measuring method may be used so far as it relates to a method in which the amount of antibody, antigen or antibody-antigen complex, depending on or corresponding to the amount of antigen (e.g. the amount of galanin receptor, etc.) in the liquid sample to be measured, is detected by a chemical or a physical means and then calculated using a standard curve prepared by a standard solution containing the known amount of antigen. For example, nephrometry, competitive method, immunometric method and sandwich method are suitably used and, in terms of sensitivity and specificity, the sandwich method which will be described herein later is particularly preferred.

Examples of the labeling agent used in the measuring method using the labeling substance are radioisotopes, enzymes, fluorescent substances, luminescent substances, colloids, magnetic substances, etc. Examples of the radioisotope are $[^{125}I]$, $[^{131}I]$, $[^3H]$ and $[^{14}C]$; preferred examples of the enzyme are those which are stable and with big specific activity, such as β -galactosidase, β -glucosidase, alkali phosphatase, peroxidase and malate dehydrogenase; examples of the fluorescent substance are fluorescamine, fluorescein isothiocyanate, etc.; and examples of the luminescent substance are luminol, luminol derivatives, luciferin, lucigenin, etc. Further, a biotin-avidin system may also be used for binding an antibody or antigen with a labeling agent.

In an insolubilization (immobilization) of antigens or antibodies, a physical adsorption may be used or a chemical binding which is usually used for insolubilization or immobilization of proteins or enzymes may be used as well. Examples of the carrier are insoluble polysaccharides such as agarose, dextran and cellulose; synthetic resins such as polystyrene, polyacrylamide and silicone; glass; etc.

In a sandwich (or two-site) method, the test liquid is made to react with an insolubilized anti-galanin receptor antibody (the first reaction), then it is made to react with a labeled anti-galanin receptor antibody (the second reaction) and the activity of the labeling agent on the insoluble carrier is measured whereupon the amount of the galanin receptor in the test liquid can be determined. The first reaction and the second reaction may be conducted reversely or simultaneously or they may be conducted with an interval. The type of the labeling agent and the method of insolubilization (immobilization) may be the same as those mentioned already herein. In the immunoassay by means of a sandwich method, it is not always necessary that the antibody used for the labeled antibody and the antibody for the solid phase is one type

or one species but, with an object of improving the measuring sensitivity, etc., a mixture of two or more antibodies may be used too.

In the method of measuring galanin receptors by the sandwich method of the present invention, the preferred anti-galanin receptor antibodies used for the first and the second reactions are antibodies wherein their sites binding to the galanin receptors are different each other. Thus, the antibodies used in the first and the second reactions are those wherein, when the antibody used in the second reaction recognizes the C-terminal region of the galanin receptor, then the antibody recognizing the site other than C-terminal regions, e.g. recognizing the N-terminal region, is preferably used in the first reaction.

The anti-galanin receptor antibody of the present invention may be used in a measuring system other than the sandwich method such as a competitive method, an immunometric method and a nephrometry. In a competitive method, an antigen in the test solution and a labeled antigen are made to react with an antibody in a competitive manner, then an unreacted labeled antigen (F) and a labeled antigen binding with an antibody (B) are separated (i.e. B/F separation) and the labeled amount of any of B and F is measured whereupon the amount of the antigen in the test solution is determined. With respect to a method for such a reaction, there are a liquid phase method in which a soluble antibody is used as the antibody and the B/F separation is conducted by polyethylene glycol, a second antibody to the above-mentioned antibody, etc.; and a solid phase method in which an immobilized antibody is used as the first antibody or a soluble antibody is used as the first antibody while an immobilized antibody is used as the second antibody.

In an immunometric method, an antigen in the test solution and an immobilized antigen are subjected to a competitive reaction with a certain amount of a labeled antibody followed by separating into solid and liquid phases; or the antigen in the test solution and an excess amount of labeled antibody are made to react, then a immobilized antigen is added to bind an unreacted labeled antibody with the solid phase and separated into solid and liquid phases. After that, the labeled amount of any of the phases is measured to determine the antigen amount in the test solution.

In a nephrometry, the amount of insoluble sediment which is produced as a result of the antigen-antibody reaction in a gel or in a solution is measured. Even when the antigen amount in the test solution is small and only a small amount of the sediment is obtained, a laser nephrometry wherein scattering of laser is utilized can be suitably used.

In applying each of those immunological measuring methods (immunoassays) to the measuring method of the present invention, it is not necessary to set up any special condition, operation, etc. therefor. A measuring system (assay system) for galanin receptor may be constructed taking the technical consideration of the persons skilled in the art into consideration in the conventional conditions and operations for each of the methods. With details of those conventional technical means, a variety of reviews, reference books, etc. may be referred to. They are, for example, Hiroshi Irie (ed): "Radioimmunoassay" (Kodansha, Japan, 1974); Hiroshi Irie (ed): "Radioimmunoassay; Second Series" (Kodansha, Japan, 1979); Eiji Ishikawa et al. (ed): "Enzyme Immunoassay" (Igaku Shoin, Japan, 1978); Eiji Ishikawa et al. (ed): "Enzyme Immunoassay" (Second Edition) (Igaku Shoin, Japan, 1982); Eiji Ishikawa et al. (ed): "Enzyme Immunoassay" (Third Edition) (Igaku Shoin, Japan, 1987); "Methods in Enzymology" Vol. 70 (Immunochemical Techniques (Part A)); ibid. Vol. 73 (Immunochemical Techniques (Part B)); ibid. Vol. 74 (Immunochemical Techniques (Part C)); ibid. Vol. 84 (Immunochemical Techniques (Part D: Selected Immunoassays)); ibid. Vol. 92 (Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods)); ibid. Vol. 121 (Immunochemical Techniques (Part I: Hybridoma Technology and Monoclonal Antibodies)) (Academic Press); etc.

As such, the amount of galanin receptor proteins can now be determined with a high precision using the anti-galanin receptor antibody of the present invention.

(5) Preparation of Animals Having the Galanin Receptor Protein-Encoding DNA of the Present Invention.

It is possible to prepare transgenic animals expressing galanin receptors using galanin receptor protein-encoding DNA. Examples of the animals are warm-blooded mammals such as rats, mice, rabbit, sheep, swines, cattle, cats, dogs and monkeys.

In transferring the galanin receptor protein-encoding DNA to the aimed animal, it is generally advantageous that said DNA is used by ligating with a site at the downstream of a promoter which is capable of expressing in animal cells. For example, when galanin receptor protein DNA is to be transferred to a rabbit, a gene construct ligated with a site at the downstream of various promoters which are capable of expressing the galanin receptor protein DNA derived from an animal compatible to the animal in animal host cells is subjected to a microinjection to the fertilized ovum (oosperm) of the aimed animal (e.g. fertilized ovum (embryo) of rabbit) whereupon the transgenic animal which produces the galanin receptor protein in a high amount can be prepared.

Examples of the promoters used are promoters derived from virus and ubiquitous expression promoters such as metallothionein promoters may be used but, preferably, enolase gene promoters and NGF gene promoters capable of specifically expressing in brain are used.

Transfer of the galanin receptor protein DNA at a fertilized ovum cell stage is secured in order that the DNA can be present in all of embryonal cells and body somatic cells of an aimed animal. The fact that the galanin receptor protein is present in the fertilized ovum cells of the produced transgenic animal after the DNA transfer means that all progeny

of the produced transgenic animal have the galanin receptor protein in all of their embryonal cells and somatic cells. Descendants (offsprings) of the animal of this type which inherited the gene have the galanin receptor protein in all of their embryonal cells and somatic cells.

5 The transgenic animal to which the galanin receptor protein DNA is transferred can be subjected to a mating and a breeding for generations under a common breeding circumstance as the animal holding said DNA after confirming that the gene can be stably retained. Moreover, male and female animals having the desired DNA are mated to give a homozygote having the transduced gene in both homologous chromosomes and then those male and female animals are mated whereby it is possible to breed for generations so that all descendants have said DNA.

10 The animal to which the galanin receptor protein DNA is transferred highly expresses the galanin receptor protein and, accordingly, it is useful as the animal for screening for an agonist or an antagonist to said galanin receptor protein.

The DNA-transferred animal can be used as a cell source for a tissue culture. For example, DNA or RNA in the tissue of the DNA-transferred mouse is directly analyzed or protein tissues expressed by gene are analyzed whereupon the galanin receptor protein can be analyzed. Cells of the galanin receptor protein-containing tissue are cultured by standard tissue culture techniques whereupon it is possible to study the function of the cells which are usually difficult to culture (e.g. those derived from brain and peripheral tissues) using the resulting culture. By using said cells, it is also possible to select the pharmaceuticals which can potentiate, for example, the functions of various tissues. Moreover, if a cell strain with a high expression is available, it is possible to separate and purify galanin receptor proteins therefrom.

15 In the specification and drawings of the present application, the abbreviations used for bases (nucleotides), amino acids and so forth are those recommended by the IUPAC-IUB Commission on Biochemical Nomenclature or those conventionally used in the art. Examples thereof are given below. Amino acids for which optical isomerism is possible are, unless otherwise specified, in the L form.

	DNA :	Deoxyribonucleic acid
	cDNA:	Complementary deoxyribonucleic acid
25	A :	Adenine
	T :	Thymine
	G :	Guanine
	C :	Cytosine
	RNA :	Ribonucleic acid
30	mRNA :	Messenger ribonucleic acid
	dATP:	Deoxyadenosine triphosphate
	dTTP:	Deoxythymidine triphosphate
	dGTP:	Deoxyguanosine triphosphate
	dCTP:	Deoxycytidine triphosphate
35	ATP :	Adenosine triphosphate
	EDTA:	Ethylenediamine tetraacetic acid
	SDS :	Sodium dodecyl sulfate
	EIA:	Enzyme Immunoassay
	G, Gly:	Glycine (or Glycyl)
40	A, Ala:	Alanine (or Alanyl)
	V, Val:	Valine (or Valyl)
	L, Leu:	Leucine (or Leucyl)
	I, Ile:	Isoleucine (or Isoleucyl)
	S, Ser:	Serine (or Seryl)
45	T, Thr:	Threonine (or Threonyl)
	C, Cys:	Cysteine (or Cysteinyl)
	M, Met:	Methionine (or Methionyl)
	E, Glu:	Glutamic acid (or Glutamyl)
	D, Asp:	Aspartic acid (or Aspartyl)
50	K, Lys:	Lysine (or Lysyl)
	R, Arg:	Arginine (or Arginyl)
	H, His:	Histidine (or Histidyl)
	F, Phe:	Phenylalanine (or Phenylalanyl)
	Y, Tyr:	Tyrosine (or Tyrosyl)
55	W, Trp:	Tryptophan (or Tryptophanyl)
	P, Pro:	Proline (or Prolyl)
	N, Asn:	Asparagine (or Asparaginyl)
	Q, Gln:	Glutamine (or Glutaminyl)
	NVal:	Norvaline (or Norvalyl)

pGlu: Pyroglutamic acid (or Pyroglutamyl)
 Blc: γ -Butyrolacton- γ -carbonyl
 Kpc: 2-Ketopiperidiny-6-carbonyl
 Otc: 3-Oxoperhydro-1,4-thiazin-5-carbonyl
 5 Me: Methyl
 Et: Ethyl
 Bu: Butyl
 Ph: Phenyl
 TC: Thiazolidinyl-4(R)-carboxamide

10 The transformant *Escherichia coli*, designated JM109/p3H2-34, which is obtained in the Example 3 mentioned herein below, is on deposit under the terms of the Budapest Treaty from October 12, 1994, with the National Institute of Bioscience and Human Technology (NIBH), Agency of Industrial Science and Technology, Ministry of International Trade and Industry, Japan and has been assigned the Accession Number FERM BP-4828. It is also on deposit from October
 15 12, 1994 with the Institute for Fermentation, Osaka, Japan (IFO) and has been assigned the Accession Number IFO 15749.

The transformant *Escherichia coli*, designated JM109/pMGR20, which is obtained in the Example 4 mentioned herein below, is on deposit under the terms of the Budapest Treaty from December 15, 1994, with NIBH and has been assigned the Accession Number FERM BP-4937. It is also on deposit from December 14, 1994 with IFO and has been
 20 assigned the Accession Number IFO 15773.

The mouse pancreatic β cell line, designated MIN6, is on deposit under the terms of the Budapest Treaty from December 27, 1994, with NIBH and has been assigned the Accession Number FERM BP-4954. It is also on deposit from April 11, 1995 with IFO and has been assigned the Accession Number IFO 50454.

25 The transformant *Escherichia coli*, designated SURE/pTS863, which is obtained in the Example 12 mentioned herein below, is on deposit under the terms of the Budapest Treaty from May 25, 1995, with NIBH and has been assigned the Accession Number FERM BP-5110. It is also on deposit from June 1, 1995 with IFO and has been assigned the Accession Number IFO 15826.

The transformant CHO cell, designated CHO/pTS863-5, which is obtained in the Example 13 mentioned herein below, is on deposit under the terms of the Budapest Treaty from May 25, 1995, with NIBH and has been assigned the
 30 Accession Number FERM BP-5111. It is also on deposit from June 1, 1995 with IFO and has been assigned the Accession Number IFO 50456.

The transformant CHO cell, designated CHO/pTS863-7, which is obtained in the Example 13 mentioned herein below, is on deposit under the terms of the Budapest Treaty from May 25, 1995, with NIBH and has been assigned the
 35 Accession Number FERM BP-5112. It is also on deposit from June 1, 1995 with IFO and has been assigned the Accession Number IFO 50457.

Each SEQ ID NO set forth in the SEQUENCE LISTING of the specification refers to the following sequence:

[SEQ ID NO: 1] is a partial amino acid sequence encoded by the mouse pancreatic β -cell line, MIN6-derived galanin receptor protein cDNA included in p3H2-34,

40 [SEQ ID NO: 2] is a full length amino acid sequence encoded by the mouse pancreatic β -cell line, MIN6-derived galanin receptor protein cDNA included in pMGR20,

[SEQ ID NO: 3] is a nucleotide sequence of the mouse pancreatic β -cell line, MIN6-derived galanin receptor protein cDNA fragment included in p3H2-34,

45 [SEQ ID NO: 4] is a nucleotide sequence of the translational unit in the mouse pancreatic β -cell line, MIN6-derived galanin receptor protein cDNA fragment included in pMGR20,

[SEQ ID NO: 5] is a full length amino acid sequence encoded by the human galanin receptor protein cDNA obtained in Example 11.

[SEQ ID NO: 6] is a nucleotide sequence of the translational unit in the human galanin receptor protein cDNA obtained in Example 11.

50 The practice of the present invention will employ, otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, pharmacology, immunology, bioscience, and medical technology, which are within the skill of the art. All patents, patent applications, and publications mentioned herein, both supra and infra, are hereby incorporated herein by reference.

55 EXAMPLES

Described below are working examples of the present invention which are provided only for illustrative purposes, and not to limit the scope of the present invention. In light of the present disclosure, numerous embodiments within the

scope of the claims will be apparent to those of ordinary skill in the art. Incidentally, the gene operation using *Escherichia coli* is carried out by a method described in Maniatis, et al.: "Molecular Cloning" (Cold Spring Harbor Laboratory, 1989).

Reference Example 1

Preparation of Synthetic DNA Primer for Amplifying DNA Coding for G Protein Coupled Receptor Protein

A comparison of deoxyribonucleotide sequences coding for the known amino acid sequences corresponding to or near the first membrane-spanning domain each of human-derived TRH receptor protein (HTRHR), human-derived RANTES receptor protein (L10918, HUMRANTES), human Burkitt's lymphoma-derived unknown ligand receptor protein (X68149, HSBLR1A), human-derived somatostatin receptor protein (L14856, HUMSOMAT), rat-derived μ -opioid receptor protein (U02083, RNU02083), rat-derived κ -opioid receptor protein (U00442, U00442), human-derived neuromedin B receptor protein (M73482, HUMNMBR), human-derived muscarinic acetylcholine receptor protein (X15266, HSHM4), rat-derived adrenaline α_1 B receptor protein (L08609, RATAADRE01), human-derived somatostatin 3 receptor protein (M96738, HUMSSTR3X), human-derived C_{5a} receptor protein (HUMC5AAR), human-derived unknown ligand receptor protein (HUMRDC1A), human-derived unknown ligand receptor protein (M84605, HUMOPIODRE) and rat-derived adrenaline α_2 B receptor protein (M91466, RATA2BAR) was made. As a result, highly homologous regions or parts were found.

Further, a comparison of deoxynucleotide sequences coding for the known amino acid sequences corresponding to or near the sixth membrane-spanning domain each of mouse-derived unknown ligand receptor protein (M80481, MUSGIR), human-derived bombesin receptor protein (L08893, HUMBOMB3S), human-derived adenosine A2 receptor protein (S46950, S46950), mouse-derived unknown ligand receptor protein (D21061, MUSGPCR), mouse-derived TRH receptor protein (S43387, S43387), rat-derived neuromedin K receptor protein (J05189, RATNEURA), rat-derived adenosine A1 receptor protein (M69045, RATA1ARA), human-derived neurokinin A receptor protein (M57414, HUMNEKAR), rat-derived adenosine A3 receptor protein (M94152, RATADENREC), human-derived somatostatin 1 receptor protein (M81829, HUMSRI1A), human-derived neurokinin 3 receptor protein (S86390, S86371S4), rat-derived unknown ligand receptor protein (X61496, RNCGPCR), human-derived somatostatin 4 receptor protein (L07061, HUMSSTR4Z) and rat-derived GnRH receptor protein (M31670, RATGNRHA) was made. As a result, highly homologous regions or parts were found.

The aforementioned abbreviations in the parentheses are identifiers (reference numbers) which are indicated when GenBank/EMBL Data Bank is retrieved by using DNASIS Gene/Protein Sequencing Data Base (CD019, Hitachi Software Engineering, Japan) and are usually called "Accession Numbers" or "Entry Names". HTRHR is, however, the sequence as disclosed in Japanese Unexamined Patent Publication No. 286986/1993 (EPA 638645).

Specifically, it was planned to incorporate mixed bases relying upon the base regions that were in agreement with cDNAs coding for a large number of receptor proteins in order to enhance base agreement of sequences with as many receptor cDNAs as possible even in other regions. Based upon these sequences, the degenerate synthetic DNA having a nucleotide sequence represented by SEQ ID NO: 7 which is complementary to the homologous nucleotide sequence and the degenerate synthetic DNA having a nucleotide sequence represented by SEQ ID NO: 8 which is complementary to the homologous nucleotide sequence were produced. Nucleotide synthesis was carried out by a DNA synthesizer.

[Synthetic DNAs]

5'-CGTGG (G or C) C (A or C) T (G or C) (G or C) TGGGCAAC (A, G, C or T) (C or T) CCTG-3' (SEQ ID NO: 7)

5'-GT (A, G, C or T) G (A or T) (A or G) (A or G) GGCA (A, G, C or T) CCAGCAGA (G or T) GGCAAA-3' (SEQ ID NO: 8)

The parentheses indicate the incorporation of a plurality of bases, leading to multiple oligonucleotides in the primer preparation. In other words, nucleotide residues in parentheses of the aforementioned DNAs were incorporated in the presence of a mixture of plural bases at the time of synthesis.

Example 1

Preparation of Poly(A)⁺RNA Fraction from Mouse Pancreatic β -Cell Strain, MIN6 and Synthesis of cDNA

A total RNA was prepared from the mouse pancreatic β -cell strain, MIN6 (Jun-ichi Miyazaki et al., Endocrinology, Vol. 127, No. 1, p.126-132) according to the guanidine thiocyanate method (Kaplan B.B. et al., Biochem. J., 183, 181-184 (1979)) and, then, poly(A)⁺RNA fractions were prepared with a mRNA purifying kit (Pharmacia Co.). Next, to 5 μ g of the poly(A)⁺RNA fraction was added a random DNA hexamer (BRL Co.) as a primer, and the resulting mixture was subjected to reaction with mouse Moloney Leukemia virus (MMLV) reverse transcriptase (BRL Co.) in the buffer attached to the MMLV reverse transcriptase kit to synthesize complementary DNAs. The reaction product was extracted with phenol/chloroform (1:1), precipitated in ethanol, and was then dissolved in 30 μ l of TE buffer (10 mM Tris-HCl at pH8.0, 1 mM EDTA at pH8.0).

Example 2

Amplification of Receptor cDNA by PCR Using MIN6-Derived cDNA and Sequencing

By using, as a template, 5 μ l of cDNA prepared from the mouse pancreatic β -cell strain, MIN6 in Example 1, PCR amplification using the DNA primers synthesized in Reference Example 1 was carried out. A reaction solution was composed of the synthetic DNA primers each in an amount of 100 pM, 0.25 mM dNTPs, 1 μ l of Taq DNA polymerase and 10 μ l of 10x buffer attached to the enzyme kit, and the total amount of the reaction solution was made to be 100 μ l. The cycle for amplification including 96 °C for 30 sec., 45 °C for 1 min. and 60 °C for 3 min. was repeated 30 times by using a Thermal Cycler (Perkin-Elmer Co.). Prior to adding Taq DNA polymerase, the remaining reaction solution was mixed and was heated at 95 °C for 5 minutes and at 65 °C for 5 minutes. The amplified products were confirmed relying upon 1.2% agarose gel electrophoresis and ethidium bromide staining.

Example 3

Subcloning of PCR Product into Plasmid Vector and Selection of Novel Receptor Candidate Clone via Decoding Nucleotide Sequence of Inserted cDNA Region

The PCR products obtained in Example 2 were separated with a 0.8% low-melting temperature agarose gel, the band parts were excised from the gel with a razor blade, and were heat-melted, extracted with phenol and precipitated in ethanol to recover DNAs. According to the protocol attached to a TA Cloning Kit (Invitrogen Co.), the recovered DNAs were subcloned to the plasmid vector, pCR™II (Invitrogen Co.). The recombinant vectors were introduced into *E. coli* JM109 competent cells (Takara Shuzo Co., Japan) to produce transformants. Then, transformant clones having a cDNA-inserted fragment were selected in an LB (Luria-Bertani) agar culture medium containing ampicillin, IPTG (isopropylthio- β -D-galactoside) and X-gal (5-bromo-4-chloro-3-indolyl- β -D-galactoside). Only transformant clones exhibiting white color were picked with a sterilized toothstick to obtain transformant *Escherichia coli* JM109/p3H2-34.

The individual clones were cultured overnight in an LB culture medium containing ampicillin and treated with an automatic plasmid extracting machine (Kurabo Co., Japan) to prepare plasmid DNAs. An aliquot of the DNAs thus prepared was cut by EcoRI to confirm the size of the cDNA fragment that was inserted. An aliquot of the remaining DNAs was further processed with RNase, extracted with phenol/chloroform, and precipitated in ethanol so as to be condensed. Sequencing was carried out by using a DyeDeoxy terminator cycle sequencing kit (ABI Co.), the DNAs were decoded by using a fluorescent automatic sequencer, and the data of the nucleotide sequences obtained were read by using DNASIS (Hitachi System Engineering Co., Japan).

Homology retrieval was carried out based upon the determined nucleotide sequence [FIG. 1]. As a result, it was learned that a novel G protein coupled receptor protein was encoded by the cDNA fragment insert in the plasmid possessed by the transformant *Escherichia coli* JM109/p3H2-34. To further confirm this fact, by using DNASIS (Hitachi System Engineering Co., Japan) the nucleotide sequence were converted into an amino acid sequence [FIG. 1], and homology retrieval was carried out in view of hydrophobicity plotting [FIG. 2] and at the amino acid sequence level to find homology relative to human somatostatin receptor subtype 4 (JN0605), human somatostatin receptor subtype 2 (B41795) and rat-derived ligand unknown receptor (A39297) [FIG. 3]. Abbreviations in parentheses are reference numbers assigned when they are registered as data to NBRF-PIR/Swiss-PROT and are usually called "Accession Numbers" or "Entry Names".

Example 4Cloning of cDNA containing Whole Coding Region for Receptor Protein from Mouse Pancreatic β -Cell Strain, MIN6-Derived cDNA Library

Superscript™ Lambda System (BRL, Cat. 8256) distributed by BRL Co. and Gigapack II Gold (Stratagene, Cat. 200215) distributed by Stratagene Co. were used to construct MIN6-derived cDNA libraries. By using the above kits, a MIN6 cDNA library with 2.2×10^6 pfu (plaque forming units) was constructed from 10 μ g of MIN6 poly(A)⁺RNA. The cDNA library was mixed with *E. coli* Y1090^r treated with magnesium sulfate, and incubated at 37 °C for 15 minutes followed by addition of 0.5% agarose (Pharmacia Co.) LB. The *E. coli* was plated onto a 1.5% agar (Wako Pure Chemical Co., Japan) LB plate (containing 50 μ g/ml of ampicillin). A nitrocellulose filter was placed on the plate on which plaques were formed and the plaque was transferred onto the filter. The filter was denatured with an alkali and then heated at 80 °C for 3 hours to fix DNAs.

The filter was incubated overnight at 42 °C together with the probe mentioned herein below in a buffer containing 50% formamide, 4 x SSPE (20 x SSPE (pH 7.4) is 3 M NaCl, 0.2 M NaH₂PO₄ · H₂O, 25 mM EDTA), 5 X Denhardt's solution, 0.1% SDS and 100 μ g/ml of salmon sperm DNA for hybridization.

The probe used was obtained by cutting the DNA fragment inserted in the plasmid, p3H2-34, obtained in Example 2, with EcoRI, followed by recovery and labeling by incorporation of [³²P]dCTP (Dupont/NEN) with a random prime DNA labelling kit (Amersham Co.).

5 It was washed with 2 x SSC (150 mM NaCl and 15 mM sodium citrate), 0.1% SDS at 55 °C for 1 hour and, then, subjected to an autoradiography at -80 °C to detect hybridized plaques.

In this screening, hybridization signals were recognized in two independent plaques. Each DNA was prepared from the two clones. The DNAs digested with Sall and NotI were subjected to an agarose electrophoresis and were analyzed. Inserted fragments were identified at about 2.0kb and 3.0kb, respectively. Between them, the DNA fragment corresponding to the band at about 3.0kb (λ No.20) was selected. The λ No.20-derived NotI-Sall fragment with about 3.0kb was subcloned into the NotI-Sall site of the plasmid, pBluescript™II SK(+), and *E. coli* JM109 was transformed with the plasmid to obtain a transformant *E. coli* JM109/pMGR20. A restriction enzyme map of the plasmid, pMGR20, was prepared relying upon a restriction enzyme map deduced from the nucleotide sequence as shown in Example 2. As a result, it was learned that it carried a full-length receptor protein-encoding DNA which was predicted from the receptor protein-encoding DNA as shown in Example 2.

15 Example 5

Sequencing of MIN6-Derived Receptor Protein Full-Length cDNA

20 Among the NotI-Sall fragments inserted in the plasmid, pMGR20, obtained in Example 4, the nucleotide sequence with total 1607bp, including not only a region that is considered to be a receptor protein-coding region (ORF) but also a neighboring region thereof was sequenced. Concretely speaking, by utilizing restriction enzyme sites that exist in the NotI-Sall fragments, unnecessary parts were removed or necessary fragments were subcloned in order to prepare template plasmids for analyzing the nucleotide sequence thereof. As for the nucleotide sequences of part of the regions, primers for sequencing were synthesized based upon the nucleotide sequences that were determined already and used to make confirmation.

The reaction for determining the nucleotide sequence (sequencing) was carried out with a DyeDeoxy terminator cycle sequencing kit (ABI Co.), the DNA was decoded with the fluorescent automatic sequencer (ABI Co.), and the data of the nucleotide sequence obtained were analyzed with DNASIS (Hitachi System Engineering Co., Japan).

30 FIG. 4 shows a nucleotide sequence around an open reading frame (ORF) of a mouse galanin receptor protein encoded by the cDNA insert in pMGR20. The nucleotide sequence of mouse galanin receptor protein-encoding DNA corresponds to from the 481st to 1525th nucleotides of the nucleotide sequence in FIG. 4. The amino acid sequence of the receptor protein encoded by the DNA insert was that as represented by SEQ ID NO: 2 (FIG. 4). Since the amino acid sequence has 92% homology to the human-derived galanin receptor protein at the amino acid sequence level, it was learned that the cDNA insert in the pMGR20 is a mouse-derived galanin receptor protein-encoding cDNA.

40 Example 6

Galanin Receptor Binding Experiment using MIN6 Cell Membrane Fraction.

(1) Preparation of Membrane Fractions from MIN6 Cells.

MIN6 cells were cultured by a known method (Endocrinology, vol. 127, pages 126-132, 1990). Thus, the culturing was carried out in a Dulbecco modified Eagle's medium containing 15% of fetal bovine serum, 4.5 g/liter of glucose, 5 μ/liter of mercaptoethanol, 75 mg/ml of penicillin and 50 mg/ml of streptomycin in the presence of 5% carbon dioxide gas. The cultured cells were washed with PBS containing EDTA and exfoliated from the culturing device. The exfoliated cells were recovered by centrifugation and subjected to the following method of preparing the membrane fractions.

50 The recovered cells (about 2.5 ml) were suspended in a buffer for homogenization (containing 10 mM of NaHCO₃, 5mM of EDTA, 0.5mM of PMSF, 10 μ g/ml of pepstatin, 20 μ g/ml of leupeptin and 4 μ g/ml of E-64; pH: 7.2) and homogenized with a polytron homogenizer (Kinematica) at 23,000 rpm for one minute. The resulting homogenate was centrifuged in a Hitachi RP24A rotor using a Hitachi High-Speed Centrifuging Machine (type: CR26H) at 5,000 rpm for ten minutes. The supernatant liquid after centrifugation was recovered and subjected to an ultracentrifugation in a Hitachi RP42 rotor using a Hitachi Ultracentrifugal Machine (type: SCP70H) at 30,000 rpm for one hour to give pellets. The resulting pellets were again suspended in a buffer for the homogenization and stored at -70 °C until its actual use.

55 (2) Receptor Binding Experiment using MIN6 Cell Membrane Fractions.

The MIN6 cell membrane fractions prepared by the method of the above-mentioned (1) were diluted with a buffer for the receptor binding experiment (containing 20mM of Tris, 1mM of EDTA, 0.03% of NaN₃, 0.1% of BSA, 0.05% of

CHAPS, 0.5mM of PMSF, 10 μ g/ml of pepstatin, 20 μ g/ml of leupeptin and 4 μ g/ml of E-64; pH: 7.4) to make the membrane protein concentration 50 μ g/ml. Each 100 μ l of the diluted membrane fractions was charged in a test tube made of polypropylene (Falcon; type 2038) and subjected to the following receptor binding experiment. In the meanwhile, porcine galanin (New England Nuclear) which was labeled with a commercially available [125 I] radioisotope was diluted with a buffer for the receptor binding experiment to make its concentration 5 nM and used in the following experiments.

Standard porcine galanin solution or galanin-related peptide solution (3 μ l) with varied concentrations and 2 μ l of 5 nM labeled galanin solution were mixed with 100 μ l of the above-mentioned membrane fraction. The mixture was allowed to stand in a water bath of 25 °C for 75 minutes to promote the receptor binding reaction. Thereafter, 1.5 ml of an ice-cooled buffer for the binding experiment was added to the reaction solution for quenching the binding reaction and filtered with a glass fiber filter (GF/F, manufactured by Whatman) immediately whereupon the membrane fractions were collected on the filter paper. Then the filter paper was washed with 1.5 ml of the same buffer and the amount of the radioisotope in the filter paper was determined by a gamma-ray detector.

Amount of the labeled galanin bound therewith was expressed in terms of PMB (percent of maximum binding) as calculated by the following equation (2):

$$\text{PMB} = [(B - \text{NSB}) / (B_0 - \text{NSB})] \times 100 \quad (2)$$

in which PMB: percent of maximum binding

B: the value when the sample is added

NSB: nonspecific binding amount (the binding amount of the labeled galanin in the presence of 1 μ M of standard galanin)

B_0 : maximum binding amount

(the binding amount of the labeled galanin in the absence of the standard porcine galanin)

The result wherein the binding amounts (PMB) of the labeled galanin as determined hereinabove were plotted against the concentrations of standard porcine galanin, rat galanin, galanin (1-16) partial peptide or galanin antagonist (galantide) is shown in FIG. 7. From the result, each of the concentrations (IC_{50}) giving 50% of PMB was calculated and given in Table 1.

Table 1

Peptides	IC_{50}
Porcine Galanin	0.12 nM
Rat Galanin	0.13 nM
Galanin (1-16)	3.3 nM
Galantide	0.69 nM

It is noted from Table 1 that, when the cell membrane fractions of MIN6 cells were used, the receptor binding affinity of the ligand to the galanin receptor was able to be determined by means of a galanin receptor binding experiments.

Example 7

Screening of Galanin Receptor Agonist/Antagonist by Galanin Receptor Binding Experiments.

It is possible to conduct a screening of galanin receptor agonist/antagonist by a method mentioned in Example 6. Thus, 1 μ l of the solution of test compounds and 2 μ l of a 5 nM labeled galanin solution are mixed with 100 μ l of MIN6 cell membrane fractions by the same manner as in Example 6. Thereafter, the binding amount is determined by the same manner as in Example 6 whereby the compounds which decreased the PMB to an extent of lower than a certain level are screened as galanin receptor agonists/antagonists.

Example 8

Detection for Biological Activity of Galanin Using MIN6 Cells.

It has been known that galanin is biologically active in inhibiting the insulin secretion of a Langerhans islet of pancreas by stimulation of glucose. Such an activity can be easily detected by the following methods using MIN6 cells. Among

the detecting methods, measurement of insulin secretion by glucose stimulation was principally conducted according to a known method (Diabetologia, volume 36, pages 1139-1145, 1993).

Briefly, 3×10^5 MIN6 cells were seeded on a 24-well plate and cultured in a Dulbecco modified Eagle's medium (supplemented with 15% of fetal bovine serum, 4.5 g/liter of glucose, 5 μ l/liter of mercaptoethanol, 75 mg/ml of penicillin and 50 mg/ml of streptomycin) in the presence of 5% carbon dioxide gas for three days.

The cells were washed for three times with a Krebs-Ringer-HEPES buffer (containing 119 mM of NaCl, 4.74 mM of KCl, 2.54 mM of CaCl_2 , 1.19 mM of MgSO_4 , 1.19 mM of KH_2PO_4 , 25 mM of NaHCO_3 , 10 mM of HEPES and 0.5% of BSA) and cultured in a Krebs-Ringer-HEPES buffer to which 5mM of glucose was added at 37 °C for 30 minutes.

Then the cells were washed with the Krebs-Ringer-HEPES buffer twice. The cells were cultured at 37 °C for 90 minutes in a Krebs-Ringer-HEPES buffer to which a varied amount of rat galanin and 25 mM of glucose. The supernatant liquid after the culturing was collected and the amount of insulin which was secreted into the supernatant liquid was determined by a commercially available radioimmunoassay kit (Amersham).

FIG. 8 shows the result in which the amount of insulin secretion was plotted against the amount of galanin. It is apparent from FIG. 8 that, when about 100 pM of galanin is added, the insulin secretion which increased by a glucose stimulation is decreased to an extent of about one half. As such, it is now clear that the activity of galanin can be easily detected using the above-mentioned method.

Example 9

Detection for Biological Activity of Galanin Using MIN6 Cells.

When MIN6 cells were treated with forskolin, the cAMP concentration in the cells increased whereupon secretion of insulin increased. Such a phenomenon can be inhibited by addition of galanin and can be used as a method of measuring the biological activity of galanin.

The cells which were cultured and pretreated (by the operations of washing, treating with 5 mM of glucose and washing) by the same manner as in Example 8 were cultured at 37 °C for 90 minutes in a Krebs-Ringer-HEPES buffer to which varied concentration of rat-type galanin, 100 μ M of forskolin, 200 μ M of isobutylmethylxanthine (IBMX) and 6.25 mM of glucose were added.

The supernatant after the culturing was recovered and the amount of insulin which was secreted into the supernatant was determined by a commercially available radioimmunoassay kit (Amersham). In addition, the cells were treated with perchloric acid to extract the cAMP in the cells and the cAMP in the extract was determined by a commercially available radioimmunoassay kit (Amersham). FIG. 9 shows the result in which the secreted amount of insulin is plotted against the amount of galanin. FIG. 10 shows the result in which the amount of intracellular cAMP was plotted. From FIG. 9 and FIG. 10, it is noted that the activity of galanin can be easily detected when secretion of insulin from MIN6 cells or cAMP concentration in MIN6 cells was measured.

Example 10

Detection for Biological Activity of Galanin Agonist/Antagonist Using MIN6 Cells.

It is possible to measure the activity of galanin agonist/antagonist by a method as mentioned in Example 8. Briefly, the cells which are cultured and pretreated (by the operations of washing, treating with 5 mM of glucose and washing) by the same manner as in Example 8 are cultured at 37 °C for 90 minutes in a Krebs-Ringer-HEPES buffer to which a suitable concentration of test compounds, 100 pM of rat galanin and 25 mM of glucose are added.

The supernatant liquid after the culturing is recovered and the amount of insulin secreted into the supernatant liquid is determined using a commercially available radioimmunoassay kit (Amersham). As a control, the amount of insulin is determined by the same manner for the supernatant liquid obtained after culturing in a Krebs-Ringer-HEPES buffer containing 25 mM glucose only and also in a Krebs-Ringer-HEPES buffer containing 100 pM of rat galanin and 25 mM of glucose. It is noted from the result that the activity of galanin agonist/antagonist can be easily measured using MIN6 cells.

Example 11

Cloning of cDNA Coding for Human Galanin Receptor Protein.

Human melanoma Bowes cells were cultured using a DMEM medium with high concentrations of glucose containing 10% fetal bovine serum at 37 °C under the condition of 95% air/5% CO_2 and, when it became almost confluent, total RNA was prepared by a guanidine-thiocyanate method. From the resulting total RNA was prepared a poly A⁺RNA fraction by an oligo(dT) cellulose column. The poly A⁺RNA (10 μ g) was treated with a random hexamer and a reverse trans-

scriptase to synthesize a single-stranded DNA and then treated with *Escherichia coli* DNA polymerase I and RNase H to synthesize a double-stranded DNA whereupon a double-stranded cDNA was synthesized from poly A⁺RNA. This double-stranded cDNA was blunt ended with a T4 DNA polymerase and then EcoRI adapters were added thereto. The resulting double-stranded cDNA wherein both terminals were added with EcoRI adapters was subjected to a gel filtration to remove cDNA of about 1,000 bp and less and then phosphate group was introduced into the EcoRI adapters using a T4 polynucleotide kinase.

Then this cDNA was incorporated into a λ gt11 EcoRI arm and subjected to an *in vitro* packaging to prepare a cDNA library (average chain length: about 1.6 kbp; rate of insertion: 98%) of melanoma Bowes cells having about 1.5×10^6 pfu in total. The λ phage of this cDNA library was infected with *Escherichia coli* Y1090r⁻ strain, seeded on each of soft agar plates at about 1.8×10^4 plaques each and incubated overnight at 42 °C to form plaques. The plaques were transferred to a nitrocellulose filter, successively treated with a modifying solution (0.5N sodium hydroxide and 1.5M sodium chloride), a neutralizing solution (0.5M Tris-HCl (pH: 7.0) and 1.5M sodium chloride) and 3 x SSC (20 x SSC= 3M sodium chloride and 0.3M sodium citrate), air-dried and baked at 80 °C for three hours whereupon the phage DNA was immobilized on the nitrocellulose filter.

On the other hand, in order to obtain the cDNA fragments to be used as a probe, synthetic oligonucleotides ① and ② were synthesized based upon a base sequence of the known human galanin receptor cDNA [Habert-Ortoll, E. et al., Proceedings of the National Academy of Sciences of the U.S.A., 91, 9780-9783 (1994)].

① 5'-TCCGTGGACCGCTACGTGGCCATCGTG-3' (SEQ ID NO: 9)

It is a synthetic oligonucleotide containing a sense sequence of +388 to +414 (wherein the translation initiation site was named +1).

② 5'-GACTTATCACACATGAGTACAATTGGTTGATGG-3' (SEQ ID NO: 10)

It is a synthetic oligonucleotide containing an antisense sequence of +1024 to +1053.

An RT-PCR was carried out using those two synthetic nucleotides as primers and 5 μ g of human melanoma Bowes cell poly A⁺RNA as a template whereupon cDNA fragments of 669 bp containing C-terminals of human galanin receptor protein were obtained. The cDNA fragments were incorporated into the HincII site of pUC119 to give a plasmid pHGR54-7. The pHGR54-7 was subjected to a double digestion with BamHI and HincII and the resulting cDNA fragments containing the human galanin receptor protein C-terminal were used as probes for screening the human melanoma Bowes cell cDNA library.

Labeling of the probes was conducted by subjecting the above-mentioned cDNA fragments to a random priming method using [α -³²P]dCTP. A hybridization was carried out at 85 °C in a buffer for hybridization (5 x SSPE, 5 x Denhardt's solution, 100 μ g/l thermally modified salmon sperm DNA, 0.1% SDS) containing labeled probes. The filter was finally washed in 0.1 x SSC, 0.1% SDS solution at 50 °C and subjected to an autoradiography to detect the plaques which were hybridized with the probes.

After the phage DNA was extracted from the phage clone lambda HGR2 obtained by that method, cDNA fragments were cut out by digesting with a restriction enzyme EcoRI and inserted into the EcoRI sites of the pUC118 plasmid to give pHGR2-3. The base sequence of the cDNA fragments inserted therein was determined by a conventional method using [α -³²P]dCTP whereupon it was found that said cDNA fragment was composed of 1,882 bp (FIG. 11 and FIG. 12; SEQ ID NO: 6). There was one substitution with a base as compared with the base sequence of the human galanin receptor cDNA which was reported already [Habert-Ortoll, E. et al., Proceedings of the National Academy of Sciences of the U.S.A., 91, 9780-9783 (1994)]. Said substitution with a base was within a translation domain and is accompanied by an amino acid substitution, i.e., ¹⁵Cys(TGT) \rightarrow ¹⁵Trp(TGG) (FIG. 11 and FIG. 12; SEQ ID NO: 6). As such, a plasmid pHGR2-3 containing the human galanin receptor DNA fragments was obtained.

Example 12

Construction of Expression Plasmid containing Human Galanin Receptor Protein cDNA.

pAKKO-111 (shown as pA1-11 in FIG. 13) was used as an expression vector. The pAKKO-111 was constructed as follows: Briefly, pTB1417 according to Japanese Unexamined Patent Publication No. Hei-05/076385 was treated with HindIII and ClaI to give DNA fragments of 1.4 kb containing SR α promoters and poly A added signals. Further, pTB348 [Naruo, K. et al., Biochemical and Biophysical Research Communications, 128, 256-264(1985)] was treated with ClaI and SalI to give DNA fragments of 4.5 kb containing dihydrofolate reductase (dhfr) genes. Those DNA fragments were blunt ended with a T4 polymerase and ligated by a T4 ligase to construct pAKKO-111 plasmid.

Human galanin receptor cDNA expression plasmid was prepared by a method as shown in FIG. 13 from the plasmids pHGR2-3 and pHGR54-7 containing the human galanin receptor cDNA fragments obtained in Example 11. First, pHGR2-3 was subjected to a double digestion using restriction enzymes BamHI and MunI and the resulting DNA fragments of about 1,190 bp were inserted between BamHI and MunI sites of pHGR54-7. In the meanwhile, pHGR2-3 was digested with NcoI, the resulting fragments of 495 bp were blunt ended with DNA polymerase I Klenow fragments, SalI linkers were added thereto, then subjected to a double digestion with AgeI and SacII and the resulting DNA fragments of 200

bp were inserted between XmaI and SacII sites of the above-prepared plasmid whereupon a plasmid pTS862 which contained the translation unit only of the human galanin receptor cDNA was obtained.

Finally, Sall DNA fragments containing the translation domain of the human galanin receptor protein cDNA of about 1.0 kbp obtained by digesting the plasmid pTS862 with Sall were introduced into the Sall site of pAKKO-111 in a regular order to give a human galanin receptor protein cDNA expression plasmid pTS863. This expression plasmid pTS863 was introduced into *Escherichia coli* to give a transformant *Escherichia coli* SURE/pTS863.

Example 13

10 Expression of Human Galanin Receptor Protein cDNA in CHO (dhfr⁻) Cells.

Four kinds of CHO (dhfr⁻) cells (in which cell numbers were stepwisely changed within a range of 3×10^4 to 1×10^6 cells) were sowed on laboratory dishes with 10 cm diameter and cultured for 24 hours with a Ham's F12 medium containing 10% of fetal bovine serum. The human galanin receptor cDNA expression plasmid pTS863 (1.5 μ g) obtained in Example 12 was transfected to the above-prepared cells by a calcium phosphate method. After 24 hours from the transfection, the medium was substituted with a DMEM medium containing 10% of dialyzed fetal bovine serum and the cells wherein the plasmid was incorporated in chromosomes were selected. Colonies of the selected cells were cloned to give two clones of cell strains CHO/pTS863-5 and CHO/pTS863-7 which highly expressed the human galanin receptor in a stable manner.

20 Example 14

Measurement of Human Galanin Receptor Activity of Human Galanin Receptor Expression CHO Cells.

Human galanin receptor expression CHO cells were seeded on a 12-well plate, cultured at 37 °C under the condition of 95% air/5% CO₂ using a DMEM medium containing 10% of dialyzed fetal bovine serum until a confluent was resulted and the medium was exchanged on one day before the binding experiment was done whereupon the human galanin receptor having an amino acid sequence having SEQ ID NO: 5 was expressed.

Then the binding experiment to [¹²⁵I] galanin (porcine) was conducted as follows. First, the cells were washed twice with each 1 ml of a buffer for measuring a binding (Hanks solution containing 0.1% BSA and 0.05% of CHAPS) warmed at 37 °C, said buffer for binding measurement was sucked, then 0.5 ml of a buffer for binding measurement containing 100 pM of [¹²⁵I] galanin (porcine) was added and a binding reaction was carried out for one hour at 37 °C under the condition of 95% air/5% CO₂. After completion of the reaction, the buffer for the binding measurement was removed and washed thrice with each 1 ml of a buffer for the binding measurement warmed at 37 °C. The amount of [¹²⁵I] galanin (porcine) bound with the cells was measured by a gamma-counter after removing the cells with 0.2N sodium hydroxide and was defined as a total binding amount. Incidentally, the same operation was conducted after adding 1 μ M of unlabeled galanin (porcine) at the binding reaction and the amount of [¹²⁵I] galanin bound with the cells was defined as the nonspecific binding amount. The results are given in Table 2.

Table 2

Cell Strain No.	Total Binding Amt. (cpm)	Nonspecific Binding Amt (cpm)
CHO/pTS863-5	50466.8 \pm 502.9	1458 \pm 100.1
CHO/pTS863-7	59158.6 \pm 2095.1	1962.4 \pm 56.3

It was confirmed from Table 2 that CHO/pTS863-5 and CHO/pTS863-7 which are cell strains expressing the human galanin receptor protein of the present invention in a high and stable manner were capable of specifically binding with galanin which is a ligand.

Example 15

55 Saturation Binding Experiments and Scatchard Plot Analysis with Human [¹²⁵I] Galanin in GAL5 Cell Membrane Fractions

CHO cells expressing human galanin receptor proteins (GAL5 cell, denoted by CHO/pTS863-5 in Example 13) were cultured in a DMEM medium containing 10% dialyzed serum, 2 mM glutamine, penicillin and streptomycin at 37 °C

under the condition of 95% air/5% CO₂. The cells were collected with a phosphate-buffered saline (PBS) containing 1 g/l EDTA, suspended in a buffer for homogenization (10 mM HEPES, 5 mM EDTA, 0.03 % NaN₃, 10 μg/ml of pepstatin, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 20 μg/ml of E-64, 40 μg/ml of leupeptin, pH 7.3) and homogenized with a Polytron homogenizer. The resultant homogenates were centrifuged at 2,500 rpm for 10 min under 4 °C. The resultant supernatant was ultracentrifuged at 30,000 rpm for 60 min under 4 °C. Pellets were suspended in a buffer for homogenization to form a suspension as a GAL5 cell membrane fraction.

The GAL5 cell membrane fraction was diluted with an assay buffer (20 mM Tris., 1 mM EDTA, 0.08 % NaN₃, 10 μg/ml of pepstatin, 0.5 mM PMSF, 20 μg/ml of E-64, 40 μg/ml of leupeptin, 0.1% BSA, and 0.05% CHAPS, pH 7.4) to make the membrane protein concentration 2 μg/ml. Each 100 μl of the diluted membrane fractions was charged in a test tube.

The GAL5 cell membrane fractions were incubated with 15 pM to 500 pM concentrations of human [¹²⁵I] galanin for 75 min at 25 °C, then diluted with 1.5 ml of a filtration buffer (20 mM Tris., 1 mM EDTA, 0.03 % NaN₃, 0.1% BSA, and 0.05% CHAPS, pH 7.4, 4 °C) and subjected to filtration through glass fiber filters (GF/F, Whatman, Kent, UK) treated with polyethylenimine. The filters were rinsed with 1.5 ml of the same filtration buffer and the radiolabeled ligands remaining were quantitated with an auto-γ-counter (Beckman Instruments, Inc., Palo Alto, CA). Nonspecific binding was determined in the presence of 20 nM of unlabeled human galanin. Scatchard plot analysis indicated its dissociation constant (K_d) of 20 pM and maximal number of binding sites (B_{MAX}) of 9.6 pmol/mg protein.

Example 16

Northern Blot Analysis Using Mouse Galanin Receptor Protein Encoding cDNA

Five micrograms of poly (A)⁺ RNAs from mouse brain, thymus, spleen, lung, heart, liver, kidney, pancreas, testis, intestinal smooth muscle, MIN6, and Neuro-2a were electrophoresed on 1.2% agarose gel after denaturation with glyoxal and dimethyl sulfoxide (Thomas, P.S., Proc. Natl. Acad. Sci. U.S.A., 77, 5201-5205, 1980). After the electrophoresis, the RNAs were transferred onto a nitrocellulose filter (Schleicher & Schuell, Dassel, Germany) and the filter was baked at 80°C for 2 hr. As a probe, the cDNA insert of p3H2-34 was excised by EcoRI digestion and labeled with [α-³²P]dCTP (222 TBq/mmol, Dupont/NEN) by a Multiprime DNA labeling kit (Amersham International PLC, Amersham Place, UK). Hybridization was conducted overnight at 42 °C in a buffer containing 50% formamide, 5 x SSC, 50mM NaHPO₄, pH 6.5, 10 x Denhardt's solution, and 100 μg/ml salmon sperm DNA. The filter was then washed with 2 x SSC, 0.1% SDS at 50 °C, and then autoradiographed at -80°C for 12 days on an X-Omat film AR (Eastman Kodak Company, Rochester, NY) with an intensifying screen. In Northern blot analysis using poly(A)⁺ RNAs from mouse tissues, the faintly hybridizing signals for the mouse galanin receptor only in the brain and small intestine (FIG. 14) were detected. The result of the Northern blot indicated that the expression level of galanin receptor mRNA was substantially lower in mouse normal tissues.

Example 17

(1) Expression of Mouse Galanin Receptor cDNA in CHO Cells

A cDNA clone with a complete translation unit, pMGR20 (obtained in Example 4), was digested with NotI, blunt ended, and ligated with XbaI linker (Takara Shuzo Co., Ltd., Kyoto, Japan). The cDNA fragment was excised by SalI and XbaI digestion and inserted between SalI and SpeI sites of a mammalian cell expression vector, pAKKO-111H (Hinuma, et al., Biochim. Biophys. Acta, 1219, 251-259 (1994)). A resultant expression plasmid with the mouse galanin receptor cDNA downstream of the SRα promoter and with dhfr gene as a selection marker was designated as pAKKOMGR20. The plasmid DNA was transfected into CHO dhfr⁻ cells with a CellPfect Transfection Kit (Pharmacia). Transformants were selected in α-MEM medium without deoxyribonucleoside and ribonucleoside (GIBCO BRL) supplemented with dialyzed fetal bovine serum (GIBCO BRL).

(2) Binding Assay with Porcine [¹²⁵I] Galanin

CHO cells transformed with pAKKOMGR20 and pAKKO-111H were grown in a 12-well tissue culture plate at 2.0 × 10⁵ cells/well and cultured for one day. After two washings with Hanks' balanced salt solution (HBSS) containing 0.1% BSA, the cells were incubated with 100 pM porcine [¹²⁵I] galanin (Dupont/NEN) at room temperature for 1 hour in the presence or absence of unlabeled porcine galanin (1 μM at final concentration). The cells were then washed three times with HBSS containing BSA, lysed with 0.1N NaOH, 1% SDS, and the radiolabeled ligands remaining were quantitated with an auto-γ-counter (Beckman Instruments, Inc., Palo Alto, CA). For competitive binding experiments and Scatchard plot analysis, membrane fractions were prepared from the transformed CHO cells. The cells grown in 225-cm² tissue culture flasks for three days were dispersed in a phosphate-buffered saline (PBS) containing 5 mM EDTA and then

harvested by centrifugation. The cells were washed with the same buffer, and then suspended in 10 mM sodium carbonate buffer (pH 7.5), including 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 20 μ g/ml of leupeptin, 4 μ g/ml of E-64, and 0.5 μ g/ml of pepstatin. After the cells were homogenized with a Polytron homogenizer, the homogenates were centrifuged at 3,000 rpm for 10 min in a Hitachi RR2A2 rotor. The resultant supernatant was ultracentrifuged at 30,000 rpm for 60 min in a Beckman Type 30 rotor. Pellet suspension was then done in a buffer containing 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.5 mM PMSF, 20 μ g/ml of leupeptin, 4 μ g/ml of E-64, and 0.5 μ g/ml of pepstatin, and used as a membrane fraction.

Competitive binding and saturation binding experiments were performed as described by Ohtaki et al. (J. Biol. Chem., 268, 26650-26657, (1993)).

In brief, the membrane fractions were incubated in a buffer containing 20 mM Tris-HCl (pH 7.5), 0.05% CHAPS, 0.1% BSA, 5 mM EDTA, 0.5 mM of PMSF, 20 μ g/ml of leupeptin, 4 μ g/ml of E-64, and 0.5 μ g/ml of pepstatin with porcine [125 I] galanin at 25 °C for 75 min. Bound and free ligands were separated by filtration through glass fiber filters (GF/F, Whatman, Kent, UK) treated with 0.3% of polyethylenimine. Nonspecific binding was determined in the presence of 1 μ M of unlabeled porcine galanin. In competitive binding experiments the concentrations of galanin and galanin analogs were added to the buffer simultaneously with porcine [125 I] galanin.

CHO cells transformed with the expression plasmid for the mouse galanin receptor cDNA bound significant amounts of [125 I] galanin as compared with control cells (FIG. 15).

Membrane fractions (1 μ g of protein) were incubated with concentrations of porcine [125 I] galanin for 75 min at 25°C in Scatchard plot analysis. The results shown are from one representative experiment performed in triplicate assays. Each symbol represents the mean value \pm S.E.M. B, [125 I] galanin bound (pmol/mg protein), B/F, bound to free ratio (pmol/mg protein \cdot nM).

Scatchard plot analysis indicated the presence of a single class of high-affinity binding site with a dissociation constant (K_d) of 45 pM and maximal number of binding sites (B_{MAX}) of 5 pmol/mg protein (FIG. 17).

Competitive experiments on the binding of porcine [125 I] galanin to mouse galanin receptor were conducted. Competitions to the porcine [125 I] galanin (100 pM at final concentrations) bindings were examined with unlabeled porcine (Δ), rat (\bullet), human (\blacksquare) galanins, galanin-(1-16) (\circ), and M15 (\blacktriangle). Membrane fractions (1 μ g of protein) were incubated with the ligands for 75 min at 25 °C. The amounts of [125 I] galanin bound were expressed as percentages against the control. Each symbol represents the mean value \pm S.E.M. of the triplicate assays. IC_{50} values were 0.25 \pm 0.03 nM (porcine galanin), 0.25 \pm 0.01 nM (rat galanin), 0.43 \pm 0.03 nM (human galanin), 0.83 \pm 0.01 nM (M15), and 3.6 \pm 0.04 nM [galanin-(1-16)], respectively.

The binding of [125 I] galanin was competitively inhibited by galanin and galanin-derived peptides. Porcine and rat galanin exhibited almost the same high efficiency in inhibiting the [125 I] galanin binding whereas human galanin was somewhat lower. The K_i values of porcine, rat, and human galanins were 0.072 \pm 0.008, 0.069 \pm 0.002, and 0.12 \pm 0.008 nM, respectively. The galanin receptor antagonists M15 and galanin-(1-16) also effectively inhibit the [125 I] galanin binding, and their K_i values were 0.23 \pm 0.003 and 1.0 \pm 0.011 nM, respectively (FIG. 18). These obtained values were almost comparable to those from MIN6 cell membranes.

(3) cAMP Assay

The CHO cells were seeded at 2.0×10^5 cells/well in 24-well tissue culture plates and cultured for two days. The cells were washed two times with HBSS containing 0.1% BSA and 1 mM IBMX, and then the same buffer with experimental agents were added to the wells. After incubation at 37 °C for 30 min, the media were discarded and intracellular cAMP was extracted with ice-cold ethanol. The aliquots of extracts were evaporated and the amounts of cAMP were quantitated by a cAMP EIA system (Amersham) as described by the manufacturer.

Galanin receptor-mediated inhibition of forskolin-stimulated cAMP production was observed. CHO-MGR20 or mock transformed CHO cells were incubated with forskolin (10 μ M) and porcine galanin (0.1 μ M) at 37°C for 30 min. The reaction was terminated by extracting the cells with ice-cold ethanol. The amounts of intracellular cAMP were quantitated by EIA. Values indicated are mean \pm S.E.M. in triplicate assays.

It is examined by the assessment of galanin-induced signal transduction to confirm further that the mouse galanin receptor expressed in CHO cells was functional. The pancreatic galanin receptor has been demonstrated to induce the inhibition of insulin release through a pathway involving G proteins negatively coupled to adenylate cyclase (Cormont, M., et al., Diabetes, 40, 1170-1176, 1991; Gillison, S., et al., Diabetes, 43, 24-32, 1994). The treatment with porcine galanin potentially inhibited forskolin-stimulated cAMP accumulation in the galanin receptor cDNA-introduced CHO cells (FIG. 19). The CHO transformants with the plasmid vector without cDNA insert also showed forskolin-stimulated cAMP accumulation, but it was not inhibited by the galanin treatment. The treatment with galanin alone did not alter the cAMP levels in CHO transformants (FIG. 19).

The galanin receptor protein of the present invention and the DNA coding for said protein can be used for ① acquisition of antibody and antiserum; ② construction of expression system for a recombinant type receptor protein;

③ development of the receptor binding assay system using said expression system and screening of the candidate compounds for pharmaceuticals; ④ conducting a drug design based upon a comparison with structurally analogous ligands and receptors; ⑤ preparation of probes and PCR primers for a gene diagnosis; ⑥ preparation of transgenic animals; and ⑦ preparation of model patient animals deficient in the receptor protein DNA. Elucidation of the structure and property of the mouse-derived galanin receptor is particularly related to the development of unique pharmaceuticals which act on such a system.

Furthermore, the human galanin receptor protein of the present invention is a novel protein having an amino acid sequence which is different from that of the known human galanin receptor protein. The cells (particularly CHO cells) retaining the expression vector containing the human galanin receptor of the present invention are capable of expressing far more amount of human galanin receptor protein than the known COS cells containing the human galanin receptor protein are.

The human galanin receptor protein of the present invention or partial peptide thereof or the cells containing the human galanin receptor protein or a cell membrane fraction thereof is capable of effectively screening the human galanin receptor agonist or antagonist.

When the screening method of the present invention is used, it is possible to advantageously select the agonist or the antagonist whereby pharmaceutical agents can be developed in earlier stage. The agonist is useful, for example, as an inhibitor for acetylcholine liberation, an inhibitor for insulin secretion, an inhibitor for a learning behavior or an inhibitor for satiety and also as a preventive and therapeutic agent for schizophrenic disease and as sedative while the antagonist is useful, for example, as an accelerator for acetylcholine liberation, an accelerator for insulin secretion, an inhibitor for growth hormone secretion, an accelerator for a learning behavior or as an accelerator for satiety and also as a preventive and therapeutic agent for diabetes, Alzheimer's disease and dementia.

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Takeda Chemical Industries, Ltd.
 (B) STREET: 1-1, Doshomachi 4-chome, Chuo-ku
 10 (C) CITY: Osaka-shi
 (D) STATE: Osaka
 (E) COUNTRY: Japan
 (F) POSTAL CODE (ZIP): 541

15 (ii) TITLE OF INVENTION: Galanin Receptor Protein,
 Production And Use Thereof

(iii) NUMBER OF SEQUENCES: 10

20 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 128
 (B) TYPE: Amino acid
 (C) TOPOLOGY: Linear

25 (ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ala Ala Met Ser Val Asp Arg Tyr Val Ala Ile Val His Ser Arg Arg
 1 5 10 15
 Ser Ser Ser Leu Arg Val Ser Arg Asn Ala Leu Leu Gly Val Gly Phe
 20 25 30
 Ile Trp Ala Leu Ser Ile Ala Met Ala Ser Pro Val Ala Tyr His Gln
 35 40 45
 Arg Leu Phe His Arg Asp Ser Asn Gln Thr Phe Cys Trp Glu Gln Trp
 50 55 60
 Pro Asn Lys Leu His Lys Lys Ala Tyr Val Val Cys Thr Phe Val Phe
 40 65 70 75 80
 Gly Tyr Leu Leu Pro Leu Leu Leu Ile Cys Phe Cys Tyr Ala Lys Val
 85 90 95
 Leu Asn His Leu His Lys Lys Leu Lys Asn Met Ser Lys Lys Ser Glu
 45 100 105 110
 Ala Ser Lys Lys Lys Thr Ala Gln Thr Val Leu Val Val Val Val Val
 115 120 125

50 (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 348
 55

(B) TYPE: Amino acid
(C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Glu Leu Ala Met Val Asn Leu Ser Glu Gly Asn Gly Ser Asp Pro
1 5 10 15
Glu Pro Pro Ala Pro Glu Ser Arg Pro Leu Phe Gly Ile Gly Val Glu
20 25 30
Asn Phe Ile Thr Leu Val Val Phe Gly Leu Ile Phe Ala Met Gly Val
35 40 45
Leu Gly Asn Ser Leu Val Ile Thr Val Leu Ala Arg Ser Lys Pro Gly
50 55 60
Lys Pro Arg Ser Thr Thr Asn Leu Phe Ile Leu Asn Leu Ser Ile Ala
65 70 75 80
Asp Leu Ala Tyr Leu leu Phe Cys Ile Pro Phe Gln Ala Thr Val Tyr
85 90 95
Ala Leu Pro Thr Trp Val Leu Gly Ala Phe Ile Cys Lys Phe Ile His
100 105 110
Tyr Phe Phe Thr Val Ser Met Leu Val Ser Ile Phe Thr Leu Ala Ala
115 120 125
Met Ser Val Asp Arg Tyr Val Ala Ile Val His Ser Arg Arg Ser Ser
130 135 140
Ser Leu Arg Val Ser Arg Asn Ala Leu Leu Gly Val Gly Phe Ile Trp
145 150 155 160
Ala Leu Ser Ile Ala Met Ala Ser Pro Val Ala Tyr His Gln Arg Leu
165 170 175
Phe His Arg Asp Ser Asn Gln Thr Phe Cys Trp Glu Gln Trp Pro Asn
180 185 190
Lys Leu His Lys Lys Ala Tyr Val Val Cys Thr Phe Val Phe Gly Tyr
195 200 205
Leu Leu Pro Leu Leu Leu Ile Cys Phe Cys Tyr Ala Lys Val Leu Asn
210 215 220
His Leu His Lys Lys Leu Lys Asn Met Ser Lys Lys Ser Glu Ala Ser
225 230 235 240
Lys Lys Lys Thr Ala Gln Thr Val Leu Val Val Val Val Val Phe Gly
245 250 255
Ile Ser Trp Leu Pro His His Val Val His Leu Trp Ala Glu Phe Gly

260 265 270
 5 Ala Phe Pro Leu Thr Pro Ala Ser Phe Phe Phe Arg Ile Thr Ala His
 275 280 285
 Cys Leu Ala Tyr Ser Asn Ser Ser Val Asn Pro Ile Ile Tyr Ala Phe
 290 295 300
 10 Leu Ser Glu Asn Phe Arg Lys Ala Tyr Lys Gln Val Phe Lys Cys His
 305 310 315 320
 Val Cys Asp Glu Ser Pro Arg Ser Glu Thr Lys Glu Asn Lys Ser Arg
 325 330 335
 15 Met Asp Thr Pro Pro Ser Thr Asn Cys Thr His Val
 340 345

(2) INFORMATION FOR SEQ ID NO: 3:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 384
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Double
 25 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE

(C) IDENTIFICATION METHOD: S

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCCGCGATGT CTGTGGATCG CTACGTGGCC ATTGTGCACT CGCGGCGCTC CTCCTCCCTC 60
 35 AGGGTGTCCC GCAACGCACT GCTGGGCGTG GGCTTCATCT GGGCGCTGTC CATCGCCATG 120
 GCCTCGCCGG TGGCCTACCA CCAGCGTCTT TTCCATCGGG ACAGCAACCA GACCTTCTGC 180
 TGGGAGCAGT GGCCCAACAA GCTCCACAAG AAGGCTTACG TGGTGTGCAC TTTCGTCTTT 240
 40 GGGTACCTTC TGCCCTTACT GTCATCTGCT TTTTGCTATG CCAAGGTCCT TAATCATCTG 300
 CATAAAAAGC TGAAAAACAT GTCAAAAAAG TCTGAAGCAT CCAAGAAAAA GACTGCACAG 360
 ACCGTCCTGG TGGTCGTTGT AGTA 384

(2) INFORMATION FOR SEQ ID NO: 4:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1044
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Double
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

55

(ix) FEATURE

(C) IDENTIFICATION METHOD: S

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ATGGAAGCTGG CTATGGTGAA CCTCAGTGAA GGAATGGGA GCGACCCAGA GCCGCCAGCC 60
 CCGGAGTCCA GGCCGCTCTT CGGCATTGGC GTGGAGAACT TCATTACGCT GGTAGTGTTC 120
 GGCCTGATTT TCGCGATGGG CGTGCTGGGC AACAGCCTGG TGATCACCGT GCTGGCGCGC 180
 AGCAAACCAG GCAACCCCCG CAGCACCACC AACCTGTTTA TCCTCAATCT GAGCATCGCA 240
 GACCTGGCCT ACCTGCTCTT CTGCATCCCT TTTCAGGCCA CCGTGTATGC ACTGCCACC 300
 TGGGTGCTGG GCGCCTTCAT CTGCAAGTTT ATACACTACT TCTTCACCGT GTCCATGCTG 360
 GTGAGCATCT TCACCCTGGC CGCGATGTCT GTGGATCGCT ACGTGGCCAT TGTGCACTCG 420
 CGGCGCTCCT CCTCCCTCAG GGTGTCCCGC AACGCACTGC TGGGCGTGGG CTTCATCTGG 480
 GCGCTGTCCA TCGCCATGGC CTCGCCGTG GCCTACCACC AGCGTCTTTT CCATCGGGAC 540
 AGCAACCAGA CCTTCTGCTG GGAGCAGTGG CCAACAAGC TCCACAAGAA GGCTTACGTG 600
 GTGTGCACTT TCGTCTTTGG GTACCTTCTG CCCTTACTGC TCATCTGCTT TTGCTATGCC 660
 AAGGTCCTTA ATCATCTGCA TAAAAAGCTG AAAAACATGT CAAAAAGTC TGAAGCATCC 720
 AAGAAAAAGA CTGCACAGAC CGTCTCTGGT GTCGTTGTAG TATTGGCAT ATCCTGGCTG 780
 CCCCATCATG TCGTCCACCT CTGGGCTGAG TTTGGAGCCT TCCCACTGAC GCCAGCTTCC 840
 TTCTTCTTCA GAATCACCGC CCATTGCCGT GCATACAGCA ACTCCTCAGT GAACCCCATC 900
 ATATATGCCT TTCTCTCAGA AAAGTCCGG AAGGCGTACA AGCAAGTGT CAAGTGTCT 960
 GTTTGCGATG AATCTCCACG CAGTGAAACT AAGGAAAACA AGAGCCGGAT GGACACCCCG 1020
 CCATCCACCA ACTGCACCCA CGTG 1044

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 349
 (B) TYPE: Amino acid
 (C) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Glu Leu Ala Val Gly Asn Leu Ser Glu Gly Asn Ala Ser Trp Pro
 1 5 10 15
 Glu Pro Pro Ala Pro Glu Pro Gly Pro Leu Phe Gly Ile Gly Val Glu

EP 0 711 830 A2

	20	25	30
5	Asn Phe Val Thr Leu Val Val Phe Gly Leu Ile Phe Ala Leu Gly Val 35 40 45		
	Leu Gly Asn Ser Leu Val Ile Thr Val Leu Ala Arg Ser Lys Pro Gly 50 55 60		
10	Lys Pro Arg Ser Thr Thr Asn Leu Phe Ile Leu Asn Leu Ser Ile Ala 65 70 75 80		
	Asp Leu Ala Tyr Leu Leu Phe Cys Ile Pro Phe Gln Ala Thr Val Tyr 85 90 95		
15	Ala Leu Pro Thr Trp Val Leu Gly Ala Phe Ile Cys Lys Phe Ile His 100 105 110		
	Tyr Phe Phe Thr Val Ser Met Leu Val Ser Ile Phe Thr Leu Ala Ala 115 120 125		
20	Met Ser Val Asp Arg Tyr Val Ala Ile Val His Ser Arg Arg Ser Ser 130 135 140		
	Ser Leu Arg Val Ser Arg Asn Ala Leu Leu Gly Val Gly Cys Ile Trp 145 150 155 160		
25	Ala Leu Ser Ile Ala Met Ala Ser Pro Val Ala Tyr His Gln Gly Leu 165 170 175		
	Phe His Pro Arg Ala Ser Asn Gln Thr Phe Cys Trp Glu Gln Trp Pro 180 185 190		
30	Asp Pro Arg His Lys Lys Ala Tyr Val Val Cys Thr Phe Val Phe Gly 195 200 205		
	Tyr Leu Leu Pro Leu Leu Leu Ile Cys Phe Cys Tyr Ala Lys Val Leu 210 215 220		
35	Asn His Leu His Lys Lys Leu Lys Asn Met Ser Lys Lys Ser Glu Ala 225 230 235 240		
40	Ser Lys Lys Lys Thr Ala Gln Thr Val Leu Val Val Val Val Val Phe 245 250 255		
	Gly Ile Ser Trp Leu Pro His His Ile Ile His Leu Trp Ala Glu Phe 260 265 270		
45	Gly Val Phe Pro Leu Thr Pro Ala Ser Phe Leu Phe Arg Ile Thr Ala 275 280 285		
	His Cys Leu Ala Tyr Ser Asn Ser Ser Val Asn Pro Ile Ile Tyr Ala 290 295 300		
50	Phe Leu Ser Glu Asn Phe Arg Lys Ala Tyr Lys Gln Val Phe Lys Cys 305 310 315 320		

55

His Ile Arg Lys Asp Ser His Leu Ser Asp Thr Lys Glu Asn Lys Ser
 325 330 335

Arg Ile Asp Thr Pro Pro Ser Thr Asn Cys Thr His Val
 340 345

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1047
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Double
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE

(C) IDENTIFICATION METHOD: S

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

ATGGAGCTGG	CGGTCGGGAA	CCTCAGCGAG	GGCAACGCGA	GCTGGCCGGA	GCCCCCGCC	60
CCGGAGCCCG	GGCCGCTGTT	CGGCATCGGC	GTGGAGAACT	TCGTCACGCT	GGTGGTGTTT	120
GGCCTGATCT	TCGCGCTGGG	CGTGCTGGGC	AACAGCCTAG	TGATCACCGT	GCTGGCGCGC	180
AGCAAGCCCG	GCAAGCCCGG	GAGCACCACC	AACCTGTTC	TCCTCAACCT	GAGCATCGCC	240
GACCTGGCCT	ACCTGCTCTT	CTGCATCCCC	TTCCAGGCCA	CCGTGTACGC	GCTGCCCACC	300
TGGGTGCTGG	GCGCCTTCAT	CTGCAAGTTC	ATCCACTACT	TCTTCACCGT	GTCCATGCTG	360
GTGAGCATCT	TCACCCTGGC	CGCGATGTCC	GTGGACCGCT	ACGTGGCCAT	CGTGCACTCG	420
CGGCGCTCCT	CCTCCCTCAG	GGTGTCCCGC	AACGCGCTGC	TGGGCGTGGG	CTGCATCTGG	480
GCGCTGTCCA	TTGCCATGGC	CTGCCCCGTG	GCCTACCACC	AGGGCCTCTT	CCACCCGCGC	540
GCCAGCAACC	AGACCTTCTG	CTGGGAGCAG	TGGCCCCGAC	CTGCCACAA	GAAGGCCTAC	600
GTGGTGTGCA	CCTTCGTCTT	CGGCTACCTG	CTGCCGCTCC	TGCTCATCTG	CTTCTGCTAT	660
GCCAAGGTCC	TTAATCACTT	GCATAAAAAG	TTGAAGAACA	TGTCAAAGAA	GTCTGAAGCA	720
TCCAAGAAAA	AGACTGCACA	GACAGTTCTG	GTGGTGGTIG	TGGTGTGTTG	AATCTCCTGG	780
CTGCCGCACC	ACATCATCCA	TCTCTGGGCT	GAGTTTGGAG	TTTCCCGCT	GACGCCGGCT	840
TCCTTCCTCT	TCAGAATCAC	CGCCCACTGC	CTGGCGTACA	GCAATTCCTC	CGTGAATCCT	900
ATCATTTATG	CATTTCTCTC	TGAAAATTTC	AGGAAGGCCT	ATAACAAGT	GTTCAAGTGT	960
CACATTCGCA	AAGATTCACA	CCTGAGTGAT	ACTAAAGAAA	ATAAAGTCG	AATAGACACC	1020
CCACCATCAA	CCAATTGTAC	TCATGTG				1047

(2) INFORMATION FOR SEQ ID NO: 7:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Single
 (D) TOPOLOGY: Linear
- 10 (ii) MOLECULE TYPE: Other nucleic acid
 Synthetic DNA
- (iii) FEATURES: N is A, G, C, or T
- 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CGTGGSCMTS STGGGCAACN YCCTG 25

(2) INFORMATION FOR SEQ ID NO: 8:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Single
 (D) TOPOLOGY: Linear
- 25 (ii) MOLECULE TYPE: Other nucleic acid
 Synthetic DNA
- (iii) FEATURES: N is A, G, C, or T
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GTNGWRRGGC ANCCAGCAGA KGGCAAA 27

(2) INFORMATION FOR SEQ ID NO: 9:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Single
 (D) TOPOLOGY: Linear
- 40 (ii) MOLECULE TYPE: Other nucleic acid
 Synthetic DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

45 TCCGTGGACC GCTACGTGGC CATCGTG 27

(2) INFORMATION FOR SEQ ID NO: 10:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33
 (B) TYPE: Nucleic acid
 (C) STRANDEDNESS: Single
 (D) TOPOLOGY: Linear

55

(ii) MOLECULE TYPE: Other nucleic acid
Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GACTTATCAC ACATGAGTAC AATTGGTTGA TGG 33

Claims

1. A galanin receptor protein comprising an amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 5 or its substantial equivalent thereto, or a salt thereof.
2. The receptor protein according to claim 1, which is produced by a transformant CHO cell.
3. A DNA which comprises a nucleotide sequence coding for a galanin receptor protein of claim 1.
4. A vector comprising the DNA according to claim 3.
5. A transformant carrying the vector according to claim 4.
6. The transformant according to claim 5, wherein the host cell is a CHO cell.
7. A process for producing a galanin receptor protein according to claim 1, which comprises culturing a transformant of claim 5 under conditions suitable to express said galanin receptor protein.
8. A screening method for an agonist or antagonist of a galanin receptor protein according to claim 1, which comprises carrying out a comparison between:
 - (i) at least one case where galanin is contacted with at least one component selected from the group consisting of a galanin receptor protein according to claim 1, a partial peptide thereof and a mixture thereof,and
 - (ii) at least one case where galanin together with a compound to be tested is contacted with at least one component selected from the group consisting of a galanin receptor protein according to claim 1, a partial peptide thereof and a mixture thereof.
9. A kit for the screening of one or more agonists or antagonists to a galanin receptor protein according to claim 1, which comprises at least one component selected from the group consisting of a galanin receptor protein according to claim 1, a partial peptide thereof and a mixture thereof.
10. An agonist or antagonist of a galanin receptor, which is obtained by the screening method according to claim 8 or the kit according to claim 9.

FIG. 1

5'	GTG	GGC	CTG	GTG	GGC	AAC	TTC	CTG	GCC	GCG	ATG	TCT	GTG	GAT	CGC	TAC	GTG	GCC
	Val	Gly	Leu	Val	Gly	Asn	Phe	Leu	Ala	Ala	Met	Ser	Val	Asp	Arg	Tyr	Val	Ala
	64					73												
	ATT	GTG	CAC	TCG	CGG	CGC	TCC	TCC	TCC	CTC	AGG	GTG	TCC	CGC	AAC	GCA	CTG	CTG
	Ile	Val	His	Ser	Arg	Arg	Ser	Ser	Ser	Leu	Arg	Val	Ser	Arg	Asn	Ala	Leu	Leu
	118					127												
	GGC	GTG	GGC	TTC	ATC	TGG	GCG	CTG	TCC	ATC	GCC	ATG	GCC	TCG	CCG	GTG	GCC	TAC
	Gly	Val	Gly	Phe	Ile	Trp	Ala	Leu	Ser	Ile	Ala	Met	Ala	Ser	Pro	Val	Ala	Tyr
	172					181												
	CAC	CAG	CGT	CTT	TTC	CAT	CGG	GAC	AGC	AAC	CAG	ACC	TTC	TGC	TGG	GAG	CAG	TGG
	His	Gln	Arg	Leu	Phe	His	Arg	Asp	Ser	Asn	Gln	Thr	Phe	Cys	Trp	Glu	Gln	Trp
	226					235												
	CCC	AAC	AAG	CTC	CAC	AAG	AAG	GCT	TAC	GTG	GTG	TGC	ACT	TTC	GTC	TTT	GGG	TAC
	Pro	Asn	Lys	Leu	His	Lys	Lys	Ala	Tyr	Val	Val	Cys	Thr	Phe	Val	Phe	Gly	Tyr
	280					289												
	CTT	CTG	CCC	TTA	CTG	CTC	ATC	TGC	TTT	TGC	TAT	GCC	AAG	GTC	CTT	AAT	CAT	CTG
	Leu	Leu	Pro	Leu	Leu	Leu	Ile	Cys	Phe	Cys	Tyr	Ala	Lys	Val	Leu	Asn	His	Leu
	334					343												
	CAT	AAA	AAG	CTG	AAA	AAC	ATG	TCA	AAA	AAG	TCT	GAA	GCA	TCC	AAG	AAA	AAG	ACT
	His	Lys	Lys	Leu	Lys	Asn	Met	Ser	Lys	Lys	Ser	Glu	Ala	Ser	Lys	Lys	Lys	Thr
	388					397												
	GCA	CAG	ACC	GTC	CTG	GTG	GTC	GTT	GTA	GTA	TTT	GCC	CTC	TGC	TGG	CTG	CCT	TTC
	Ala	Gln	Thr	Val	Leu	Val	Val	Val	Val	Val	Phe	Ala	Leu	Cys	Trp	Leu	Pro	Phe

TAC 3'

Tyr

FIG. 2




FIG. 3

p3H2-34	1	VGLVGNFLAA	20	MSVDRYVAIV	30	HSRRSSSLRV	40	SRNALGVGF	50	IAALSIAMAS	50
JN0605	1	MFTSVFCLIV		LSVDRYVAIV		HPLRRAITYRR		PSVAKLINLG		WFLASLLVTL	50
B41795	1	QFTSIFCLIV		MSIDRYLAAV		HPIKSAKWR		PRTAKMIIMA		WGVSLLVIL	50
A39297	1	MFTSIYCLIV		LSVDRYVAIV		HPIKAARYRR		PTVAKWNLG		VFVLSLLVIL	50
p3H2-34	51	PVA-YHORLF	60	HRDSNQTFQW	70	EQHPNKLHK-	80	-KAYV/CITFV	90	FGYMLPPLTI	100
JN0605	51	PIAIEADIRP		AGGQAVACN		LQHPHFWS-		-AVEVAYTEL		LGFLLPVLA	100
B41795	51	PIMLYGLS		QWGRSS-CT		INWFGESGA		YTGFLIYTHI		LGFLVPLTI	100
A39297	51	PIWFSRFAA		SSDGIVA-CT		MLMEEPFOR		LVGEVLYTEL		MGFLLPVGA	100
p3H2-34	101	FCI-----AK	110	VLNHLHKLK	120	NMSFKSEASK	130	KRTAQT/INV	140	AVTEALCHLE	150
JN0605	101	GLCYLLINGK		SRVAVLRAGK		QQRKRSE---		KKITTEL/LENV		VAVEVLCMP	150
B41795	101	CLCYLFILIK		VKSSGIRVGS		SKRKRSF---		KKVTRRVSIIV		VAVEVLCMLP	150
A39297	101	CLCYVILIAK		SRVAVLRAGK		QQRKRSE---		RKILLIMMNV		VAVEVLCMP	150
p3H2-34	151	FY.....	160		170		180		190		200
JN0605	151	FY.....									200
B41795	151	FY.....									200
A39297	151	FY.....									200

FIG. 4

1	CAAAGCAACAGGTGCAACCTCAAGGCACTGAAAGCAAGGGACGCGAGCTCACAAGGGCCAAGGGATTGAACC	72
1		1
73	CATAACCGCTCAGAAGATTCTCCGCTGCGGAGAGCTGCGGAGGAGTCCACCCGTCAGCTTGCTGACTGC	144
1		1
145	GAGCAGTGAGAGTCGCTAGACCGTACCTCTGTGTTCTGGAGCCTGCGGCCCCCGCACGGGAAGGCTTAG	216
1		1
217	CTCGGCACTTGCGAGCACCGCTCTCTTTAGCCAGGCCAGGCAGGAGTAGTGTGATCGGGCACAGCCAGG	288
1		1
289	GTCGCTCTTCCAGGCTTTCTTGCGGGTTGCGGGAGGTAAGTGTGGAGACGGCGCGCTCGCTCTCGCGGCT	360
1		1
361	CTGTCTGGGCCACTCCGTGATCCTAGGCTACCTCCAGAGCCAGTTTTCCTGGCTGGCACAACTCTCCAGG	432
1		1
433	GCGCTCCGGTCCGTTGACAGCGCCCCAAGGGGGTATCCAGTAAGTGATGGAAGTGGCTATGGTGAACCTC	504
1	MetGluLeuAlaMetValAsnLeu	8
505	AGTGAAGGAATGGGAGCGACCCAGAGCGCCAGCCCGGAGTCCAGGCGGCTCTTGGGCATTGGCGTGGAG	576
8	SerGluGlyAsnGlySerAspProGluProProAlaProGluSerArgProLeuPheGlyIleGlyValGlu	32
577	AACTTCATTACGCTGGTAGTGTGTGGCCTGATTTTCGGATGGGCGTCTGGGCAACAGCCTGGTGATCACC	648
32	AsnPheIleThrLeuValValPheGlyLeuIlePheAlaMetGlyValLeuGlyAsnSerLeuValIleThr	56
649	GTGCTGGCGCGCAGCAAAACCAGGCAAGCGCGCAGCACCAACCTGTTATCCTCAATCTGAGCATCGCA	720
56	ValLeuAlaArgSerLysProGlyLysProArgSerThrThrAsnLeuPheIleLeuAsnLeuSerIleAla	80
721	GACCTGGCCTACCTGCTCTTCTGCATCCCTTTTCAGGCCACCGTGTATGCACTGCCACCTGGGTGCTGGGC	792
80	AspLeuAlaTyrLeuLeuPheCysIleProPheGlnAlaThrValTyrAlaLeuProThrTrpValLeuGly	104
793	GCCTTCATCTGCAAGTTTATACACTACTTCTTACCGTGTCCATGCTGGTGAGCATCTTCAACCTGGCGCG	864
104	AlaPheIleCysLysPheIleHisTyrPhePheThrValSerMetLeuValSerIlePheThrLeuAlaAla	128
865	ATGTCTGTGGATCGCTACGTGGCCATTGTGCACTCGCGCGCTCTCTCTCCCTCAGGGTGTCCCGCAACGCA	936
128	MetSerValAspArgTyrValAlaIleValHisSerArgArgSerSerSerLeuArgValSerArgAsnAla	152
937	CTGCTGGCGGTGGGCTTCATCTGGCGCTGTCCATCGGCATGGCTCGCGGTGGCTACCCACGCGTCTT	1008
152	LeuLeuGlyValGlyPheIleTrpAlaLeuSerIleAlaMetAlaSerProValAlaTyrHisGlnArgLeu	176
1009	TTCCATCGGACAGCAACCCAGACCTTCTGCTGGGAGCAGTGGCCCAACAGCTCCACAAGAGGCTTAGGTG	1080
176	PheHisArgAspSerAsnGlnThrPheCysTrpGluGlnTrpProAsnLysLeuHisLysLysAlaTyrVal	200
1081	GTGTGCACCTTCGTCTTTGGGTACCTTCTGCGCTTACTGCTCATCTGCTTTTGCTATGCCAAGGTCTTAAT	1152
200	ValCysThrPheValPheGlyTyrLeuLeuProLeuLeuLeuIleCysPheCysTyrAlaLysValLeuAsn	224
1153	CATCTGCATAAAAAGCTGAAAAACATGTCAAAAAGTCTGAAGCATCCAAGAAAAGACTGCACAGACCGTC	1224
224	HisLeuHisLysLysLeuLysAsnMetSerLysLysSerGluAlaSerLysLysLysThrAlaGlnThrVal	248
1225	CTGGTGGTGGTGTAGTATTGGCATATCTGGCTGCGCCATCATGTGTCCACCTCTGGGCTGAGTTTGA	1296
248	LeuValValValValValPheGlyIleSerTrpLeuProHisHisValValHisLeuTrpAlaGluPheGly	272
1297	GCCTTCCCACTGACGCCAGCTTCCTTCTTCTCAGAATCACCGCCCATGCGTGGCATACAGCAACTCTCTCA	1368
272	AlaPheProLeuThrProAlaSerPhePhePheArgIleThrAlaHisCysLeuAlaTyrSerAsnSerSer	296
1369	GTGAACCCCATCATATATGCCCTTCTCTCAGAAAAGTCTCCGGAAGGCGTACAAGCAAGTGTTCAGTGTAT	1440
296	ValAsnProIleIleTyrAlaPheLeuSerGluAsnPheArgLysAlaTyrLysGlnValPheLysCysHis	320
1441	GTTTGGCATGAATCTCCACGAGTGAAACTAAGGAAACAGAGCGGATGGACACCGCGCATCCACCAAC	1512
320	ValCysAspGluSerProArgSerGluThrLysGluAsnLysSerArgMetAspThrProProSerThrAsn	344
1513	TGCACCCACGTGTGAAGGTTTGGCGGAGCCTCCCGACTTCCAGCTCCCATGTGTGTAGAGAGAGGAGGGGG	1584
344	CysThrHisVal***	349
1585	GAGCGAATTATCAAGTAACATGG	1607
349		349

FIG. 5




FIG. 6

MOUSEGALRECE HUMGALAMI	1 1	10 10	20 20	30 30	40 40	50 50
	1	MELAMNLSE	GNSSDPEPPA	PERPLFGIG	VENETFLAVF	GLIFAMGVIG
	1	MELAMNLSE	GNSSDPEPPA	PERPLFGIG	VENETFLAVF	GLIFAMGVIG
MOUSEGALRECE HUMGALAMI	51 51	60 60	70 70	80 80	90 90	100 100
	51	NSLVITVLAR	SKPGKPRSTT	NLFILNLSIA	DLAYLLFCIP	FOATVVALPT
	51	NSLVITVLAR	SKPGKPRSTT	NLFILNLSIA	DLAYLLFCIP	FOATVVALPT
MOUSEGALRECE HUMGALAMI	101 101	110 110	120 120	130 130	140 140	150 150
	101	WVLGAFICKF	IHYFFTVMIL	VSIFTLAAMS	VDRYVAIVHS	RRSSLRVSR
	101	WVLGAFICKF	IHYFFTVMIL	VSIFTLAAMS	VDRYVAIVHS	RRSSLRVSR
MOUSEGALRECE HUMGALAMI	151 151	160 160	170 170	180 180	190 190	200 200
	151	NALLGVGCTK	ALSIAMASPV	AYHQRLEH-R	DSNOTFCMEQ	WPNKLHKRAY
	151	NALLGVGCTK	ALSIAMASPV	AYHQRLEH-R	DSNOTFCMEQ	WPNKLHKRAY
MOUSEGALRECE HUMGALAMI	201 201	210 210	220 220	230 230	240 240	250 250
	201	WVCTFVFGYL	LPLLLLICFCY	AKVLNHLHKK	LKNMSKKSEA	SKKKTAQTVL
	201	WVCTFVFGYL	LPLLLLICFCY	AKVLNHLHKK	LKNMSKKSEA	SKKKTAQTVL
MOUSEGALRECE HUMGALAMI	251 251	260 260	270 270	280 280	290 290	300 300
	251	WVVVFGISG	LPHHVHLWA	EFGAFPLTPA	SFFERITAHG	LAYSNSSVNP
	251	WVVVFGISG	LPHHVHLWA	EFGAFPLTPA	SFFERITAHG	LAYSNSSVNP
MOUSEGALRECE HUMGALAMI	301 301	310 310	320 320	330 330	340 340	350 350
	301	IYYAFLESENF	KKAYKQVFEC	IYVDESPRSE	TKENKSRMDT	PPSTNCTHVX
	301	IYYAFLESENF	KKAYKQVFEC	IKRKDSLSD	TKENKSRMDT	PPSTNCTHVX
MOUSEGALRECE HUMGALAMI	351 351	360 360	370 370	380 380	390 390	400 400
	351
	351	X.....

FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

1	CGCGGATTTTCAGCCGAGCTGTTTTTCGCCTCTCAGTTGCAGCAGAGAAGCCCCCTGGCACCC	60
1		1
61	GACTCTATCCACCACCAGGAAGCCTCCCAAAAGAGCTCTCGCCCTGTGGACGACTCGGAA	120
1		1
121	TCCCTGGAAGCCGGGAGGGAGTCGGAGGCCAGCCCACTGGGGAGGTGGCGCTGGGC	180
1		1
181	GCGCGGATGCGCGGGAGCCTTCTCTGCAGGAGCCGCACAGTGCACTGCTGCGCGCTGG	240
1		1
241	GCAGTGCGGGGAAGCGCCGCGGAAGGAGCGGCTCCGAGCAACAGGTGCAGCACGCAGCC	300
1		1
301	GCTCCGGGAGCCAGGAAAACCGCCGGCGAAGATCTGGAGCGGTAAGGCGGAGAGAAGGG	360
1		1
361	TCTTTCCACCTGCGCGGCTGCAGCCGGCGGATCCCTCTTCCAGGCTCCGTGGTGGCGCA	420
1		1
421	GCGGGCGGAGGCGCCCGGGCAGGGACCCCCAGTGCTCTCGAGATCACCGTCCCTTCCCC	480
1		1
481	AGAAGGTCCAGCTCCGGGCTCCCGAACCCACCTCTCTCAGAAGGTCCGGCGCAAAGAC	540
1		1
541	GGTGCCACCAGGCACGGCCACCGGATCCCCGCTCCCGCTGGCTCGCGCCTCCGGGGAACC	600
1		1
601	TCAGACTCCTAAACTCGCACTCTCCGTGCTTTGCGCCGGGACCCCTGGCCACCCCGGGC	660
1		1
661	CCTGCTATCCCGCCCTCCCTCCCCGCGCGCCCCGCGCTCGCCGGGACAGCCCCGCGGGC	720
1		1
721	CATG GAG CTG GCG GTC GGG AAC CTC AGC GAG GGC AAC GCG AGC TGG	766
1	Met Glu Leu Ala Val Gly Asn Leu Ser Glu Gly Asn Ala Ser Trp	15
767	CCG CAC CCC CCC CCC CCG GAG CCC GGG CCG CTG TTC GGC ATC GGC	811
15	Pro Glu Pro Pro Ala Pro Glu Pro Gly Pro Leu Phe Gly Ile Gly	30
812	GTG GAG AAC TTC GTC ACG CTG GTG GTG TTC GGC CTG ATC TTC GCG	856
30	Val Glu Asn Phe Val Thr Leu Val Val Phe Gly Leu Ile Phe Ala	45
857	CTG GGC GTG CTG GGC AAC AGC CTA GTG ATC ACC GTG CTG GCG CGC	901
45	Leu Gly Val Leu Gly Asn Ser Leu Val Ile Thr Val Leu Ala Arg	60
902	AGC AAG CCG GGC AAG CCG CCG AGC ACC ACC AAC CTG TTC ATC CTC	946
60	Ser Lys Pro Gly Lys Pro Arg Ser Thr Thr Asn Leu Phe Ile Leu	75
947	AAC CTG AGC ATC GCC GAC CTG GCC TAC CTG CTC TTC TGC ATC CCC	991
75	Asn Leu Ser Ile Ala Asp Leu Ala Tyr Leu Leu Phe Cys Ile Pro	90
992	TTC CAG GCC ACC GTG TAC GCG CTG CCC ACC TGG GTG CTG GGC GCC	1036
90	Phe Gln Ala Thr Val Tyr Ala Leu Pro Thr Trp Val Leu Gly Ala	105
1037	TTC ATC TGC AAG TTC ATC CAC TAC TTC TTC ACC GTG TCC ATG CTG	1081
105	Phe Ile Cys Lys Phe Ile His Tyr Phe Phe Thr Val Ser Met Leu	120
1082	GTG AGC ATC TTC ACC CTG GCC GCG ATG TCC GTG GAC CGC TAC GTG	1126
120	Val Ser Ile Phe Thr Leu Ala Ala Met Ser Val Asp Arg Tyr Val	135

FIG. 12

1127	GCC	ATC	GTG	CAC	TCG	CGG	CGC	TCC	TCC	TCC	CTC	AGG	GTG	TCC	CGC	1171
135	Ala	Ile	Val	His	Ser	Arg	Arg	Ser	Ser	Ser	Leu	Arg	Val	Ser	Arg	150
1172	AAC	GCG	CTG	CTG	GGC	GTG	GGC	TGC	ATC	TGG	GCG	CTG	TCC	ATT	GCC	1216
150	Asn	Ala	Leu	Leu	Gly	Val	Gly	Cys	Ile	Trp	Ala	Leu	Ser	Ile	Ala	165
1217	ATG	GCC	TCG	CCC	GTG	GCC	TAC	CAC	CAG	GGC	CTC	TTC	CAC	CCG	CGC	1261
165	Met	Ala	Ser	Pro	Val	Ala	Tyr	His	Gln	Gly	Leu	Phe	His	Pro	Arg	180
1262	GCC	AGC	AAC	CAG	ACC	TTC	TGC	TGG	GAG	CAG	TGG	CCC	GAC	CCT	CGC	1306
180	Ala	Ser	Asn	Gln	Thr	Phe	Cys	Trp	Glu	Gln	Trp	Pro	Asp	Pro	Arg	195
1307	CAC	AAG	AAG	GCC	TAC	GTG	GTG	TGC	ACC	TTC	GTC	TTC	GGC	TAC	CTG	1351
195	His	Lys	Lys	Ala	Tyr	Val	Val	Cys	Thr	Phe	Val	Phe	Gly	Tyr	Leu	210
1352	CTG	CCG	CTC	CTG	CTC	ATC	TGC	TTC	TGC	TAT	GCC	AAG	GTC	CTT	AAT	1396
210	Leu	Pro	Leu	Leu	Leu	Ile	Cys	Phe	Cys	Tyr	Ala	Lys	Val	Leu	Asn	225
1397	CAC	TTG	CAT	AAA	AAG	TTG	AAG	AAC	ATG	TCA	AAG	AAG	TCT	GAA	GCA	1441
225	His	Leu	His	Lys	Lys	Leu	Lys	Asn	Met	Ser	Lys	Lys	Ser	Glu	Ala	240
1442	TCC	AAG	AAA	AAG	ACT	GCA	CAG	ACA	GTT	CTG	GTG	GTG	GTT	GTG	GTG	1486
240	Ser	Lys	Lys	Lys	Thr	Ala	Gln	Thr	Val	Leu	Val	Val	Val	Val	Val	255
1487	TTT	GGA	ATC	TCC	TGG	CTG	CCG	CAC	CAC	ATC	ATC	CAT	CTC	TGG	GCT	1531
255	Phe	Gly	Ile	Ser	Trp	Leu	Pro	His	His	Ile	Ile	His	Leu	Trp	Ala	270
1532	GAG	TTT	GGA	GTT	TTC	CCG	CTG	ACG	CCG	GCT	TCC	TTC	CTC	TTC	AGA	1576
270	Glu	Phe	Gly	Val	Phe	Pro	Leu	Thr	Pro	Ala	Ser	Phe	Leu	Phe	Arg	285
1577	ATC	ACC	GCC	CAC	TGC	CTG	GCG	TAC	AGC	AAT	TCC	TCC	GTG	AAT	CCT	1621
285	Ile	Thr	Ala	His	Cys	Leu	Ala	Tyr	Ser	Asn	Ser	Ser	Val	Asn	Pro	300
1622	ATC	ATT	TAT	GCA	TTT	CTC	TCT	GAA	AAT	TTC	AGG	AAG	GCC	TAT	AAA	1666
300	Ile	Ile	Tyr	Ala	Phe	Leu	Ser	Glu	Asn	Phe	Arg	Lys	Ala	Tyr	Lys	315
1667	CAA	GTG	TTC	AAG	TGT	CAC	ATT	CGC	AAA	GAT	TCA	CAC	CTG	AGT	GAT	1711
315	Gln	Val	Phe	Lys	Cys	His	Ile	Arg	Lys	Asp	Ser	His	Leu	Ser	Asp	330
1712	ACT	AAA	GAA	AAT	AAA	AGT	CGA	ATA	GAC	ACC	CCA	CCA	TCA	ACC	AAT	1756
330	Thr	Lys	Glu	Asn	Lys	Ser	Arg	Ile	Asp	Thr	Pro	Pro	Ser	Thr	Asn	345
1757	TGT	ACT	CAT	GTG	TGA	TAA	AAGATAGAGTATCCTTATGGTTGAGTTTCCATATA									1809
345	Cys	Thr	His	Val	***	***										351
1810	AGTGGACCAGACACAGAAACAAACAGAATGAGCTAGTAAGCGATGCTGCAACTTGTATATC															1869
351																351
1870	TTAACAAGAATTC															1882
351																351

FIG. 13




FIG. 14




FIG. 15




FIG. 16

	10	20	30	(I)	40	50
m	MELAMVNLSE	GNGSDPEPPA	PESRPLFGIG	VENF	ITLVVF	GLIFAMGVLG
	::::	::::	::::	::::	::::	::::
h	MELAVGNLSE	GNASCEPPA	PEPGPLFGIG	VENF	VTLVVF	GLIFALGVLG
	::::	::::	::::	::::	::::	::::
	60	70	(II)	80	90	100
m	NSLVITVLAR	SKPGKPRSTT	NLFILNLSIA	DLAYLLFCIP	FOATVYALPT	
	::::	::::	::::	::::	::::	
h	NSLVITVLAR	SKPGKPRSTT	NLFILNLSIA	DLAYLLFCIP	FOATVYALPT	
	::::	::::	::::	::::	::::	
	110 (III)	120	130	140	150	
m	WVLGAFICKF	IHYFFTVMML	VSIFTLAAMS	VDRYVAIVHS	RRSSSLRVSR	
	::::	::::	::::	::::	::::	
h	WVLGAFICKF	IHYFFTVMML	VSIFTLAAMS	VDRYVAIVHS	RRSSSLRVSR	
	::::	::::	::::	::::	::::	
	(IV)	160	170	180	190	200
m	NALLGVGFIW	ALSIAMASPV	AYHQRLFH-R	DSNOTFCWEQ	WPNKLHKKAY	
	::::	::::	::::	::::	::::	
h	NALLGVGCIW	ALSIAMASPV	AYHQGLFHPR	ASNQFCWEQ	WDPHRHKKAY	
	::::	::::	::::	::::	::::	
	(V)	210	220	230	240	(VI) 250
m	VVCTFVFGYL	LPLLLCFCY	AKVLNHLHKK	LKNMSKKSEA	SKKKTAQTVL	
	::::	::::	::::	::::	::::	
h	VVCTFVFGYL	LPLLLCFCY	AKVLNHLHKK	LKNMSKKSEA	SKKKTAQTVL	
	::::	::::	::::	::::	::::	
	260	270	280 (VII)	290	300	
m	VVVVVFGISW	LPHHVHLWA	EFGAFPLTPA	SFFFRITAHC	LAYSNSSVNP	
	::::	::::	::::	::::	::::	
h	VVVVVFGISW	LPHHIIHLWA	EFGVFPLTPA	SFLFRITAHC	LAYSNSSVNP	
	::::	::::	::::	::::	::::	
	310	320	330	340	350	
m	IIYAFLS	ENF RKAYQVFKC	HVCDESPRSE	TKENKSRMDT	PPSTNCTHV	
	::::	::::	::::	::::	::::	
h	IIYAFLS	ENF RKAYQVFKC	HIRKDSHLSD	TKENKSRIDT	PPSTNCTHV	
	::::	::::	::::	::::	::::	

FIG. 17




FIG. 18




FIG. 19

